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Abstract 
Local anaesthetic drugs are usually administered as symptom relieving drug 
formulations for the treatment of pain in superficial skin extremities. The 
anaesthesia is delivered into skin tissues at the site of pain because of nociceptive 
receptors. Concerns that exist regarding local anaesthetic drug formulations are low 
drug encapsulation efficiency, polydispersity of colloidal formulations, chemical 
interactions of released local anaesthetic drug with skin proteins and bulk 
viscoelastic properties. Complimenting drug formulation characteristics are the 
desirable rates of controlled release of drug molecules from chosen formulations 
pertaining to favourable in vitro skin permeation kinetics are imperative 
pharmaceutics based research areas because skin percutaneous delivery has 
distinct barrier property restrictions for passive diffusion (PD) of active molecules.  
Lidocaine is currently the active anaesthetic molecule of choice in local anaesthesia 
by clinicians because of minimum toxicity and good potency. It is a low molecular 
weight drug comprising of electron donating and electron withdrawing functional 
groups with the capacity to interact by hydrogen bonding and electrostatic 
interactions with several drug formulation vehicles.  
 
In this work, a naturally occurring bi-polymeric formulation was achieved with 
lidocaine NaCMC:gelatine hydrogel. Lidocaine NaCMC:gelatine ratio of 1:2.3 was 
the most favourable formulation because of faster skin permeation kinetics. 
Lidocaine NaCMC:gelatine 1:2.7 provided the highest drug encapsulation 
efficiency. This resulted in high, sustained permeation rates after adaptation of the 
microneedle (MN) “poke and patch” technique, past the stratum corneum layer of 
skin for quick target delivery in attaining a maximum permeation flux of near 6.0 
µg/cm2/h in the hypodermis layer. Mass balance of in vitro studies using an indirect 
approach to quantify lidocaine permeation showed significant lidocaine permeation 
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in skin. Subsequent vertical and horizontal (depth averaged) in vitro studies using 
similar MN techniques resulted in crossing minimum therapeutic level across a 10 
mm radius from the epicentre of the skin sample at major reduced lag times of 
minutes for vertical permeation and within 0.5 hours for horizontal permeation. 
Furthermore, the spreadability of lidocaine NaCMC:gelatine hydrogel shows 
favourability in the control of droplet spreading on MN treated skin.  
 
Keywords: Lidocaine, In Vitro drug release, Microneedles, Hydrogel, Polymer, drug 
permeation, Passive diffusion, Spreadability 
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Glossary 
Aspect ratio 
Scalar dimensional length against width ratio of a micron scale needle, e.g. an aspect 
ratio of 4:1 means a factor 4 increase in length in relation to the width with a factor of 1. 
Auricle 
Anatomical name for the external and visible part of the ear located on the head.  
B. mori cacoons  
Natural silk cocoon fibrons spun by the silkworm, Bombyx mori. 
Biodegradable polymer    
A polymer which degrades mainly by hydrolysis over time into smaller molecular weight 
monomer units. 
Bipolymer 
A polymer vehicle consisting of two polymers chemically bound. For example, NaCMC 
and gelatine combined are known as a bipolymer.  
Bolus 
An fast administered quantity of intravenous drug for rapid drug delivery. 
Co-drug 
Two or more active drugs joined by covalent bonds for the purpose of improving the drug 
delivery of one or more drugs. A co-drug is pharmaceutically inactive before cleavage of 
covalent bonds by enzymes in target tissues. 
Coat and poke 
Technique for coating microneedles in a layer of drug and piercing the microneedles 
through the skin, the drug coating dissolves into the skin. The coating can be applied 
by rolling, spraying or dipping the formulation onto the microneedles. 
Daltons 
A unit of measure of the total molecular weight of biomacromolecules. Permissible 
values are from hundreds to hundred thousands of daltons. 
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Diffusion Coefficient (D) 
A mass of a compound diffusing into a specified unit surface in a defined unit time at a 
concentration gradient of unity. 
Dissolution 
A process in which a solute dissolves in a solvent forming a solution, e.g. saline is a 
result of sodium chloride dissolving into water. 
Dissolving array    
The drug formulation is combined with biocompatible excipients and moulded into 
microneedles in the fabrication process. The principle is that the drug formulation 
matrix dissolves into the skin compartment; drug acting normally on its target 
molecules and the excipients degrade as non-toxic metabolites. 
Emulsion   
An immiscible colloidal system of liquid dispersed in one or two liquid mediums. 
Empirical    
A source of knowledge acquired by observation and experiment.  
Encapsulation   
The enclosure or trapping of a core material (solid, liquid or gas) inside a solid or liquid 
matrix for the purpose of controlled release.  
Eutectic mixture   
A composition consisting of two or multiple lead components forming a lowest crystal-
lisation temperature system.  
Fick’s law 
A theory that describes the diffusion of exogenous/active molecules along a 
concentration gradient.  
Flux (J) 
The vector quantity of a property of matter, e.g. concentration, permeating through a 
given area in a given time interval and through a defined surface area for that period of 
duration. The defined surface area can be a skin section or filter membrane. 
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Franz diffusion cell (FDC) 
An upright glass container shaped like a small teapot with a spout and water jacket. 
Used in in vitro experimental analysis of drug permeation through a dissected organ, e.g. 
skin. 
Gelatine type A    
Animal protein derived from the collagen and tendons of porcine or bovine origin and 
treated by strong acids in the manufacturing process. The isoelectric point is 7 - 9. 
Glutaraldehyde (IUPAC name: 1,5 pentanedial)  
A crosslinking molecule used for the hardening and solidifying of biochemical micro-
particles such as protein derivatives. 
High performance liquid chromatography (HPLC) 
An analytical method of separating organic molecules usually on a non-polar, reversed 
phase column. The inside of a reversed phase column contains carbon molecules of 
specific molecular size, bonding and stereochemistry such as C4, C8, C18.  
Homogeneous 
A compound or a mixture of substances with a uniform characteristic or composition 
that is often clearly observable. 
Hydrogel   
A substance or compound that is immiscible in aqueous solvent with the potential to 
swell or shrink in specific physicochemical conditions e.g. temperature.  
In Vitro    
An anatomical segment or component of material in experimentation of a biological 
sample. 
Intercellular 
A molecule residing or moving in a region located outside the cell membrane and 
between cells. N.b. it is outside the cell wall when discussing plant cells.  
Intracellular 
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A molecule residing or moving inside cells. The movement is past cell membranes and 
inside cells, mainly cell cytoplasm, and into cell membranes.  
Lidocaine   
A local anaesthetic drug used in the prevention or treatment of localised pain.  
Local anaesthetics   
A group of drugs which target Na/K ion channels of sensory nerves, blocking 
superficial nerve impulses and preventing pain. 
Liquid chromatography-diode array (LC-DA) 
A more specific description of HPLC analysis in particular the diode array (DA) 
detector component involves detecting specific chromophores of an organic molecule 
(See HPLC). Distinct chromophore of a molecule are interpreted as a signal peak 
wavelength (λmax) and correspond to the chosen wavelength peak.  
Micelles 
A surfactant composed of ampiphilic groups arranged usually as spherical particles. 
The hydrophobic or hydrophilic region will orientate according to the polarity of the 
solvent environment, taking the “like dissolves like” rule. 
Microneedles 
A device composed of a solid base with minute projection of needles. Those minute 
needles are nearly visible to the naked eye.  
Microgel   
Hydrogels with particle morphology on a micron scale. 
mPEG2000-PLLA 
Methoxy poly(ethylene glycol) (mPEG), 2000 Da, Poly-L-lactide. 
mPEG5000-PSA 
Methoxy poly(ethylene glycol) (mPEG), 5000 Da, Poly(sebacic anhydride). mPEG is 
hydrophilic region and Poly(sebacic anhydride) is the hydrophobic region.  
n-hexane    
A colourless volatile organic liquid with a boiling point temperature of 69.0 °C. 
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n-octanol/water partition coefficient 
A measure of substances solubility between a non-polar and polar solvent phase and 
hence the deduction of the nature of polarity of a substance. A substance of known 
quantity added to a two phase n-octanol and water mixture with subsequent agitation 
will eventually concentrate more or less in either the organic or aqueous phase. The 
n-octanol and water mixture are immisble equal volumes. 
Paraffin liquid    
A fraction of crude oil consisting of a mixture of alkanes from six carbon chain to 
twelve carbon chain lengths. The physical property is a low density, non-polar liquid. 
Percutaneous    
An adjective for administering or absorbing an active molecule in a defined skin layer 
or organ tissue layer. Alternatively percutaneous absorption is used to describe 
transdermal delivery.   
pH    
A measure of substance acidity or alkalinity from a scale of 0 - 14; defined: pH = - log 
[H+].  
PHCL-g-PLLA 
Poly(4-hydroxyl-ε-caprolactone-co-ε-caprolactone)-g-poly(L-lactide). A blended 
polymer to combine degradation and mechanical properties. 
Physiological conditions 
Biological environment refering to a plasma fluid pH 7 and temperatures of 37°C. 
P(LLA-b-εCL) 
A diblock co-polymer with a MW 15200 Da. Combines mechanical and degradation 
properties. 
P(LLA-co-εCL)  
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A diblock random polymer with MW 51000 Da. Combines mechanical and degra-
dation properties. 
 
Poke with patch    
Technique in which microneedles penetrate the skin through the SC layer and create 
pores, followed by the placement of drug on the treated site. 
Polymer   
A continuously high molecular weight molecule comprising of repeating monomers. 
Sirolimus 
An immunosuppressant drug.  
Sodium carboxymethyl cellulose (NaCMC)    
A polyanionic derivative of cellulose with hydrophilic and biodegradable properties.  
Stratum Corneum (SC)   
A protective and insensitive top layer of the epidermis which is usually 15 - 20μm 
thick. 
SU-8  
A high viscosity, negative based photo resist structure for moulding applications. 
Suspension    
A specific colloidal system of solid particles dispersed in a liquid medium such as 
water. 
Tissues    
A group of similar cells in a multicellular organism or dissected body segment. 
Topical  
The application of medication on the surface of skin or mucous membranes. 
Transdermal 
Drug delivery into the skin hypodermis and subsequent systemic circulation. 
Vehicle 
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Excipients, additives or reagents temporarily binding with drug molecules for the 
purpose of bulk handling, physicochemical stability during storage and controlled 
pharmacokinetics.  
W/O   
Aqueous droplets dispersed in continuous oil phase. 
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Chapter 1 
Introduction 
Lidocaine is a local anaesthetic for symptomatic pain sensation blockade below the 
stratum corneum (SC) layer of epidermis. The localised anatomical target for 
lidocaine are peripheral nerves inherent in cells of skin tissue involved in the 
nervous system concerning the function of pain and touch in the viable epidermis 
(VE) and dermis. Local anesthetics are used in symptomatic treatment of 
dermatological diseases, wound treatment or minor surgery associated with pain in 
the region of skin. Lidocaine was first synthesised by chemists Holger Erdtman and 
Nils Löfgren during the early 1940s leading to first clinical trials in 1944 before 
entering the pharmaceutical market in the 1950s as a bolus solution. Lidocaine’s 
success as a solution based local anesthetic has expanded towards topical based 
and patch based modes of delivery, i.e., transdermally. However, there is a 
significant gap in knowledge regarding the percutaneous based delivery of 
lidocaine. There is also a significant gap in knowledge in the formulation of 
lidocaine hydrogel using natural polymers and natural excipients encompassing a 
biocompatible concoction. The focus towards desirable permeation kinetics of 
lidocaine with the implementation of a microneedle (MN) patch is another significant 
gap in knowledge. 
 
The aim of this research is to therefore develop a hydrogel based formulation for 
enhanced lidocaine delivery using a MN patch in balancing ideal formulation and 
physicochemical properties of a natural bipolymeric hydrogel to achieve increased 
permeation kinetics below the stratum corneum (SC) layer of skin. Known 
therapeutic permeation thresholds of lidocaine in the viable epidermis (VE) layer is 
compared with experimentally derived permeation profiles of lidocaine. 
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Figure 1.1: The frequency of lidocaine publications during time. (Web of knowledge) 
 
 
Figure 1.2: The frequency of lidocaine MNs publications during time. (Web of 
knowledge) 
 
A frequency distribution plot of lidocaine publications (Figure 1.1) outlines an 
increasing trend for lidocaine before an early stage plateau effect is observed after 
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1999. The keyword “lidocaine” implies lidocaine, lidocaine HCl and it’s numerous 
formulations. There is a likelihood that new research interests for lidocaine have 
decreased significantly after the year 2000. The highest number of lidocaine based 
publication recorded was approximately 9415 from a year range 1995 till 1999. 
Unlike the decreasing publication numbers for general lidocaine based publications, 
there is still a significantly large demand for lidocaine microneedles as a potentially 
new drug delivery device (Figure 1.2) (Web of knowledge).  
 
A short lag time for bypassing the SC layer in lidocaine permeation and a therapeutic window 
sustained between 30 to 45 minutes is ideal in emergency treatment of localised lacerations 
and painful skin wounds. In achieving faster and sustainable lidocaine permeation, the 
compression forces and MN microcavity depths were compared with the skin permeation 
rates. 
 
1.1 Specific objectives in formulating a lidocaine hydrogel for MN “poke and 
patch” delivery 
 
The specific objectives in the current research of a lidocaine NaCMC/gelatine 
hydrogel are as follows: 
 
1) To determine suitable biocompatible polymers and excipients for the 
encapsulation of lidocaine that is generally regarded as safe.  
2) To attain maximum dispersion of lidocaine microgel microparticles in water 
from favourable Zeta potentials and particle size distribution analysis. 
3) To attain favourable pseudoplasticity of lidocaine NaCMC/gelatine hydrogel 
from mass ratios. 
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4) To sustain the percutaneous delivery of lidocaine within or above minimum 
therapeutic levels from NaCMC/gelatine hydrogel contained in the viable 
layers of skin by mass transfer with minimum clearance via the blood stream.    
5) To compare and enhance the delivery of lidocaine percutaneously by MN 
“poke and patch” method on skin. 
6) To compare and enhance the skin percutaneous delivery of lidocaine 
vertically and horizontally (depth averaged) above minimum therapeutic 
levels.  
7) To ensure that the skin permeation of lidocaine is sustained within a 
therapeutic threshold for significantly long periods before drug depletion in 
the skin. 
8) To control the spreading of lidocaine NaCMC/gelatine hydrogels across MN 
treated skin and compare it with non MN treated skin. 
 
1.2 Structure of thesis 
The thesis is divided into a total of seven chapters as discussed below. Chapter 1 outlines 
the specific aims of this study. Chapter 2 reviews the important areas in the current literature 
of natural polymers as vehicles and devices in drugs and lidocaine based MNs. This review 
discusses the success and limitations of current patch based systems and biodegradable 
lidocaine MNs. Chapter 3 is concerned with the specific areas of formulation development 
and the ‘poke and patch’ method of lidocaine hydrogel delivery. Chapter 4 discusses mass 
transfer of lidocaine in skin and the use of low frequency sonophoresis (LFS) as a technique 
for lidocaine delivery through skin. The mechanism of LFS as an added permeation 
enhancer for lidocaine is discussed. Chapter 5 is based on a method that was implemented 
in determining depth averaged mass transfer of lidocaine in the VE layer of skin. Chapter 6 
discusses the control in the spreadability of lidocaine NaCMC/gelatine microgels on skin and 
artificial membrane. Chapter 7 concludes lidocaine NaCMC/gelatine hydrogel as a potential 
hydrogel formulation inconjunction to the MN assisted method for superficial pain treatment 
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on skin. This chapter also discusses possibilities of future work. Chapter 8 lists all references 
used in this research work.  
 
Literature review 
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Chapter 2 
Literature review 
 
Chapter overview 
There has been an increasing interest in applying biotechnology in formulating and 
characterising new and innovative drug delivery methods, e.g. Drug loaded 
biodegradable microneedles within the area of transdermal delivery (TD) 
technology. Recently, microneedles have been proposed for use in pain 
management, e.g., post operative pain management through delivery of a local 
anaesthetic, namely, lidocaine. Lidocaine is a fairly common, marketed prescription-
based, local anaesthetic pharmaceutical, applied for relieving localised pain and 
lidocaine loaded microneedles have been explored. The purpose of this literature 
review is to evaluate the properties of biodegradable polymers that may allow the 
preparation of microneedle systems, methods of preparing them and 
pharmacokinetic conditions in considering the potential use of lidocaine for delivery 
through the skin. This chapter continues with the pharmaceutical application of 
natural polymers derived from carbohydrate and protein sources in modified and 
unmodified forms for pharmaceutical applications such as production of TD and 
percutaneous drug delivery systems, oral and topical drug delivery systems. 
Hydrogel and microgel based drug delivery systems are also included due to their 
increasing impact and potential in the pharmaceutical industry. A detailed overview 
of the distinctive properties of natural polymers suitable for pharmaceutical 
applications is provided from the most recent applications reported in literature. 
 
2.1 Introduction 
A lidocaine drug vehicle composed of natural polymers and delivered 
percutaneously by a microneedle patch was researched as a poke and patch 
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device. Therefore, this chapter aims to provide a comprehensive insight into 
lidocaine microneedles and natural polymer vehicles, especially hydrogels. 
 
2.2 Microneedles as a drug delivery vehicle for lidocaine 
There has been an increasing interest in applying biotechnology in formulating new 
and innovative drug delivery methods, including biodegradable microneedles within 
the area of TD drug delivery technology (Orive et al., 2003; Olatunji and Das 2010, 
2011). Conventional hypodermic needle delivery causes pain and anxiety, and 
requires medical personnel for administration. In contrast, the biodegradable 
microneedle, a drug loaded vehicle moulded into an all-in-one drug formulated 
micro-structure constructed from either biopolymer or sugar excipients, can be used 
to deliver drug almost painlessly to humans (e.g., Donnelly et al., 2010; Lhernould 
and Delchambre, 2011; Olatunji et al., 2014; Olatunji and Das, 2011; Gittard et al., 
2012). These microneedles are economical due to using fairly cheap materials 
(Olatunji et al., 2014), give reproducible results and are generally safe even if 
microneedle fragments break off after piercing the skin surface as compared to 
other microneedles made with glass or metal. 
 
Large molecular weight proteins such as bovine serum albumin, growth hormones 
and vaccines have been successfully loaded into biodegradable microneedles (Lee 
et al., 2008, 2011a; Raphael et al., 2010).  Recently, the microneedles have also 
been explored for use in post operative pain management through delivery of a 
local anaesthetic, lidocaine. Lidocaine provides short duration, superficial 
anaesthesia, to the pain affected area (Kissin. 2012). Lidocaine (Figure 2.1) 
comprises of a polar tertiary amine and a hydrophobic aromatic group on the 
opposite ends of the acetamide bond (Costa et al., 2008). It is hydrophobic as the 
basic drug but it is soluble in water as the ionised form of lidocaine HCl (Figure 2.2) 
in which the tertiary amine is protonated (Ullah et al. 2012; Rajabi et al., 2011 
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Shaikh et al., 2011). The physico chemical properties of drug prior to vehicle 
encapsulation are imperative for relating the structure with function, E.g. solubility 
effecting the in vitro drug permeation in receptor solvent. The solubility of lidocaine 
HCl does not equal the solubility of sodium chloride in water thus potentially leading 
to a saturated solution. Sodium chloride is a known ionic salt. If lidocaine HCl was 
ionic the saturated concentration would provide inaccurately high cumulative 
amounts in a known receptor volume of water, thus representing a false positive in 
IV studies. This is the receptor compartment of a Franz diffusion cell as discussed 
in Chapter 3. Lidocaine can be encapsulated or dispersed in a drug delivery vehicle 
which could be either hydrophobic or hydrophilic. 
 
 
 
 
 
Figure 2.1: The chemical structure of hydrophobic form of local anaesthetic lidocaine (Costa et 
al., 2008).  
 
Figure 2.2: The hydrophilic form of lidocaine known as lidocaine hydrochloride (Shaikh 
et al., 2011). 
 
In the present context, a vehicle for drug delivery is taken as a support material for 
formulating drugs usually in liquid based or a semi-solid form to remain on the skin 
surface and facilitate the conditions necessary for TD drug delivery (Allen et al., 
2005; Djabri et al., 2012; Subedi et al., 2010). An ideal drug carrier system or 
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vehicle is sought for identifying optimal conditions in controlled release and TD 
permeation kinetics of the drug lidocaine. The main objective of using a vehicle is 
either to allow for fast initial release or permeation in skin with consideration to the 
suitability of suturing a superficial cut or a slow initial release and longer steady 
state conditions lasting several hours with an alternative consideration to suturing 
and treating multiple lacerations at the localised area. 
 
A formulation of lidocaine has been developed by Fiala et al. (2011) for EMLA 
(eutectic mixture of local anaesthetics) containing lidocaine and prilocaine in 
hydrofluoroalkane as a propellant enhancer spray. Kaewprapan et al. (2012) 
studied lidocaine loaded nanoparticles of dextran decanoate esters with varying 
degrees of substitution for suspension in aqueous medium. Petrisor et al. (2012) 
mixed lidocaine with silicone elastomer and analysed the controlled release effects 
of modifiers such as poly(vinylpyrrolidone), PVP, and poly(vinyl alcohol), PVA. 
Components in drug vehicles have the purpose of mass bulking, preservation of 
drug, rheological properties and drug release properties in biological target.  
Compared with injectable and skin surface drug applicants, microneedles are highly 
beneficial in terms of constant needle lengths being below the length causing 
epidermal pain stimulation during insertion (Cheung and Das, 2014), while being 
described as minimally invasive in forming micro-spaces (Cheung and Das, 2014) 
in conjunction to enhancing the movement of the active compounds through the 
skin (Ameri et al., 2010; Chu et al., 2010). Besides the laboratory based studies 
mentioned above, there are a number of proprietary TD delivery systems for 
lidocaine. These include proprietary medicines in solution, semi-solid and patch 
delivery system. For example, lidocaine in solution is combined with a bacterially 
derived hyaluronic acid gel formula to minimise the discomfort of injection as tissue 
filler in the cosmetics industry (Monheit et al., 2009). The proprietary name of the 
formulation is Prevelle Silk (Mentor Pharmaceuticals, www.mentorcorp.com). 
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Lidocaine solution is marketed under the proprietary name of Xylocaine and is also 
available in an injectable format (www.astrazeneca.co.uk). Clinical research has 
shown that a 1 % (w/v) lidocaine subcutaneously injected once into the location of a 
lacerated, injured or tumour affected hand allows for successful local anaesthesia 
followed by surgical treatment (Tzeng and Chen, 2012). A lidocaine patch for the 
application to skin is also marketed with the proprietary name Lidoderm 
(www.Lidoderm.com). A Lidoderm (5 % w/v) patch has been applied for the 
treatment of postherpetic neuralgia (Katz et al., 2002) and in the reduction of pain 
during treatment of Dercum’s disease (Desai et al., 2008; Martinenghi et al., 2015).  
 
Conceptually, microneedle technology provides an attractive method for delivering 
lidocaine. For example, it may be possible to apply the drug over a large surface 
area on the body with no or little pain in contrast to traditional hypodermic 
injections. With microneedles it may be possible to control the drug delivery rate as 
well besides reducing wastage of the drug. As far as we know, there is no 
commercially based FDA approved lidocaine microneedle product available from 
pharmacies. However, there seems to be some developmental research for 
lidocaine microneedles. Recently, the 3M Group developed a lidocaine solution 
mixed with dextran to uniformly coat medical grade, liquid crystalline polymer (class 
VI) for pre-clinical in vivo studies using biopsy porcine skin of live pigs. This resulted 
in successful delivery of lidocaine in a faster time compared to EMLA composed of 
lidocaine and prilocaine as a combined eutectic formulation (Zhang et al., 2012a; 
Schreiber et al., 2013). A highly significant development was made by Theraject 
Inc. (Kwon, 2004) with regards to determining the permeation flux of lidocaine 
through the skin by testing a Theraject MAT dissolvable microneedle system. This 
vehicle comprised sodium carboxymethyl cellulose (NaCMC) mixed with lidocaine 
and was cast, compressed and moulded to dryness with a subsequent diffusion 
characterisation that confirmed the permeation flux had increased up to 12 fold 
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compared to 10 % (w/v) lidocaine as control (Kwon, 2004). The degree of 
subsitition, in terms of exchanged hydroxyl groups to carboxymethyl groups in 
NaCMC, effected solubility, viscosity, gel strength and electro-analytical behaviour 
as an anionic polymer in solution requires further work in order to aim for a plastic 
material property (Kundu et al., 2011). Further details on degree of substitution are 
mentioned in section 2.4.2. 
 
While the above studies show the potential for applying the principles of 
biotechnology for preparing lidocaine loaded microneedles, there is a clear need to 
make further progress on the methods of preparation and characterisation of the 
microneedles for drug delivery. It may also be necessary to learn from what have 
been done elsewhere while loading and delivering other molecules (e.g., insulin) 
using biodegradable microneedles. To address these issues, this chapter aims to 
evaluate critically the current developments in biodegradable microneedle systems 
for possible applicability in TD lidocaine delivery. In particular, this chapter reviews 
the methods of preparation and the properties of biodegradable polymers that may 
allow for the development of a desirable microneedle system for lidocaine delivery. 
It is expected this would be helpful in preparing biodegradable microneedle for 
lidocaine delivery. 
 
2.2.1  Preparation of microneedles 
The first published paper on microneedles was in 1947 in which soft glass material 
(30 μm tip diameter and 2.5 cm long) was an example of early microneedles in 
assisting the isolation of yeast ascospores (Thaysen and Morris, 1947). Gerstel and 
Place. (1976) were the first to obtain a patent for the architecture of microneedle 
arrays, outlining a drug solution reservoir to a flow through hollow microneedle. In 
1998, a paper on the fabrication of microneedles used silicon layered chromium for 
‘coat and poke’ delivery of drugs (Henry et al., 1998). The first published fabrication 
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of biodegradable microneedles used micromachining technology to mould 
polycaprolactone polymer into microneedles (Armani and Chang, 2000; Park et al., 
2003). At the moment, there is clearly an increasing interest in preparing 
biodegradable microneedles for a variety of applications. Those applications are 
considered as drug molecular delivery, cosmoseutical based molecular delivery and 
adsorption or binding of cellular components for diagnostics.   
 
Preparation and treatment of normal skin surface (e.g. antiseptic wipes) before the 
application of a microneedle has not been recommended. Most scientific papers 
suggest that pathogenic infections are not caused by using microneedles (Arora et 
al., 2008; Donnelly et al., 2009; Han et al., 2012). As long as there is no potential 
risk of pathogenic infections caused by poor hygiene, it can be assumed that the 
patient using microneedles has normal immunity to infections. The removal of 
microneedles leaves indents on the skin and the main factors, such as microneedle 
length, number in an array and microneedle cross-sectional area, effect the time for 
natural skin re-sealing (Gupta et al., 2011a). For example, Kalluri and Banga. 
(2011) have characterised the micro-conduit channels caused by microneedles and 
pore re-sealing. They show that skin pores close partially in approx. 12 h and 
completely in approx. 15 h. Micro-conduit re-sealing is shortly discussed in Chapter 
5. Considerations on pore re-sealing can affect the controlled drug release over 12 
h for a poke and patch system. 
 
A direct thumb application for microneedles allow the drugs encapsulated inside the 
microneedles to diffuse into the VE layer of the skin as outlined schematically in 
Figure 2.3a (Shakeel et al., 2011; Kim et al., 2012a). However, in the case of 
lidocaine, if the drug is concentrated in the middle to lower portion of the 
microneedle than the tip, the permeation is expected to be near the SC layer of the 
skin to anaesthetise a superficial cut. As such, one needs to consider where the 
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drug is loaded in the microneedle. Compared with glass and metal microneedles, 
biodegradable microneedles have no or little safety concern if they break and 
become embedded in the skin as a foreign body (Park et al., 2007a). This is due to 
the brittle properties of glass and malleability of soft metal which can potentially 
break apart. Usually the manufacturing process and reproducibility of biodegradable 
microneedles are economical compared with conventional micro-machining 
manufacture (Donnelly et al., 2010). Figure 2.3b is a scanning electon microscope 
(SEM) plan view of poly (lactic-co-glycolic acid) (PLGA) microneedles and Figure 
2.3c is an image of NaCMC microneedles encapsulated with a dye molecule 
representing a possible drug, sulforhodamine B (Jeong et al., 2008; Park et al., 
2007a). 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic outline of (a) diffusing biodegradable MN after skin insertion. (b) SEM 
image of conical PLGA microneedles (Park et al., 2007a). (c) Pyramidal NaCMC microneedles 
containing sulforhodamine B (Jeong et al., 2008). 
 
Microneedles have been fabricated by a variety of means. For example, silicon 
master substrate is adapted in microelectronic mechanical systems applications 
and less time consuming, mass producing techniques were researched via 
operations from the microelectronics industry, known as microelectronic mechanical 
systems for the fabrication of a master microneedle array prior to micromoulding 
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(Fujita, 1997; Walraven, 2003; Trautmann et al., 2005). SU-8, 1-methoxy-2-propyl 
acetate, (Microchem Corp, MSDS) is a negative photoresist material mixed with a 
sulfonium salt photoinitiator for inducing the mechanism of cationic polymerisation 
in epoxy groups of SU-8 monomers under UV (Zhang et al., 2001; Qvortrup et al., 
2011). It is photosensitive to UV light and a special mask diffraction grating is 
required to direct a particular wavelength onto the SU-8 (Ami et al., 2011). SU-8 
does not always provide accurate structures and cases of bending brought by high 
residual stress were observed when photoresist and substrate possess 
incompatible thermal expansion coefficients. As such, the UV exposure time and 
wavelength range need close monitoring to prevent the distorting structure 
(Safavieh et al., 2010; Del Camp and Greiner, 2007). Marasso et al. (2011) 
implemented double spin coating with two different viscosities of SU-8 and 
observed good adhesion properties between copper substrate and SU-8 in 
conjunction to an aspect ratio of 7:1 without additional steps such as wafer removal 
and seed layer introduction, extending production period over 24 h. Also, the 
viscosity and set thickness of the SU-8 photoresist are dependent on the amount of 
c-butyrolactone solvent dissolved in producing the solution (Lorenz et al., 1997).  
 
A recent starting material for production of master templates was reported by Viero 
et al. (2012). They used reactive ion etching on a silicon based master for the 
construction of microneedles. Chen et al., (2008) also outlined a fabrication process 
which used silicon oxide layers on silicon followed by a positive photoresist 
treatment for pattern transfer onto the silicon oxide layer via reactive ion etching 
and finally producing microneedle tips using an isotropic reactive ion etching 
process. Lhernould and Delchambre. (2011) arrived at a design fabrication process 
of implementing laser ablation to create microchannels in polycarbonate material. 
Matteucci et al. (2009) adapted the micro-fabrication process known in German as 
Lithographie, Galvanoformung, Abformung (lithography, electroplating and molding) 
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by Hruby (2001) which produced microneedles by double exposure, deep X-ray 
lithography (Kim et al., 2004; Miller et al., 2011) using microcrystalline silicon wafers 
surfaced with Cr/Au bilayer as a template. Even though complicated multi-step 
processes and specialist resources are required in the production of a large 
quantity of master microneedles, the production of a single master is economical 
and time saving when considering the transferability in creating inverse micromould 
microneedles (Kim et al., 2009, 2012b).  
 
2.2.2  Fabrication of microneedles from moulds 
Microneedles have been manufactured from micromoulds that are non-
interconnecting micro-well structures (Ryu et al., 2007). There is a lack of 
publications that outline the micro-moulding fabrication processes methodically. 
However, the manufacturing processes of casting and hot embossing are common 
for microneedles and are now discussed briefly. In the casting process, a master 
template is fabricated to develop a mould template for a molten drug formula to fill 
the mould contours, solidify under favourable temperature and pressure conditions 
and finally removal of the mould from the solidified drug formula (Bariya et al., 
2011). Polydimethylsiloxane (PDMS) is an ideal material for replica moulding of 
microneedles because of its non-toxicity, elastic properties and low cost 
(Saliterman., 2006; Lee and Lee, 2008) and, as such, it has been used in many 
studies. Laser ablation by focusing a CO2 laser was used to create conical shaped 
voids in PDMS material moulds for vacuum setting NaCMC and polyacrylamide 
solution into solid microneedles (Kim et al., 2009). In another study, a pre-fabricated 
PDMS mould was used to vacuum set PLGA microneedles containing hydrogels 
(Kim et al., 2012b). PLGA is composed of D,L-polylactic acid (PLLA) and 
polyglycolic acid (PGA) monomers (Gabor et al., 1999; Danhier et al., 2012). As a 
biocompatible polymer, PLGA is used in biotechnology for the goal of preparing 
microneedles and scaffolds in tissue engineering (Lee et al., 2004). It has been 
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argued that PLGA with low molecular weights of less than 50 kDa and a D,L-
lactide/GA ratio of 50:50 are the most suitable for controlled drug release with 
respect to faster degradation rates (Fredenberg et al., 2011; Mundargi et al., 2008). 
PLGA in the context of merchandise is commercially and readily available from 
many suppliers. Stages in a typical casting process (Figure 2.4a; Chu et al., 2010) 
start with a PDMS mould (step 1), pre-fabricated from a PDMS male master coated 
with gold, and the mould is filled with sulforhodamine B (step 2). The residual drug 
solution is pipette extracted half way to be reused later (step 3) and the remaining 
drug solution in the mould crevice is dried by centrifugation. The PVA/PVP blend 
devoid of drug is casted into the mould by vacuum pressure (step 4), the combined 
polymer is air dried or is centrifuged at a low speed in drying (step 5) and an 
adhesive backing is used to prise the formed polymer microneedles from the PDMS 
mould (step 6). 
 
 
 
 
 
 
 
 
Figure 2.4: Stages in micromoulding of (a) PVP/PVA microneedles (Chu et al., 2010). (b) Stages 
in micromoulding of PLGA microneedles (Park et al., 2003) 
 
Another polymer system from PLGA, fabricated by Park et al. (2003) (Figure 2.4b) 
commenced with SU-8 substrate (step 1) by using the same PLGA polymer as a 
sacrificial filler on SU-8 (step 2) followed by copper coating deposition and acid 
etching to cover the SU-8 epoxy cylinders as a pattern (step 3) with subsequent 
a b 
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reactive ion etching to asymmetrically etch the tips of epoxy cylinders (step 4) and 
an inverse PDMS mould was created (step 5) with the prior master structure from 
reactive ion etching method before casting new PLGA microneedles as the final 
product (step 6) (Park et al., 2003). Advanced micro-molding components such as 
copper or SU-8 are either unavailable or very expensive in less industrialised 
geographical locations. A more economical method using a natural clay, Chinese 
purple ceramic mould was formed by hydraulic pressing a bed of steel sticks into 
the soft pliable clay before furnace heating, slow cooling followed by pouring a 
mixture of PVA, dextran and carboxymethylcellulose polymers into the mould then 
vacuum setting, freeze thawing and finally drying into microneedles (Yang et al., 
2012b). A less common fabrication technique, known as hot embossing, requires 
the application of heat above the glass transition temperature of the polymer 
product in contact with the mould followed by force to emboss the mould pattern to 
the polymer product and then cooling below the glass transition temperature before 
separation of mould and polymer product (Bodhale et al., 2009).  
 
PLLA is commercially and readily available from many chemical suppliers. It is 
similar to PLGA. PLLA microneedles were fabricated by a hot embossing technique 
through a multi-step process via a PDMS replication and then heating and 
pressuring the PDMS mould and PLLA grains followed by unmoulding at room 
temperature to obtain the microneedles (Han et al., 2009). A more efficient process 
was studied by Youn et al. (2008) by fabricating silicon moulds using focused ion 
beam and then pressing the silicon mould in poly-methylmethacrylate (PMMA) 
polymer under applied temperatures above the glass transition temperature of 
PMMA and pressure followed by slow cooling resulted in good reproducibility of 
replicated structures (Youn et al., 2008). Hot embossing appears only suitable for 
high temperature stable drugs in a biodegradable polymer vehicle as temperatures 
of over 100 ˚C are required. As a substantial number of microneedles are classed 
 Literature review 
 
17 
 
polymers, a supposedly third fabrication technique called investment moulding has 
been used suitably for hollow non-biodegradable polymers in which a drug solution 
flows through the hollow part of the microneedles into the skin (Lippmann, 2007; 
Lippmann and Pisano, 2006). Melt injection processes in investment moulding are 
suitable for thermoplastics because in adaptation of micromoulding, very high shear 
is required to allow for lower viscous melt and low resistant flow but heat generation 
can cause degradation of the drug formulation (Zhao et al., 2003). As mentioned 
earlier, currently there seems to be no lidocaine loaded biodegradable microneedle 
polymer systems published at present. Table 2.1 outlines the dissolvable or 
biodegradable materials as a vehicle for the drug and the method and conditions in 
manufacturing in-conjunction to significant dissolution or permeation results. 
 
Table 2.1: Fabricated MNs according to manufacture, dissolution and permeation of drug 
Microneedle 
materials 
Method of  
ma n u f a c t u r e 
Conditions and type of  
ma n u f a c t u r e  
Results of drug 
permeation or 
dissolution of vehicle 
Poly (lactic acid) 
(PLA), Poly (lactic-
co-glycolic acid) 
(PLGA; 50/50) and 
PEG unmixed initially 
(Park et al., 2007b). 
Casting with PDMS 
(Park et al., 2007b; 
Xiangdong et al, 2009) 
SU-8 photoresist 
master (Natarajan et 
al., 2008), gold coating 
o f  5 0 0 Ǻ . 
Ultrasound pulses to 
weld polymer micro-
particles within 
mould to create 
porous structure 
(Park et al., 2007b). 
Vacuum pressure 
and oven heating for 
microneedle static 
shaping (Park et al., 
2007b). 
No publication found. 
Silk fibroin from B. 
mori   cocoons (You 
et al., 2011).  
Epoxy microneedle 
master from X-ray 
lithography to produce 
female PDMS mould (You 
et al., 2011). Molten 
fibroin drug set into PDMS 
and mould removed (You 
et al., 2011). 
Oven drying and 
vacuum pressure for 
shaping and solidifying 
microneedles (You et 
al., 2011). 
Tetracyline loaded 
on silk MN. A 10 fold 
decrease in 
Staphylococcus 
aureus growth in 
nutrient culture at 
37˚C overnight 
(Tsioris et al., 2012). 
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Table 2.1: Continued 
Microneedle 
materials 
Method of  
ma n u f a c t u r e 
Conditions and type of  
ma n u f a c t u r e  
Results of drug 
permeation or 
dissolution of vehicle. 
Silk fibroin from B. 
mori   cocoons (You 
et al., 2011). 
Epoxy microneedle 
master from X-ray 
lithography to produce 
female PDMS mould (You 
et al., 2011). Molten 
fibroin drug set into PDMS 
and mould removed (You 
et al., 2011). 
Oven drying and 
vacuum pressure for 
shaping and solidifying 
microneedles (You et 
al., 2011). 
Tetracyline loaded 
on silk MN. A 10 fold 
decrease in 
Staphylococcus 
aureus growth in 
nutrient culture at 
37˚C overnight 
(Tsioris et al., 2012). 
Poly (methyl vinyl 
ether co-maleic acid) 
(Garland et al., 
2012). 
Blulase  laser cutting for 
fabricated silicone 
elastomer moulds using 
Aluminium template 
(Garland et al., 2012). 
40°C heat for curing 
mould and 
centrifugation at 3500 
g for 15 min and 
microneedles dried for 
24 h under ambient 
temperature (Garland 
et al., 2012). 
In vitro studies with 
Neonatal procine 
skin reported 59%, 
39% and 23% 
cumulative release of 
caffeine, lidocaine 
and metronidazole 
respectively for 
combined concoction 
microneedles were 
tested (Garland et 
al., 2012). 
20% (w/w) aqueous 
blends of co-polymer 
Gantrez® AN-139 
(Donnelly et al., 
2011). 
Galvanometer controlled 
excimer laser for variable 
height and interspacing of 
microneedle mould setup 
(Donnelly et al., 2011). 
 
Blulase  laser cutting for 
fabricated silicone 
elastomer moulds using 
Aluminium template 
(Donnelly et al., 2011). 
40°C heat for curing 
mould and 
centrifugation at 3500 
g for 15min and 
microneedles dried for 
24hrs under ambient 
temp. (Donnelly et al., 
2011). 
83% of the drug, 
theophylline, 
contained in 
microneedles, 
permeated past the 
skin compared to 
5.5% with patch 
delivery over a 24hr 
period (Donnelly et 
al., 2011) The 
percentage is out of 
total drug loaded.  
Trehalose/mannitol  
(50:50w/w), 
trehalose dihydrate/ 
sucrose (75:25w/w), 
trehalose/sucrose 
(75:25w/w) and 
trehalose/sucrose 
(50:50w/w) (Martin et 
al., 2012).  
PDMS mould created 
from wet etched silicon 
male master (Martin et al.,  
2012) 
1 h vacuum pressure 
of (100 mbar) at room 
temperature conditions 
followed by 48 h 
dehydration without 
vacuum (Martin et al., 
2012).  
Sugar glass 
microneedles 
containing 2% (w/w) 
methylene blue 
powder showed 
complete dissolution 
between 10 to 20 
minutes after 
insertion into full 
thickness human 
skin (Martin et al., 
2012). 
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Table 2.1: Continued 
Microneedle 
materials 
Method of  
ma n u f a c t u r e 
Conditions and type of  
ma n u f a c t u r e  
Results of drug 
permeation or 
dissolution of vehicle. 
Maltose mono-
hydrate (1 g/ml) in 
DI water (Lee et al., 
2011b). 
Stainless steel pillars and 
syringe pump to directly 
draw molten maltose into 
conical microneedles (Lee 
et al., 2011b). 
Axial drawing at 400 
μm/s for 1 s at 100 °C 
then 400 μm/s for 3 s at 
96 °C, cooling to 60 °C 
and separation from 
attached support pillars 
at 700 μm/s (Lee et al.,  
2011b). 
Optical micro-graphy 
showed complete 
dissolution of 
maltose micro-
needle containing 
sulfor-hodamine B in 
guinea pig skin after 
20 min (Lee et al.,  
2011b). 
Maltose (analytical 
grade) in water 
(Kolli and Banga, 
2008).  
Pre-fabricated inverse 
moulds formed by etching 
process (Texmac Inc). 
Direct pouring of molten 
maltose at 95 °C into 
mould within one minute 
and gradual cooling to 
55 °C to prise out the 
mould from shaped 
microneedles (Kolli and 
Banga. 2008; Miyano et 
al., 2005).  
Nicardipine- 
hydrochloride loaded 
maltose micro-
needles recorded a 
mean flux of 7.05 
μg/ml/h compared 
with control value of 
1.72 μg/ml/h (Kolli 
and Banga, 2008). 
 
2.2.2.1  Possible biomaterials for controlled lidocaine release from microneedles 
Lidocaine requires controlled release microneedles that allow for initial fast release 
into skin but reaches the desired plateau levels in which finite dosage is achieved. 
Therefore, the microneedles have to dissolve or disintegrate in the tissue fluids of 
physiological conditions at that site near the laceration before medics can treat the 
area by cleaning and suturing. 
 
Drug molecules directly suspended in a well mixed polymer microneedle matrix 
contribute to faster recorded time release than those encapsulated in 
microparticles, followed by suspension in a second matrix vehicle as it is a two 
stage release mechanism with outer matrix dissolving first. For example, the time of 
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drug release was 4 h when calcein was released directly from PLGA (85/15) 
compared with calcein in NaCMC followed by the outer core matrix, PLGA, in which 
a duration of 4 days’ release was observed (Garland et al., 2011; Park et al., 2006). 
The calcein was obtained commercially in the solid state from pre-processed 
moulds (Garland et al., 2011). The polymer and co-polymer monomeric ratios are 
influential in degradation for drug release. For example, single carbohydrate 
polymer PLLA dichloromethane solution with intrinsic viscosity value 2.38 dL/g was 
acquired commercially as a solid and processed into films (Loo et al., 2010). This 
resulted in significantly slower degradation by hydrolysis in the release of lidocaine 
as compared with PLGA (80:20) films which controlled the release of over 60 % 
cumulatively from initial loading of lidocaine in 40 days (Loo et al., 2010). PLGA 
50:50 microparticles loaded with lidocaine resulted in much faster controlled release 
of over 50 % from intial loading in 10 days (Klose et al., 2010). 
 
Lidocaine loaded PLGA would be highly suitable for relieving long duration 
symptoms of skin irritation and discomfort caused by illnesses such as postherpetic 
neuralgia, previously mentioned for commercially available lidoderm. PLLA’s 
starting monomer, L-lactic acid (LLA), is derived using lactic acid bacteria (Garlotta, 
2001; Roy et al., 1982). The distinct synthetic step in the production of PLLA is the 
condensation polymerisation of LLA in which ester linkages between LLA 
monomers are formed and water is the by product (Mehta et al., 2005; Garlotta, 
2001). PLGA is synthesized by the mechanism of structural ring opening 
polymerisation of DL-lactide and glycolide by catalysis from stannous 2-ethyl 
hexanoate in conjunction with a molecular weight regulating additive, 
triphenylsilanol with the overall objective of consistent chain length and reduction of 
side branch chains (Ouyang et al., 2011; Mazarro et al., 2009). Biodegradation in 
the context for polymers is the breakdown of a high molecular weight molecule into 
smaller components of low molecular weight molecules caused by enzymes from 
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microorganisms and/or environmental catalysts (Luckachan and Pillai, 2011; Wang 
et al., 2003). Table 2.2 provides a summary of biodegradable polymer systems with 
respect of morphological properties and biodegradation measurements while 
physiological conditions according to plasma fluid are kept constant. The overall 
trend for Table 2.2 shows that the degradation is faster for PLLA blends than PLLA 
itself. Also, it seems that PLGA 50:50 is much faster degrading than PLGA 75:25. 
 
Table 2.2: Polymer biodegradation and morphology according to physiological plasma fluid 
conditions 
Polymer Morphological properties Degradation studies in physiological 
conditions 
Poly–Ɛ-caprolactone 
(PCL). 
Injection moulded matrix, 
films and sheets via 
temperature settings 
(Wahit et al., 2012). 
General long term degradation from 
weeks to months (Dash and Konkimalla, 
2012). In vivo degradation cannot occur 
readily due to unavailability of desired 
enzymes and surface erosion caused by 
hydrolysis is the primary mechanism and 
the main reason for slow degradation of 
PCL (Ginde and Gupta, 1987; Woodruff 
and Hutmaker, 2010).  
PLLA. 200 micron and 20 micron 
films (Mattioli et al., 2012).  
5% weight loss by hydrolytic degradation 
after 49 days (Mattioli et al., 2012).  
Mixed mPEG5000–PSA 
and mPEG2000–PLLA 
(Lai et al., 2012). 
Spherical micelles with 
hydrophobic matrix and 
hydrophilic exterior layer 
(Lai et al., 2012). 
Degradation measured from calculation 
percentage release of curcumin in PBS. 
Burst release of curcumin near to 40%. 
Maximum 75% approximate release of 
curcumin on day 15 (Lai et al., 2012).  
P(LLA-co-ƐCL) and 
P(LLA-b-ƐCL) (Choi et 
al., 2002). 
P(LLA-co-ƐCL) (90/10) 
(Kalpan et al., 2007).  
 
PHCL-g-PLLA (Dai et al., 
2009). 
 
240 micon thickness films 
(Choi et al., 2002). 
Smooth surface 
Microspheres (Kalpan et 
al., 2007).  
 
Comb graft polymer films 
of 110 -120 microns (Dai 
et al., 2009). 
No degradation studies carried out at 
physiological conditions so far. 
60% decrease by hydrolytic degradation 
in molecular weight after 112 days 
(Kalpan et al., 2007).  
55% weight loss after 70 days (Dai et al., 
2009). 
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Table 2.2: Continued 
Polymer Morphological properties Degradation studies in 
physiological conditions 
PLGA. 
 
 
 
5600 micron diameter Sirolimus 
loaded films (Ro  et al., 2012). 
25% weight loss after 13 days 
for Sirolimus loaded PLGA 
50:50 (Ro et al., 2012). 
 
22% mass loss after 55 days 
for Sirolimus loaded PLGA 
75/25 (Ro et al., 2012). 
 
2.2.3  Tensile properties of polymeric microneedles 
Dissolvable/biodegradable microneedles require quality testing to determine the 
maximum direct force required on the base unit before fracturing or crumbling 
occurs from the tip to the body of the microneedles. Such a test can be done using 
an axial load testing station which relies on gradually moving the microneedles into 
a block of metals (e.g. aluminium) until needle breakages are evident (Bariya et al., 
2011). A measured section of the metal block contains a pre-determined thickness 
of skin attached by dual sticky tape and the other section of the block is connected 
to a compression cell containing microneedles and motorised actuator. The 
actuator provides a method for constant speed of microneedles insertion into the 
skin with the output measurement as force (Khanna et al., 2010). A number of 
components have been used to control tensile strength of dissolving microneedles 
as shown in Table 2.3. 
 
Table 2.3: Mechanical force properties of microneedle material and force test results of the 
microneedle system. 
Microneedle System Component with external force 
tolerance 
Results of force tests  
PLA (Wang and Jeng, 2009). Injection grade PLA (Wang and 
Jeng. 2009). 
73.11% impact on structural due 
to melt temperature variable 
(Wang and Jeng, 2009). 
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Table 2.3: Continued 
 
 
 
Microneedle System Component with external 
force tolerance 
Results of force tests  
NIPAAm based hydrogel 
loaded into PLGA (Kim et al., 
2012). 
Mainly PLGA (Kim et al., 
2012). 
PLGA microneedles with 18% v/v 
hydrogel deformed less than the 
31% v/v hydrogel ones (Kim et al., 
2012). 
Sugar glass disaccharide 
mixture of two sugar 
components except xylitol 
(Martin et al., 2012). 
Similar molecular weight of 
two specific disaccharides 
that formed solid sugar 
(Martin et al., 2012). 
Qualitative skin penetration tests 
showed most microneedles 
penetrated skin and complete 
dissolution in skin after 10 minutes 
(Martin et al., 2012). 
PVP, PLGA, PVA (Ke et al., 
2012). 
PVP (10000 MW) (Ke et al., 
2012). 
Microneedles fabricated with 600 
mg/ml and 1000 mg/ml PVP were 
robust as confirmed from SEM 
images after insertion. The latter 
PVP concentration showed no 
geometric change (Ke et al., 2012). 
PVP, PVP-MAA poly(vinyl 
pyrrolidone-co-methacrylic 
acid (Sullivan et al., 2008). 
PVP (8970 MW), MAA 
(Sullivan et al., 2008). 
Displacement force tests proved 
that 1% MAA in PVP-MAA 
contributed to nearly double the 
strength of PVP alone (Sullivan et 
al., 2008). 
PVA/PVP blends (Chu et al., 
2010). 
PVA (2000 MW) (Chu et 
al., 2010). 
Qualitative skin penetration tests 
showed 80% of microneedle tips of 
length 450 μm dissolved in porcine 
skin after 2 minutes with bright field 
microscopy (Chu et al., 2010). 
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2.3 Application of natural polymers for TDD 
Polymers are used extensively in TDD drug delivery systems. They control the rate 
of drug release from the device, act as primary packaging parts, coatings, 
penetration enhancers and provide ease in drug device handling and structural 
support to the device in the form of a backing layer. Their unique properties make 
them ubiquitous component of TDD patches. As petrochemical based resources for 
the production of synthetic polymers can potentially cause environmental problems; 
such resources are in short supply and the production of TDD delivery device 
components from more readily available natural polymers becomes eminent.  
 
Polymers have been in use in TDD delivery as far back as the 1980s. Polymers are 
used more extensively in TD than any other material as they possess unique 
properties which are significant to the drug delivery process (Kim, 1996). They are 
effective in aiding the control of drug release from carrier formulations (Cleary, 
1993). Natural polymers are a preferable option in TDD as they are readily 
available, inexpensive, potentially biodegradable and biocompatible and can 
undergo various chemical and surface modifications to fit the requirement of the 
TDD system. A TDD system comprises of a combination of one or more polymers 
and an embedded drug to be delivered into or through the skin in a controlled and 
sustained manner (Tojo, 2005). 
 
Polymers used for TDD systems are required to be chemically inert and pure 
according to high analytical product yields. It should also possess adequate 
physical properties which correspond with the intended application. The material 
must not age easily and be suitable for processing. Furthermore biodegradability 
and safety are paramount properties in the design of a TD patch system due to the 
long term exposure of the skin in contact withto the patch (Pietrzak et al., 1997; 
Sonia and Sharma, 2012). 
 Literature review 
 
25 
 
  2.4  Hydrogel based drug delivery systems 
The need in optimised semi-solid, biocompatible, polymeric formulations in drug 
loading and routes of entry in the human body is still a growing area in 
pharmaceutics. Gel and ointment based drug formulations are normally oily and 
thick in appearance (Mueller et al., 2012). A common purpose of such semi-solid, 
polymeric gel/ointment formulations are to enhance the viscoelasticity 
(Teeranachaideekul et al., 2008; Silva et al., 2007) and improve target based 
pharmacokinetics such as enhanced permeability of luteinizing hormone releasing 
hormone (LH-RH) from polycarbophil hydrogels inside the vagina compared with 
solution (Valenta, 2005). Hydrogels can be considered as a semisolid matrix for the 
purpose of controlled drug release (Jacobs, 2014; York, 1996). A hydrogel is a solid 
or semi-solid hydrophilic matrix comprising of polymeric macromolecules cross-
linked by varying combinations of hydrogen bonding, Van der Waals, ionic 
electrostatic based and covalent based intermolecular interactions (Laftah et al., 
2011; Huang et al., 2007). Hydrogels can change structural configuration during 
certain temperature or pH induced environments in bodily systems (Cai et al., 2013; 
Nguyen and Lee, 2010). Usually hydrogels are known to release trapped drug 
molecules by swelling in watery plasma solvent (Li et al., 2014). A growing demand 
for hydrogel based drug delivery since 1980 onwards shows increasing treads 
(Figure 2.5). 
 
This section focuses on hydrogels obtained from natural polymers. It outlines the 
structure and function of natural polymeric hydrogels in the area of Pharmaceutics 
based drug delivery. The distinct sub classification of a less common form of 
hydrogels, known as microgels, explains this difference. Also another area of this 
review focuses on the physico-chemical properties of hydrogels as a drug delivery 
system with ideal pharmacokinetic targeting areas. 
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Figure 2.5: The number of hydrogel drug publications according to year range (Web of Science) 
 
Hydrogels possess matrix swelling or shrinkage properties in physico-chemical 
solvent media such as pH, temperature and ionic strength of electrolytes in solution 
(Chang et al., 2010; Li et al., 2014). Usually solvent ion concentrations at medium 
ionic strengths allow for ion exchange between polyelectrolyte gel and solvent ions 
resulting in osmotic pressure increases inside hydrogel and thus causing swelling 
(Richter et al., 2008).  
 
The polymeric macromolecules in hydrogels can be cationic, anionic or entirely 
neutral with regards to interacting with another macromolecule or drug molecules 
(Van Vlierberghe et al., 2011; Singh and Lee, 2014). The control in the polymeric 
swelling release rates of drugs with possible subsequent degradation of hydrogels 
is very much a sought after challenge in matching the duration of drug release 
across a therapeutic range and target specificity in the body. There are constraints 
and possible major limitations in stabilising porous combination of polymers in 
defined mass ratios in attaining desirable controlled release of drug molecules. 
However the complex chemical structures of hydrogels can pose challenges in 
synthesis coupled with mass reproducibility and end product purification (Martín del 
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Valle et al., 2009). Although synthetic polymers seem to have largely dominated 
over natural polymers in the past decade due to their relatively long service life, 
high water absorption capacity and gel strength and the possibility of tailored 
degradation and functionality, natural polymers are highly sort after for their 
biocompatibility, availability and low cost (Ahmed, 2015). Hydrogels from natural 
source usually require inclusion of synthetic components as, for example 
crosslinkers or the hydrogel could be a blend of both natural and synthetic polymers 
for improved functionality, degradation or biocompatibility (Kamoun et al., 2015).  
  
2.4.1  Polymeric crosslinking in hydrogels 
An important characteristic of a hydrogel is the polymeric strand crosslinking. 
Crosslinking of hydrogels with morphologically cross hatched or entangled 
macromolecular architecture allows a 3D structure and avoids immediate 
dissolution of separate macromolecular strands in hydrophilic solvent (Hennick and 
van Nostrum, 2012). The crosslinking of hydrogels combines highly desirable 
characteristics such as mechanical strength, pseudoplasticity, drug and 
macromolecular intermolecular interactions and plasma swelling (Zhao et al., 2014; 
Kurland et al., 2014). The macromolecule respresents a polymeric drug vehicle and 
chemical bonding interactions with specific drugs is just as important as release in 
skin stratra or plasma medium. The porosity of the crosslinked hydrogel matrix 
determines aqueous solvent adsorption and rate of drug release (Hoare and 
Kohane, 2008). However, the immiscibility of hydrogels swelling in water is 
attributed to the networking arrangement of crosslinks between polymer chains thus 
maintaining physical structure (Gupta et al., 2002). Physical crosslinking of 
polypeptides are attributed to ionic bonding, hydrogen bonding and hydrophobic 
interactions in aid of bi-polymeric crosslinking (Nonoyama et al., 2012; Hu et al., 
2010). Physically crosslinked hydrogels are inhomogeneous due to more than one 
type of intermolecular based interaction (Hoffman, 2002). Chemically crosslinked 
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hydrogels involve covalent linkages in bridging two different polymeric strands and 
the use of crosslinking agents that can react with specific functional groups in 
polymeric macromolecules (Hennick and van Nostrum, 2012). Chemically 
crosslinked hydrogels permit bigger volume increases during sol-gel transition than 
physically crosslinked hydrogels (Jonker et al., 2012). The use of chemical 
crosslinking agents to bind specific functional groups for crosslinking polymers is 
shown in Table 2.4. The process and target application of hydrogel and microgel 
polymers is outlined in Table 2.5. 
 
Table 2.4: Chemical agents for the chemical crosslinking of functional groups in hydrogels. 
Crosslinker 
 
Functional 
groups 
Reaction or functional 
group interactions 
Chemical reaction conditions 
Glutaraldehyde 
(Berger et al., 2004; 
Costa-Júnior et al., 
2009). 
di-aldehydes 
(Berger et al., 
2004). 
Imine group formed by 
Schiff base formation. 
(Berger et al., 2004; 
Costa-Júnior et al., 
2009). Acetal group 
formation from hydroxyl 
groups (Costa-Júnior et 
al., 2009). 
No heat required and slow 
addition is usual (Costa-Júnior 
et al., 2009). 
Poly(ethylene 
glycol)–propion 
dialdehyde (PEG–
diald) (Luo et al., 
2000). 
Amine (Luo et 
al., 2000). 
Azide addition (Luo et 
al., 2000). 
Unimolecular addition of PEG-
diald and polymer in ambient 
temperature conditions (Luo et 
al., 2000).  
methylene 
bis-acrylamide 
(Berger et al., 
2004). 
acrylamide, 
ethylene (Berger 
et al., 2004; 
Bhattacharyya 
and Ray, 2014). 
Variable (Berger et al., 
2004). 
Hydrophobic and therefore 
solubility in water is low (Yang 
et al., 2012a). 
Genipin (Song et 
al., 2009; 
Muzzarelli, 2009). 
Amino acid 
groups and 
secondary 
amino group in 
acidic and 
neutral pH 
(Muzzarelli, 
2009). 
Amino acid groups 
(Song et al., 2009). 
Condensation reactions 
in acidic or neutral 
conditions and aldol 
condensation in basic 
conditions (Muzzarelli, 
2009). 
Set pH conditions (Muzzarelli, 
2009).  
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Table 2.5: Recent examples of hydrogels developed in drug delivery.  
Polymer Composition  Process Target/ 
delivery 
Reference(s) 
Casein. 100 %. Temperature based 
gelation. 
Bovine Serum 
Albumin 
molecule into 
buffered 
solution. 
Song et al. 
(2009). 
poly(N-isopropyl-
acrylamide- 
co-Acrylamide)  
poly(NIPAAm-co- 
AAm). 
NIPAAm and 
AAm, 
83.3:16.7 (% 
mol ratio). 
Poly(NIPAAm-co-AAm) 
synthesis: free radical 
copolymerisation with 
AIBN initiator. Micro-
sphere process: W/O 
emulsification and 
copolymer solubilised 
by acidic DI water and 
crosslinking using 
glutaraldehyde. 
Propranolol and 
Lidocaine. 
Fundueanu 
et al. (2009). 
Alginate (Monomer 
unit: 1,4-linked b-D-
mannuronic 
acid and a-L-
guluronic acid). 
Methacrylated 
alginate (5.7 
to 45.3 %). 
Photocrosslinking of 
methacrylated alginate 
at 365 nm and 0.05 % 
w/v Irgacure D-2959 
photo initiator. 
 
Bovine 
chondrocytes for 
cytocompatiblity 
for cell culture.   
Jeon et al. 
(2009). 
NaCMC:Cellulose 
(Cell). 
NaCMC:cell 
(5:5 to 9:1 by 
wt). A 
hydrogel film. 
Solubilisation of Cell 
and NaCMC and 
crosslinking with 
Epichlorohydrin (ECH).  
In vitro release 
of Bovine Serum 
Albumin. 
Chang et al. 
(2010). 
poly(ethylene oxide)-
poly(propylene 
oxide)-poly(ethylene 
oxide) (PF127) and 
Poly(methy vinyl 
ether-co-maleic 
anhydride) (GZ).  
GZm/PF127 
molar ratio 
from 1 to 20. 
(GZm is the 
monomer,  
methy vinyl 
ether-co-
maleic 
anhydride). 
Esterification between 
carboxyl groups of 
maleic anhydride and 
hydroxyl groups of 
PF127. Subsequent 
solvent evapor- ation of 
tetra- hydrofuran 
followed by precipitate 
copolymer filtration and 
collection.   
Bovine Serum 
Albumin,    
glucoprotein 
rKPM-11 and 
Dextran in PBS 
(pH 7.4). 
Moreno et al. 
(2014). 
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2.4.2  Natural polymers in hydrogels 
Polysaccharides such as hyaluronic acid, chondroitin sulfate, chitosan, carboxy-
methylcellulose, hydroxypropylmethylcellulose, methycellulose, bacterial cellulose 
and sodium alginate are common examples of carbohydrate derived polymers in 
hydrogels (Van Vlierberghe et al., 2011). Examples of proteins used in hydrogels 
include gelatine, collagen, elastin, ovalbumin, β-lactoglobulin and silk fibroin from 
both plant and animal sources (Jonker et al., 2012). Polymer strands from natural, 
synthetic and partially synthetic sources are acquired as drug delivery vehicles 
(Gupta et al., 2002). 
 
Cellulose is a highly abundant natural polymer in plants, bacteria, algae and fungi 
phylum. The unbranched chains consist of 1,4 glycosidic linkage of monomer units, 
D-glucopyranose (DGP) and presence of three hydroxyl groups per DGP monomer 
(Kamel et al., 2008; Carter Fox et al., 2011). NaCMC is a cellulose derived water 
soluble polymer (Venkata Prasad et al., 2011). NaCMC is grossly anionic because 
of the negative electron density with respect to the carboxymethyl substitution 
region. Hence, polyanionic NaCMC has the potential to electrostatically interact with 
gelatine below its isoelectric point (Devi and Kumar, 2009). NaCMC and gelatine 
are biocompatible as NaCMC is biologically excreted and gelatine is degraded by 
natural enzymes (Rathna and Chatterji, 2003). NaCMC is able to hydrogen bond 
with water molecules hence hydrogel NaCMC crosslinked gelatine possesses 
swelling properties which is reported by Tataru et al. (2011). Individual polymers of 
NaCMC and gelatine have the tendency to swell in ambient temperature water. As 
far as we know there is no published literature comparing swelling rates of 
individual NaCMC and gelatine with post bi-polymeric NaCMC/gelatine microgel. 
Ionic interactions are dominant intermolecular forces in crosslinking polyanionic 
NaCMC with polycationic polymers such as polyvinylamine (PVAm) (Chang and 
Zhang, 2011). The degree of substitution defines this structure when hydroxyl 
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groups in the glycopyranose monomer are replaced with carboxymethyl groups in 
which the number of substituted hydroxyls accounts to the degree of substitution 
(Rokhade et al, 2006). The higher the degree of substitution and quite significantly 
the lower the MW of NaCMC allows for increased in ionic conductivity (Lee and Oh, 
2013). The discharge capacity of NaCMC (0.9 degree of substitution and 250 kDa) 
upto 0.5 current density (C-rate) was 165mAh g-1 compared with NaCMC (0.9 
degree of substitution and 700 kDa) at 155mAh g-1 (Lee and Oh, 2013). 
Potentiometric titration with hydrochloric acid as a carboxylate proton donor coupled 
with Infrared spectroscopy in knowing the relative amount of carboxyl groups is 
implemented in calculating degree of substitution (Pushpamalar et al., 2006). 
 
2.4.3  Preparation techniques of hydrogels 
There are numerous engineering techniques for the preparation of natural 
hydrogels. Natural polymers such as gelatin, κ-carrageenan, agarose and gellan 
gum in hot solutions undergo random coil to helix transitions with the support of 
ionic salts such as Na+ which lowers the repulsive forces between same 
electrostatic charges, allowing ionic interaction and the polymeric crosslinking to 
occur (Figure 2.6) (Coutinho et al., 2010; Gulrez et al., 2011).  
 
 
 
 
 
 
 
Figure 2.6: Illustration of random coil to helical transition of anionic, natural polymers, eg. gellan 
gum during the cooling of a hot polymeric solution 
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A process known as complex coacervation involves the electrostatic attraction of 
oppositely charged polyelectrolytes such as precipitate or gel in solution because of 
change of factors such as pH, ionic strength and polymeric mass ratios (Jin and 
Kim, 2008; Hoffman, 2002). An alginate/β-lactoglobulin lipid droplets contained in 
hydrogel matrices were complex coacervated with alginate (-NH3+) and cationic 
chitosan (-COO-) at acidic pH ranges of 3.5 to 6.5 in the formation of beads for 
gastrointestinal active molecule delivery (Li and McClements, 2011). An example of 
a complex coacervate bi-polymer is NaCMC and gelatine in the formation of a 
complex coacervate. 
 
2.5 Mathemathatical description of percutaneous based pharmacokinetics in targeting 
the viable epidermis layer 
Fick’s law of diffusion for molecules is applicable in calculating a concentration 
gradient from a high concentration area to a concentration low area. The diffusion 
of molecules across a gradient concentration from a planar surface is outlined from 
Fick’s 2nd law (equation 2.1) (Brazel and Peppas, 2000; Lin and Metters, 2006). 
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
=  𝜕𝜕
𝜕𝜕𝜕𝜕
�𝐷𝐷
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
�                                                                                     (2.1) 
Equation 2.1 is a one dimensional, non-steady state, concentration dependent 
diffusion coefficient. Also equation 2.1 is suitable for a drug system consisting of 
drug molecules uniformly distributed in the matrix vehicle. The conditions in order to 
solve the equation according to initial drug distribution and diffusion conditions of 
delivery system boundary, the boundary conditions are defined as: 
 
At t=0, c(x,t) = C0                                                              (2.1.1) 
At x = δ(t), C = Cb                                                                                                (2.1.2) 
At x=0, δc/δx = 0                                                              (2.1.3) 
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C0 is the uniform, initial drug molecule concentration (equation 2.1.1), δ(t) is the 
drug molecule distance from the centre to the surface which increases when the 
hydrogel swells (equation 2.1.2), Cb is the bulk loading concentration of the drug in 
the polymeric surface (equation 2.1.2), it is 0 in perfect sink conditions and x is axial 
plane for drug diffusion (equation 2.1.3). The pharmacokinetics in the permeation of 
drugs past the SC layer when a reservoir drug system is adopted requires 
computation using Fick’s 1st law of diffusion (equation 2.2) (Couto et al., 2014; Lin 
and Metters, 2006).  
𝐽𝐽 =  −𝐷𝐷𝑚𝑚 𝑑𝑑𝑑𝑑𝑑𝑑𝜕𝜕                                                                                            (2.2) 
Where J is the drug diffusion flux, C is the drug concentration, x is the thickness of 
membrane and Dm is the membrane drug diffusion coefficient. The steady state flux 
of active molecules between vehicle and a skin layer across a concentration 
gradient mapping one compartment model defined by Fick’s 1st law (equation 2.2.1) 
(Scheuplein et al., 1969; Couto et al., 2014).  
𝐽𝐽𝑠𝑠 = 𝑘𝑘𝑝𝑝∆𝑑𝑑𝑣𝑣𝑠𝑠 =  𝐾𝐾𝐷𝐷𝑚𝑚∆𝐶𝐶𝑣𝑣𝑣𝑣𝐿𝐿                                                               (2.2.1) 
Where Js is the steady state diffusion coefficient, kp is the permeability coefficient 
comprising of three individual parameters, ΔCvs is the drug concentration gradient 
between vehicle and skin and K is the partition coefficient between drug and skin. 
For simplicity sake, the VE and Upper dermis will be referred to as VE here and the 
amount of drug detected can be quantified when the scaler unit of time is outlined in 
the main equation (2.3).  
𝑄𝑄 = 𝐷𝐷𝑚𝑚 𝐴𝐴𝐿𝐿 𝜕𝜕∆𝑑𝑑𝑣𝑣𝑠𝑠                                                                      (2.3) 
Where Dm is the diffusion coefficient of a skin layer, Q is the amount of active 
molecule, A is the skin surface area, t is the time taken for a particular skin path 
length travelled L. 
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2.6 Chapter summary 
Although a number of lidocaine based TD products can be found in the market 
there is a large gap for lidocaine microneedle products, especially biodegradable 
microneedles. This implies that considerable amount of new research is required at 
the developmental and pre-clinical setting in order to achieve the desired controlled 
release of lidocaine into skin and maintain a steady drug concentration for a short 
duration of time for the purpose of superficial suturing of a cut. A biodegradable 
lidocaine microneedle system formulated from carboxymethylcellulose 
demonstrated the increase in pharmacokinetic permeation flux, thus highlighting 
further interest in research of other biodegradable materials as drug vehicles for 
lidocaine with the aim of achieving faster permeation kinetics in skin with the 
general idea of a minimal delayed therapeutic action. Also, the development of 
lidocaine microneedles may provide a scope for a cheaper product as compared 
with current EMLA formulations containing lidocaine in which a second local 
anaesthetic, prilocaine add to the material costs. Manufacturing of biodegradable 
microneedles via a casting process with usage of SU-8 or PDMS moulds is 
economical mainly because these moulds can be reused numerous times in mass 
production of biodegradable microneedles. The mechanical penetration strengths 
are a highly important physical challenge seen in biodegradable microneedles. Not 
only is a sharp tip of microneedle necessary for cutting through skin but the casted, 
dissolvable material requires adequate resistant to compression forces that mimic 
finger or thumb pressures. Dissolvable materials with soft solid or brittle physical 
properties require mucoadhesive co-polymer agents, such as PVA or PVP, in the 
mixture to provide for mechanical strength. 
 
Natural polymers are very much taken as a substitute to synthetic based 
petrochemical products because of an environmentally friendly impact. The main 
criteria is to match the structure with function inconjunction to ideal reproducible 
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pharmcokinetics in order enhance drug specificity in targeting the disease in a 
biological system. Nevertheless synthetic petrochemical products cannot be 
completely removed in the fabrication of certain drug vehicles eg. transdermal 
patches. This is because certain desirable properties from synthetic products are 
not observed in common natural polymers hence the adaptation of blended 
polymeric vehicles. Such petrochemical products can be treated as additives as 
long as low amounts are permitted to form the polymeric blend.  
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Chapter 3 
Microneedle-assisted permeation of lidocaine carboxymethyl-
cellulose with gelatine co-polymer hydrogel 
 
Chapter overview 
Lidocaine was formulated in NaCMC/gelatine hydrogel and a ‘poke and patch’ 
microneedle delivery method was used to enhance the skin permeation rates and 
flux parameter of lidocaine. The microparticles were formed by electrostatic 
interactions between NaCMC and gelatine macromolecules within a water/oil 
emulsion in paraffin oil and the covalent crosslinking was supported by additional 
organic molecules, glutaraldehyde. The gelatine to NaCMC mass ratio was varied 
between 1.6 and 2.7. The lidocaine encapsulation yield in the hydrogel formulation 
was 1.2 to 7% w/w. Lidocaine NaCMC/gelatine hydrogels was assessed for 
encapsulation efficiency, Zeta potential, mean particle size and morphology. 
Subsequent in vitro skin permeation studies were performed via PD and 
microneedle assisted permeation of lidocaine NaCMC/gelatine to determine the 
maximum permeation rate through full thickness skin. Lidocaine 2.4% w/w 
NaCMC/gelatine 1:1.6 and 1:2.3 respectively, possessed optimum Zeta potential. 
Lidocaine 2.4% w/w NaCMC/gelatine 1:2.3 and 1:2.7 demonstrates higher 
pseudoplastic behaviour. Encapsulation efficiency (14.9–17.2%) was similar for 
lidocaine 2.4% w/w NaCMC/gelatine 1:1.6–1:2.3. Microneedle assisted permeation 
flux was optimum for lidocaine 2.4% w/w NaCMC/gelatine 1:2.3 at 6.1 μg/ml/h. 
Lidocaine 2.4% w/w NaCMC/gelatine 1:2.3 crossed the minimum therapeutic drug 
threshold with microneedle skin permeation in less than 70 min. 
 
3.1 Introduction 
The delivery of local anaesthesia to lacerated skin regions remains a major 
challenge for injectable and ointment drugs (Smith and Wilson, 2013). For example, 
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the subcutaneous injection delivery of local anaesthetics, specifically lidocaine is 
clinically reported to cause a burning type feeling when infused directly into the 
skin. Also, lidocaine requires additional active drug molecules in an ointment 
formulation to compete with injectable lidocaine (Smith and Wilson, 2013; Hogan et 
al., 2011; Capellan and Hollander, 2003). A bolus dosage of lidocaine by injection is 
suitable for short duration of action (Smith and Wilson, 2013; Hogan et al., 2011; 
Capellan and Hollander, 2003; Bekhit, 2011). However, the treatment of multiple 
lacerations in skin may need co-drugs such as epineprine to aid longer time for 
lidocaine action, which may be ineffective due to a shorter sustained subcutaneous 
infiltration or simply a second bolus injection after the first lag time (Bekhit, 2011; 
Chale et al., 2006; Pregerson, 2007). Lidocaine’s characteristic amide functional 
group (Braga et al., 2013) and its weak base molecule (pKa 7.7) with a lipophilic 
function while permeating through biological membranes is still a highly attributable 
choice of local anaesthesia since its first chemical synthesis in 1943 (Braga et al., 
2013; Conroy and O’ Rourke, 2013). Similarly, the protonated lidocaine is a weakly 
acidic, hydrophilic molecule which is easily soluble in water at ambient temperature. 
Injectable lidocaine solution in either the basic or acidic form shares the same local 
anaesthetic mechanism for the antagonism of nerve signals in cells by inhibiting the 
influx of sodium ions through the sodium channels of biological cell membranes 
resulting in a response to temporary pain blockage on the skin surface (Xia et al., 
2002; Cepeda et al., 2010; Columb and Ramsaran, 2010). Lidocaine is dependent 
on a drug vehicle as a support material with respect to viscoelastic bulking and 
balancing of the encapsulation efficiency with enhanced skin permeation 
pharmacokinetics. NaCMC polymer and gelatine co-polymer, according to a defined 
mass ratio are suitable candidates in mapping the crosslinking structure with the 
functional role of trapping lidocaine and with the goal for optimised skin. The aim of 
this chapter is to formulate an ideal gelatine to bipolymeric NaCMC mass ratio with 
lidocaine before determining promising permeation trends for skin based delivery. 
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NaCMC/gelatine microparticulates form covalent linkages between NaCMC’s 
hydroxyl group lactonisation with the aldehyde of glutaraldehyde’s –CHO group in 
the formation of ether bonds under low pH conditions (Buhus et al., 2009) (Figure 
3.1a). A schiff base association between glutaraldehyde and gelatine is formed by 
covalent linkage in minimising ionic dissociation between NaCMC with gelatine in 
neutral media (Buhus et al., 2009; Mu et al., 2012) (Figure 3.1a). Also, ionic 
interactions occur between polyanionic NaCMC, glycine and proline amino acids of 
a polycationic gelatine and cationic lidocaine with the effect of charge neutralisation 
(Becker and Reed, 2012; Alvarez-Lorenzo et al., 2013) (Figure 3.1b). Overall, this 
process forms a pH sensitive hydrogel network of NaCMC intertwined with gelatine 
crosslinks for trapping active molecules such as lidocaine (Hoare and Kohane, 
2008; Matricardi et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: (a) Crosslinking between NaCMC and gelatine via ether bonds between 
NaCMC and glutaraldehyde and schiff’s base C=N linkage between glutaraldehyde and 
proline of gelatine. R1, R2, R3 are repeating monomeric units of each polymer. (b) Ionic 
interactions between NaCMC, proline of gelatine and lidocaine. R1, R2, R3 are repeating 
monomeric units of each polymer.  
Lidocaine 
gelatine 
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The most ideal pH for electrostatically crosslinking NaCMC with gelatine is at pH 
4.0 from the view point of Zeta potential analysis. The lidocaine NaCMC/gelatine 
vehicles are hydrogel microparticles because of pH sensitivity across a factor of 3.5 
which interrupts the electrostatic interactions, allowing the release of trapped drug 
molecules (Qiu and Park, 2012).  
 
The microparticles in lidocaine NaCMC/gelatine hydrogel alone cannot optimise 
skin permeation kinetics and a minimally invasive skin puncturing device is 
essential in aiding the optimisation of skin permeation kinetics. Recent advances in 
microneedle technology promises to resolve this issue and allow microneedle 
assisted lidocaine delivery from NaCMC/gelatine hydrogel. Microneedles are 
minimally invasive micron scale needles protruding perpendicularly from a laterally 
mounted platform. It is a painless method of micro-injection for not hitting pain 
receptors concentrated in the dermal layer of skin (Patel et al, 2011). The planar 
surface and geometrical properties of the MNs, and the texture of skin, which is 
relatively impermeable to large aqueous, active molecules and drug molecules in a 
bulk polymeric formulation, can increase permeation through the VE layer of skin 
via micro-channel cavities created by MNs (Al-Qallaf and Das, 2008; Henry et al., 
1998).  
 
Biomedical grade stainless steel is a suitable metallic alloy for MNs as it allows for 
fast and economical shape cutting to specific dimensions in-conjunction to retaining 
its highly desirable compressive strength properties (Henry et al., 1998; Donnelly et 
al., 2010). For example, we find that Type 304 stainless steel has been chosen to 
prepare MNs in some studies because of its biocompatibility and inherently good 
compressive and shear force properties (Davis et al, 2003). Recent advances in 
lidocaine delivery methods involved liquid crystalline polymeric MN arrays which 
successfully delivered 71% of lidocaine by mass using a coat and poke method with 
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a therapeutic level maintained for approximately 5 min (Zhang et al., 2012a). Solid 
MNs were also structured from solution components of lidocaine, mixed with 
sodium chondroitin sulfate and cellulose acetate as water soluble vehicles (Ito et 
al., 2013). Skin permeation analysis sustained a therapeutic threshold of lidocaine 
between 89 and 131 μg/g for an approximate duration of two and a half minutes 
before crossing the maximum therapeutic level pertaining toxicity greater than 131 
μg/g for over 10 min (Ito et al., 2013). A detailed review explaining the current 
material properties, fabrication process and pharmacokinetic delivery of lidocaine in 
polymeric microneedles are discussed in detail by Nayak and Das, 2013.  
 
The development of lidocaine NaCMC/gelatine hydrogel coupled with microneedle 
delivery via a ‘poke and patch’ method is a promising approach (Nayak and Das, 
2013). The approach requires no additional active co-drugs when formulated with 
NaCMC/gelatine polymeric mass ratios as the most abundant drug vehicle 
reagents. Co-drugs for lidocaine significantly add to the cost of the final product 
than NaCMC and gelatine vehicles in abundance. However, at the moment, there is 
little known about the significance of MN assisted permeation of lidocane from the 
micro-particles in NaCMC/gelatine hydrogel, and in particular, the relationship of the 
permeation kinetics with the geometrical parameters of MNs, e.g., the length of the 
MNs. In addressing these issues, this work aims to develop a lidocaine formulation 
in NaCMC/gelatine hydrogel and, explore, for the first time, a ‘poke and patch’ MN 
delivery method for the purpose of improved drug permeation rates and permeation 
flux of lidocaine.  
 
The overall goal is towards an optimised cumulative amount of lidocaine in watery 
plasma media, enhanced lidocaine permeation flux and encapsulation efficiency in-
conjunction with a sustained therapeutic permeation range transdermally of over 15 
min. As explained in detail previously, lidocaine, as a weak acid, can be bound 
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electrostatically within soluble drug vehicles consisting of crosslinked NaCMC and 
gelatine macromolecules. NaCMC, gelatine and glutaraldehyde are cheap, bio-
compatible and readily available compounds as potential drug formulas in 
constructing a carrier for lidocaine. Lidocaine molecules diffuse from the 
electrostatically formed microparticle to the surrounding DI water, analogous to the 
watery plasma of the VE layer of skin. The operation of the ‘poke and patch’ 
technique allows for lidocaine from hydrogel to permeate through microneedles 
formed holes on the skin and dissolve into the VE layer. The microparticles in the 
lidocaine NaCMC/gelatine hydrogel are hydrophilic in nature. A concentration 
gradient between lidocaine NaCMC/gelatine hydrogel and underlying watery 
plasma of skin allows for lidocaine to dissociate from NaCMC/gelatine hydrogel and 
associate as lidocaine into the neutral watery plasma. Skin permeating rates will be 
compared for PD and MN assisted diffusion of lidocaine NaCMC/gelatine 
hydrogels. 
 
3.2  Materials and methods 
A laboratory scale batch process for the formulation of lidocaine NaCMC/gelatine 
hydrogel is highly advantageous with respect to low heat treatment and quite 
efficient preparation times in reaching the desired product. Also laboratory scale 
processes are essential before devising new process control method plans on a 
pilot plant scale. A brief mention of pilot plant scale methods does not imply further 
objectives in this thesis. The high degree of carboxylate substitution of NaCMC of 
0.9 enhances the possibility of greater crosslinking with type A, i.e., high bloom 
gelatine. As explained in the introduction, the crosslinking is electrostatically 
achievable at pH 4. Lidocaine is a favourable drug molecule in association with 
NaCMC/gelatine at pH 4 for encapsulation purposes. The glutaraldehyde is 
necessary in defining spherical microparticles from water in oil (w/o) droplets. 
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3.2.1  Materials 
NaCMC (Degree of substitution: 0.9; MW: 250 kD), sorbitan monooleate (SPAN 80), 
glutaraldehyde (stock solution of 50% w/w), paraffin liquid (density: 0.859 g/ml), Lidocaine (MW: 
288.81 g/mol) and porcine gelatine (type A, Bloom 300) were purchased from Sigma Aldrich Ltd, 
Dorset, UK. Acetic acid (analytical grade), acetonitrile (HPLC grade), ammonium bicarbonate 
(analytical grade) and n-hexane (95% w/w) were purchased from Fisher Scientific Ltd, 
Loughborough, UK. DI water was the common solvent for aqueous solutions unless otherwise 
stated. 
 
3.2.2 Constant loading of drug lidocaine in hydrogel of different NaCMC/gelatine mass 
ratios 
The mass ratio of NaCMC/gelatine outlines one of the formulation characteristics in 
relation to lidocaine pharmacokinetics in this study. Therefore, different 
NaCMC/gelatine mass ratio polymers were encapsulated with a constant lidocaine 
dosage. The individual reagents/chemicals chosen for this purpose are represented 
in Table 3.1. The overall batch process for lidocaine NaCMC/gelatine hydrogels is 
outlined in Figure 3.2. A non-ionic surfactant, Span 80 (0.5% w/w), was dispersed 
dropwise in 100 ml of light paraffin oil, which was continuously stirred at 400 rpm in 
a rotating vessel (IKA-Werke, Staufen, Germany) until a slightly cloudy, 
homogeneous mixture was formed. NaCMC was observed to swell before 
dissolution in DI water. NaCMC was manually sheared and gently heated (~50˚C) in 
DI water in order to increase surface area of swollen NaCMC gelly like clumps and 
accelerate dissolution. Aqueous NaCMC (1.2% w/w) was then dispersed dropwise 
into the paraffin/surfactant mixture with shear induced at 400 rpm using the same 
rotating vessel followed by aqueous dropwise dispersion of gelatine (cG,% w/w) 
until a viscous w/o emulsion was formed (Table 3.1). Prior to gelatine dispersion, 
gelatine solid was gently heated (~60˚C) to accelerate dissolution until a clear 
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solution was observed. This gelatine solution was allowed to cool slightly in ambient 
room temperature to ~40˚C before dropwise dispersion.  
The variable mass percentage of the gelatine is denoted by the term cG. In the next 
step, the pH of the w/o mixture was decreased to pH 4 using acetic acid (∼1% 
w/w). Continuous gentle shear was induced so that the dispersed ionically charged 
droplets are detected by the pH electrode. The continuous oil component in a w/o 
immiscible mixture is non-ionic and therefore the pH is not registered. The chosen 
value, pH 4 was based on Zeta potential as discussed later in this chapter. 
Lidocaine (2.4% w/w) was then dispersed drop wise into the emulsion and cooled in 
a refrigerator (4–6ºC) for 30 min. The cooled lidocaine NaCMC/gelatine emulsion 
was agitated in a rotating vessel (IKA-Werke, Staufen, Germany) at 400 rpm to re-
suspend the emerging hydrogel microparticles before the drop wise addition of 
glutaraldehyde (0.1% w/w). The w/o droplets were transformed into microparticles 
by the glutaraldehyde and stirred at 1000 rpm for a duration of 2 h to ensure 
thorough mixing. The resultant lidocaine NaCMC/gelatine formulation was stored at 
2–4°C in a laboratory refrigerator (Liebherr-Great Britain Ltd, Biggleswade, UK) for 
a period of 4 hours to allow for the separation of residual paraffin liquid (organic 
layer) from a dense lidocaine NaCMC/gelatine formulation layer. The organic layer 
was cloudy in appearance as compared with the lower dense layer. After 
refrigeration, the organic layer was syringe removed. The refrigerated lidocaine was 
mixed with an organic solvent, n-hexane (50% v/v) for the subsequent removal of 
residual organic solvent. Any remaining residual organic solvent was oven dried 
under vacuum at 40°C to enhance solvent evaporation (Technico, Fistreem 
International Ltd, Loughborough, UK). Finally, any unbound lidocaine was removed 
through filter washing with DI water. The grade 3 filter (Whatman International Ltd, 
Oxon, UK) that was used for the formulation washing stage had an average pore 
size of 6 μm. The lidocaine NaCMC/gelatine hydrogels were collected in amber 
vials and characterised for PD and MN assisted skin permeation. 
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Figure 3.2: Batch processing of lidocaine NaCMC:gelatine hydrogel formulation 
 
Table 3.1: Composition of reagents used in formulating distinct lidocaine NaCMC/gelatine 
(NaCMC/G) hydrogels 
 
Drug Form-
ulation 
 
Lido-
caine 
HCl 
(% w/w) 
 
DI water 
 
 
(% w/w) 
 
cG 
 
 
(% w/w) 
 
Paraffin 
oil 
 
(% w/w) 
 
SPAN 
80 
 
(% w/w) 
 
Na-
CMC 
 
(% w/w) 
 
Acetic 
acid 
 
 
(~ %w/w) 
 
Glutar- 
alde- 
hyde 
 
 
(% w/w) 
 
Lidocaine 
NaCMC/G 
hydrogel 
 
2.4 
26.1 2.0  
 
66.7 
 
 
0.5 
 
 
1.2 
 
 
1.0 
 
 
0.1 
25.6 2.5 
25.3 2.8 
24.9 3.2 
 
 
4-6˚C,  
30 min 
2) Temp. 2-4˚C, 4 h 
50 % v/v 
n-hexane 
40˚C 
Vacuum 
x 3 washing 
with DI water 
Lidocaine HCl 
hydrogels 
1) Paraffin oil 
2) SPAN 80 
2) Gelatine            
(Cg %  w/w) 
pH 4.0 
Lidocaine HCl 
Glu (0.1% w/w) 
Mixing  ≤ 400rpm 
1) NaCMC  
     (1.2% w/w) 
1) Mixing: 1000rpm (2 h) 
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Table 3.1: Continued 
 
3.2.3  Different loading of drug lidocaine in hydrogel of constant NaCMC/gelatine mass 
ratio 
The plausible effect of varying lidocaine concentration on constant NaCMC/gelatine 
mass ratios is necessary in exploring significant changes in pseudoplasticity and 
microparticle dispersion. In this case, the preparation methods and conditions were 
replicated as those adopted for constant lidocaine encapsulation experiments 
described earlier. Also the outlined batch process was the same (Figure 3.2). 
However, on this occasion, the initial lidocaine concentration in the NaCMC/gelatine 
hydrogel was varied in the range 1.2–7.0% w/w prior to achieving a hydrogel of 
certain NaCMC/gelatine mass ratio. Lidocaine NaCMC/gelatine with 1:1.6 and 1:2.3 
mass ratios of microparticles were prepared to evaluate visco-elasticity and Zeta 
potential effects for a variable lidocaine encapsulated concentration (Table 3.1). 
 
Drug Form- 
ulation 
 
Lido-
caine 
HCl 
(% w/w) 
 
DI water 
 
 
(% w/w) 
 
cG 
 
 
(% w/w) 
 
Paraffin 
oil 
 
(% w/w) 
 
SPAN 
80 
 
(% w/w) 
 
Na-
CMC 
 
(% w/w) 
 
Acetic 
acid 
 
 
(~ %w/w) 
 
Glutar- 
alde- 
hyde 
 
 
(% w/w) 
Lidocaine 
NaCMC/G 
1:1.6 
hydrogel 
 
1.2 27.3  
 
2.0 
 
 
 
 
66.7 
 
 
 
 
0.5 
 
 
 
 
1.2 
 
 
 
 
1.0 
 
 
 
 
0.1 
2.4 26.1 
2.8 25.8 
7.0 21.5 
 
Lidocaine 
NaCMC/G  
1:2.3 
hydrogel  
1.2 26.5  
 
2.8 
2.4 25.3 
2.8 25.1 
7.0 20.7 
 
Unloaded 
NaCMC/G 
1:2.3 
hydrogel  
 
 
0 
 
27.7 2.8 
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3.2.4  The unloaded NaCMC/gelatine 1:2.3 mass ratio hydrogel 
The effect of varying pH on Zeta potential for unloaded NaCMC/gelatine 1:2.3 mass 
ratio hydrogel was used as a drug free control in this study to explore the ideal pH 
conditions for microparticle dispersion. Unencapsulated gelatine to NaCMC mass 
ratio of 2.3 for hydrogel microparticles, which were devoid of lidocaine were 
replicated from the same methods and conditions as for the constant lidocaine 
encapsulation to evaluate the Zeta potential effects (Table 3.1). 
 
3.2.5  In vitro permeation of lidocaine from NaCMC/gelatine microparticles 
An FDC for vitro skin permeation was used in exploring and understanding the 
pharmacokinetics of lidocaine prepared with different NaCMC/gelatine mass ratios. 
The FDC is a common method for TD permeation studies. It has two compartments 
which comprises of a donor (open cylinder lid) and a receptor. The skin sample is 
sandwiched between the two compartments (Kϋchler et al., 2013). The donor 
compartment represents the interface between the drug component and skin 
surface (Karadzovska et al., 2013). In particular, this research infers the receptor 
compartment is the interface between lower VE/upper dermis regions of porcine 
skin with deeper dermis layer of skin in the water plasma, receptor compartment 
(Karadzovska et al., 2013). In this work, MN assisted diffusion of lidocaine 
NaCMC/gelatine (Figure 3.3) were studied using full thickness porcine skin.  
 
All skin samples were excised from an ear auricle with approximate dimensions of 20.0 x 
20.0 x 0.73 mm which were acquired from 4 to 5 months old piglets and stored at −20.0°C. 
The procurement of swine auricles were confirmed to be pre−washed in plain water and 
purchased in a non-mutilated condition from swine cadaver. An approximate force of 0.57 N 
per array perpendicular to the base was directed on AdminPatch MNs (Nano-biosciences, 
Sunnyvale, CA, USA) pre-fabricated from stainless steel with arrow head geometry. 
                    
MN-assisted permeation of lidocaine carboxymethylcellulose with gelatine co-polymer hydrogel 
 
 
47 
 
MN assisted delivery                                        PD delivery 
 
Figure 3.3: Pathways for miconeedle assisted and PD studies of lidocaine 
NaCMC/gelatine on porcine skin via FDCs. Porcine skin was treated with microneedles 
before the addition of lidocaine NaCMC/gelatine (A) for FDC. The direct addition (B) of 
lidocaine NaCMC/gelatine is the start of the PD pathway. Sample lidocaine 
NaCMC/gelatine (C) added to skin undergoes FDC experimentation for both 
microneedle and PD delivery. The FDC receptor amount was removed and centrifuged 
(D). The supernatant removed was then analysed using liquid chromatography – diode 
array (LC-DA) (E). Inset is a stainless steel micrnoneedle array with needle aspect ratio 
of 1:4 and a tip to tip needle spacing of 1100 μm. 
 
The MNs were applied on the skin for a total duration of 5 min. This corresponds to 
the time duration we needed to pierce the skin without bending or damaging the 
MN. We wanted to ensure that each experiment with MN is conducted for a 
consistent time of application and thumb force. From our experiments (e.g, staining 
experiments) we found that it was necessary to apply the MNs for about 5 min on 
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the skin sample before we obtained detectable holes on the MN. Many MNs (e.g., 
those which are coated with drugs or biodegradable in nature) are designed to stay 
in the skin for longer duration (e.g., 30 min - 4 h) so that the drugs loaded on the 
MNs are released. This is not the case in this study and we apply the MNs for 5 min 
to create the holes on the skin. The force inducer supporting a flat based punch dye 
was lowered below the flat MN base before the application of forces was directed 
on the MN array by hand leverage. At the end of 5 min the applied force was 
released, the microneedle array was carefully removed and a constant mass of 
lidocaine formulation (0.10 ± 0.03 g) was placed on the skin. This technique is a two 
stage process commonly described as “poke and patch” (Van der Maaden et al., 
2012) where the “patch” in this context is the applied hydrogel formulation. 
 
 It is known that the penetration depth of the MNs is less than the actual MN 
lengths. Further, the penetration depth depends on the MN density on the patch, 
and other factors (e.g., tissue) remaining the same. From the histology of the skin 
with and without MNs, we observe that the lengths of the holes created by the MN 
are roughly about 50–60% of the actual MN length for normal thumb force applied 
in this work. PD studies (Figure 3.3) using lidocaine NaCMC/gelatine hydrogel were 
conducted on the adjacent section of the same square skin section of precisely the 
same average dimensions as previously stated. The same mass of formulation 
(0.10 ± 0.03 g) was placed onto the middle of the skin to conduct the PD studies. 
The FDC set up with a receptor compartment aperture area of 1.93 ± 0.0005 cm2 
was connected to an instrument module in supporting water circulation and 
magnetic stirring induction used in measuring the permeation kinetics of lidocaine 
through the skin. The SC layer in skin was facing the donor lid and the dermis layer 
was facing the receptor aperture. The skin surface which is part of the SC layer was 
exposed to a room temperature of 20°C. A stretchable parafilm seal (Fisher 
Scientific, Loughborough, UK) placed on the open aperture lid of the donor 
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compartment prevented air influx to the receptor compartment during syringe 
removal of DI water. The receptor compartment which has a volume of 5.3 ± 0.05 
ml contained DI water at 37.0°C stirred at 300 rpm to represent a well-mixed liquid. 
Unlike most clinical studies concerning physiological pH mimicked by PBS 
(Heilmann et al., 2013), this work used DI water with respect to mimicking watery 
plasma in the lower VE layer of skin. The use of DI water is consistent with 
developmental stage of in vitro skin permeation studies (Han and Das, 2013). A 
receptor volume (1.5 ± 0.05 ml) was syringe removed (Cole-Palmer, Hanwell, UK) 
at 30 min and subsequent 1 h intervals. This amount was put in a centrifuge vial 
and centrifuged (1300 rpm) for 6 min and the clear supernatant was pipetted out 
into 2 ml vials for LC-DA (Agilent technologies, Wokingham, UK) analysis of 
lidocaine concentration.  
 
All HPLC analyses were performed within 24 h of sample collection from the FDC 
receptor. The results were obtained in duplicate which were then used to determine 
average pharmacokinetic variables for further analysis. The permeation flux was 
calculated based on two data sets of mass ratio hydrogel formulations, plotted with 
error bars representing the random error at 90% confidence level. In this work, the 
in vitro permeation of lidocaine were interpreted by constructing a profile of 
cumulative amount of the drug against time as distinct charts in the section for both 
microneedle assisted and PD. A percentage adjustment of 28.0% was calculated 
from taking the 1.5 ml syringe removal volume as the numerator and the 5.3 ml 
receptor compartment volume as the denominator in obtaining a percentage from a 
fraction. This percentage adjustment (28.0%) from the previous dilution was added 
to the next detected concentration during a lapsed time period in obtaining a 
cumulative concentration profile. The cumulative concentration detected was 
interpreted into a more tangible parameter of cumulative amount permeated when 
taking into account of the receptor compartment’s distinct aperture. The cumulative 
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amount permeated (Q) was determined by equation (3.1) (Auner and Valenta, 
2004; Zhao et al., 2006) with coefficient, Cx, the lidocaine concentration in receiver 
compartment at the specific time (h), V is the volume of DI water in receptor 
compartment (ml) and A is the cross sectional diffusion area of receptor aperture 
(cm2). 
𝑄𝑄 =  𝑑𝑑𝑥𝑥𝑉𝑉
𝐴𝐴
                                                                                          (3.1)  
The flux permeation at steady state (Js) was determined by Fick’s first law using 
equation (3.2) with coefficients, Δm/Δt, the amount of drug permeating through the 
skin per incremental time at steady state (μg/h) (Kang et al., 2000; Poet and 
McDougal, 2002). 
𝐽𝐽𝑠𝑠 =  ∆𝑚𝑚𝐴𝐴∆𝜕𝜕                                                                                          (3.2) 
 
3.2.6  Analysis of particle size distribution 
The particle size distributions in the hydrogel were analysed using laser diffraction 
particle size analyser (Series 2000, Malvern Instruments, Malvern, UK). A sample 
hydrogel volume ̴ 10 ml was dispensed inside the instrument sample fask 
containing DI water (100 ml). Low shear was gradually increased and maintained 
upto a spped of 200 rpm. The instrument lasers were aligned and ready to take 
sample readings of the hydrogel. The data were obtained in duplicate per repeated 
hydrogel mass ratio sample via superimposition of data points and the particle size 
distributions were plotted as particle diameter against percentage particle volume. 
Particle diameters were compared at 10% (d10), 50% (d50) and 90% (d90) regions 
of total percentage particle volume. The refractive index of water as the continuous 
phase medium was adapted in determining hydrogel microparticle sizes for the 
particle size analyser. 
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3.2.7  Optical micrography of microparticles in lidocaine NaCMC/gelatine hydrogel 
The microparticles in lidocaine NaCMC/gelatine hydrogel are visible optically and 
the increasing mass of gelatine in the lidocaine NaCMC/gelatine hydrogel provides 
a significant trend in microparticle morphology. A sample volume of ~30 μl 
containing the microparticles of lidocaine NaCMC/gelatine hydrogel was pipetted 
onto a slide placed on the stage of an optical microscope (BX 43, Olympus, 
Southend-on-Sea, UK) which was used to obtain the micrographs. The micrograph 
scale was calibrated with a certified external slide graticule using Imagej. ImageJ is 
a Java based open source image processing and analysis program developed at 
the National Institute of Health (NIH), USA. 
 
3.2.8  Determination of lidocaine encapsulation efficiency (EE) 
The experimentally determined amount of lidocaine contained in a sample of 
NaCMC/gelatine micro-particles was interpreted in terms of encapsulation efficiency 
(EE). For the purpose of determining lidocaine EE, a sample weight (5.0%) of 
lidocaine NaCMC/gelatine microparticles from the overall lidocaine bipolymeric 
hydrogel batch was measured. DI water representing excess watery plasma (20.0 
ml ± 0.1 ml) was pipetted into the weighed lidocaine hydrogel sample and heated to 
37.0 ± 1°C in a pre-heated bath (Grant Instruments Ltd, Shepreth, UK). This sample 
was then sonicated using a vessel sonifier (Fisher Scientific, Loughborough, UK) at 
35 W for 10 min. It was then filtered using Nylon 6,6 membranes of 0.1 μm pore 
size (Posidyne membranes, Pall Corporation, Portsmouth, UK) under gentle 
vacuum using a Buchner filter setup (Fisher Scientific, Loughborough, UK). The 
filtrate was immediately dispensed into a HPLC vial of volume 1.5 ml. The HPLC 
results were obtained in triplicate which were then used to determine the mean 
percentage encapsulation efficiency by using equation 3.3 (Naidu and Paulson, 
2011; Al-Kahtani and Sherigara, 2009). 
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% EE =  actual 5.0% wt of lidocaine from polymeric ratio sample (g)5.0% theoritical encapulsaion wt of lidocaine (g)  x 100           (3.3) 
 
3.2.9  Zeta potential analysis 
The measurement of Zeta potential provides a valid indication for microparticle 
dispersion with respect to charged particle repulsion between microparticles, and as 
such, the Zeta potential of the microparticles was measured in this study. Ideal Zeta 
potential thresholds will be discussed in detail later. The Zeta potential of lidocaine 
loaded microparticles was measured using a Zetasizer (Malvern 3000 HAS, 
Malvern, Malvern, UK). The microparticles in the developed lidocaine 
NaCMC/gelatine hydrogel (2.0 ± 0.5 g/ml) diluted in DI water were injected into the 
sample port, temperature maintained at 20.0°C and the results were obtained in 
duplicate. Unloaded NaCMC/gelatine 1:2.3 mass ratio hydrogels without any 
lidocaine were also subject to Zeta potential analysis. Likewise, the temperature 
was maintained at 20.0°C and the results were obtained in duplicate. 
 
3.2.10  Measurement of viscosity 
The overall viscoelastic property of lidocaine NaCMC/gelatine hydrogel formulation 
requires investigation so as to maintain consistency of the formulation and since the 
rheological properties of the hydrogel affects its flow through the holes created by 
the MNs. In this case, we used a rotational viscometer (Haake VT 550, Thermo 
Fisher Inc, Massachusetts, USA) for determination of bulk (average) dynamic 
viscosity of the samples of lidocaine NaCMC/gelatine hydrogels (maximum volume 
25 ml). An NV cup and rotor segment (dimensions of length: 60 mm and radius: 
20.1 mm) with a gap of 0.35 mm was acquired after a brief qualitative observation 
of samples as a thick, semi-solid texture. The shear rate was ramped from 1 s-1 to 
200 s-1 and held constant at 200 s-1 for 30 s. The viscosity measurement 
experiments were carried out at ambient condition of 20°C. NaCMC/gelatine 
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hydrogel is not a thermoresponsive polymer, so the effects of viscosity against 
temperature at different, shear rates were not considered in this thesis. Rheological 
properties of the hydrogel in this thesis represent the normal condition for storage at 
ambient temperature and not the body temperature. 
 
3.2.11  Analysis of lidocaine concentration using HPLC 
Lidocaine concentrations were analysed by using HPLC. The mobile phases for 
eluting lidocaine were acetonitrile (HPLC grade) and 10 mM ammonium 
bicarbonate solution (pH 7.5), respectively, in an isocratic ratio of 50:50. The flow 
rate of 0.4ml/min and column temperature of 20.0°C (Perkin Elmer, Series 1100, 
Cambridgeshire, UK) was kept constant. Lidocaine molecule was detected by a 
diode array detector with the wavelength set at 210 nm (Agilent, Series 1100, 
Berkshire, UK). The system’s tube lines were purged after eluent degrassing with 
helium. The baseline corrections were performed before the injection of 5 μl of 
lidocaine standard and a characteristic peak was identified and recorded. Standard 
solutions of lidocaine HCl were prepared in ultrapure water with concentrations 
ranging from 1.0 to 64.0 μg/ml from a stock solution of 1.0 mg/ml. Each standard 
solution was analysed by HPLC in duplicate to obtain a linear profile of known 
concentration against mean area under curve of the integrated lidocaine peak. The 
HPLC column specifications are Gemini-NX 3 μm particle size of reverse phase, 
C18 compound composition and physical dimensions of 100 x 2 mm, which was 
purchased from Phenomenex, Cheshire, UK. The mean area under signal peak 
corresponding to serial standard concentrations for lidocaine (0.5–64.0 ppm) was 
plotted with a linear regression analysis (R2 = 0.999) which showed very good 
agreement with the data points. 
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3.3 Results 
Desirable trends and outlines of results are organised with subheadings concerning 
lidocaine NaCMC/gelatine hydrogel MN-assisted permeation of lidocaine 
formulation and pharmacokinetics of lidocaine permeation through the skin with 
relation to therapeutic levels. 
 
3.3.1  Encapsulation of lidocaine in NaCMC/gelatine microparticles 
The mean percentage of lidocaine encapsulated in the NaCMC/gel microparticles 
as a function of mass ratio of NaCMC to gelatine is plotted in Figure 3.4. Lidocaine 
2.4% w/w NaCMC/gelatine 1:2.7 mass ratio showed the highest encapsulation 
efficiency of 32% (SD = 1.2%) as compared with the microparticles of lower 
NaCMC/gelatine polymeric ratios. 
 
Figure 3.4: Percentage encapsulation efficiency of lidocaine in hydrogel particles as a 
function of NaCMC/gelatine (NaCMC/gel) mass ratio. The concentration of lidocaine in 
the initial emulsion was 2.4% w/w (Results represent arithmetic mean ± SD values 
based on data from there reproduced hydrogel samples per mass ratio).  
 
3.3.2  Viscoelasticity of lidocaine NaCMC/gelatine hydrogel 
The results in this work (Figure 3.5a) suggest that the increase in lidocaine 
concentration had no significant effect on the average dynamic viscosity of the 
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hydrogel. In particular, the data points after the shear rate of 100 s-1 outlined a 
single asymptote and they super imposed well (Figure 3.5a). The minimum dynamic 
viscosity of constantly encapsulated lidocaine NaCMC/gelatine hydrogels (Figure 
3.5b) from the shear range 100 to 200 s-1 asymptote is found to be 0.14 Pa.s for 
lidocaine NaCMC/gelatine 1:2.0 mass ratio, which may provide a low pseudo 
plasticity to the hydrogel. Within the shear range 100 to 200 s-1 asymptotes of 0.28 
and 0.31 Pa.s are found for lidocaine NaCMC/gelatine 1:2.3 and 1:2.7 mass ratios, 
respectively and they account for little difference in pseudo-plasticity. But a marked 
difference in pseudo-plasticity is observed when lidocaine NaCMC/gelatine 1:2.0 
mass ratio is compared with lidocaine NaCMC/gelatine 1:2.7 mass ratio (Figure 
3.5b). Substantially, there is no significant difference in shear thinning dynamic 
viscosity induced by a constant maximum shear of 200 s-1 when comparing 
lidocaine 2.4% w/w NaCMC/gelatine variable mass ratio hydrogels. This outlines 
very good reproducibility with SD of 0.02 for each lidociane NaCMC/gelatine 
hydrogel mass ratios (Figure 3.6).  
 
 
 
Figure 3.5: (continued to next page). 
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Figure 3.5: (a) Dynamic viscosity of lidocaine NaCMC/gelatine (NaCMC/GEL) hydrogels 
as a function of shear rate. (b) Dynamic viscosity of lidocaine 2.4 % w/w in 
NaCMC/gelatine hydrogels as a function of shear rate (Results represent data points 
from individual hydrogel samples per mass ratio). 
 
Figure 3.6: Constant shear induction (200 s-1) for lidocaine 2.4 % w/w NaCMC/gelatine 
(NaCMC:gel) hydrogel as a function of mass ratio NaCMC to gelatine (Results represent 
arithmetic mean ±SD values based on data from two reproduced hydrogel samples per mass 
ratio).  
b 
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3.3.3  Distribution of microparticles in lidocaine NaCMC/gelatine hydrogel 
The particle size distribution curves were noticeably similar for lidocaine 2.4% w/w 
NaCMC/gelatine 1:2.3 and 1:2.7 mass ratios with the same mean particle diameter 
of 140 μm (Figure 3.7) for each one. As found, the d10 values were 29 μm and 35 
μm for lidociane NaCMC/gelatine 1:2.3 and 1:2.7 mass ratios, respectively. Also, 
the d90 values were 305 μm and 277 μm for lidocaine NaCMC/gelatine 1:2.3 and 
1:2.7 mass ratios, respectively (Figure 3.7). The particle size distribution was 
considerably left skewed, less broad in describing the peak outline for lidocaine 
2.4% w/w NaCMC/gelatine 1:1.6 mass ratio with a mean particle diameter of 98.65 
μm where d10= 19.3 μm and d90 = 301.78 μm were recorded (Figure 3.7). 
 
Figure 3.7: Lidocaine 2.4 % (w/w) NaCMC/gelatine (NaCMC/GEL) particle size 
distribution as a function of mass ratio of the two polymers (Results represent 
superimposed data points of each repeated hydrogel sample from a total of six 
individual hydrogel samples). 
 
3.3.4  Zeta Potential of lidocaine NaCMC/gelatine mass ratio and pH effects in micro-
particles 
In developed microparticles, lidocaine loading ranges from 1.2–2.8% w/w for 
NaCMC/gelatine 1:1.6 mass ratio resulted in no significant change in Zeta potential 
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(SD=0.09) and showed excellent reproducibility in comparison to the high Zeta 
potential values and poor reproducibility of lidocaine 7.0% w/w NaCMC/gelatine 
1:1.6 mass ratio (SD=1.84) (Figure 3.8a).  
 
Lidocaine 2.4% w/w and 2.8% w/w, loaded each in NaCMC/gelatine 1:1.6 and 1:2.3 
mass ratios showed good reproducibility (SD=0.10 and SD=0.05 respectively) and 
desirably low Zeta potential values approaching −40 mV (Figure 3.8b). Lidocaine 
2.4% w/w NaCMC/gelatine 1:1.6 till 1:2.3 mass ratios provided desirably low Zeta 
potential values approaching -40 mV and good reproducibility (SD=0.76) compared 
with lidocaine NaCMC/gelatine 1:2.7 mass ratio in which the Zeta potential was 
undesirably high and, hence, agglomeration was more significant due to the high 
gelatine concentration (Figure 3.8c).  
 
The hydrogel microparticles may have unbound gelatine flocculating and diverting 
the innermost negative charge boundaries of defined lidocaine loaded 
NaCMC/gelatine microparticles. Lidocaine 2.4% and 2.8% w/w encapsulated 
NaCMC/gelatine 1:2.3 mass ratio depict desirable and stable Zeta potential values 
close to −40 mv despite lidocaine 2.8% w/w loaded NaCMC/gelatine 1:2.3 mass 
ratio outlining a slightly lower reproducibility (SD=0.80) (Figure 3.7d). Also lidocaine 
7.0% w/w encapsulated NaCMC/gelatine 1:2.3 mass ratio depicted a repeat of the 
high Zeta potential behaviour in terms of an undesirably high and slightly more 
agglomeration effect due to high loading of lidocaine (Figure 3.8d). The effect of pH 
on NaCMC/gelatine 1:2.3 resulted in a minima point near -60 mV on the 
experimental curve observed at pH 4.0 (Figure 3.8e). Buffering the continuous 
phase containing bi polymeric microgels at pH 4.0 is favourable in allowing larger 
microparticle dispersion in the media. 
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Figure 3.8: (Continued to next page). 
a 
b 
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Figure 3.8: (Continued to next page). 
 
c 
d 
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Figure 3.8: (a) Zeta potential of lidocaine NaCMC/gelatine (NaCMC:gel) 1:1.6 mass 
ratio microparticles. Values 1.2-7.0 are lidocaine loaded yields in % w/w. (b) Zeta 
potential of lidocaine (2.4-7.0 % w/w) NaCMC/gelatine mass ratio 1:1.6 and 1:2.3 
microparticles. Values 2.4-7.0 are lidocaine loaded yields in % w/w. (c) Zeta potential of 
lidocaine (2.4 % w/w) NaCMC/gelatine mass ratio 1:2.3 microparticles. (d) Zeta 
potential of lidocaine NaCMC/gelatine mass ratio 1:2.3 microparticles. (e) pH effects on 
unloaded NaCMC/gelatine 1:2.3 microparticles as a function of Zeta potential. Values 
2.4-7.0 are lidocaine loaded yields in % w/w (results represent arithmetic mean ± SD 
values based on data from two reproduced hydrogel samples per mass ratio or 
concentration).  
 
3.3.5  Morphology of microparticles in lidociane NaCMC/gelatine hydrogel 
The micro-particles of lidocaine 2.4% w/w NaCMC/gelatine 1:1.6 to 1:2.7 mass ratio 
were found to be spherical. However they show small areas of agglomeration with 
respect to microparticulate hydrogel morphology (Figure 3.9a-d). The microparticles 
in lidocaine 2.4% w/w NaCMC/gelatine 1:1.6, 1:2.3 and 1:2.7 mass ratios appear 
slightly more distinct spherically and dispersed with less agglomeration compared 
with lidocaine 2.4% w/w NaCMC/gelatine 1:2.0 mass ratio. More significantly in the 
quantity with regards to larger microparticle sizes were observed for lidocaine 2.4% 
w/w NaCMC/gelatine 1:2.7 mass ratio hydrogel (Figure 3.9d). 
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Figure 3.9: Micrograph of lidocaine 2.4 % w/w NaCMC/gelatine microparticles prepared using 
different polymeric ratios: (a) 1:1.6, (b) 1:2.0, (c) 1:2.3, (d) 1:2.7 (Scaling bar units: μm).  
 
3.3.6  Microneedle-assisted and passive diffusion of lidocaine from NaCMC/gelatine 
hydrogel 
Clinical research has shown that lidocaine in hypodermal plasma fluid is able to 
sustain localised drug action at a normal threshold range of 1.2 to 5.5 μg/ml or 3.11 
μg/cm2 to 14.25 μg/cm2 after conversion into cumulative permeated amounts for 
lidocaine (Stenson et al., 1971; Greco, 2011). MN assisted diffusion of lidocaine 
NaCMC/gelatine 1:2.3 mass ratio showed a fast time taken for the cumulative 
amount permeated at 1.1 h after crossing the minimum lidocaine therapeutic level. 
Comparatively, the same lidocaine formulation used for PD studies showed the 
fastest time in crossing the minimum therapeutic level regarding the cumulative 
amount permeated was 1.5 h (Figure 3.10a). During the MN assisted diffusion of 
lidocaine NaCMC/gelatine, 1:1.6 and 1:2.0 mass ratios both outlined faster times 
taken for the cumulative amount permeated past 1.25 h when extrapolated towards 
a minimum lidocaine therapeutic level. Comparatively the PD of lidocaine 
NaCMC/gelatine 1:1.6 mass ratio and PD of lidocaine NaCMC/gelatine 1:2.0 mass 
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ratios crossed the minimum therapeutic level at 2 h and 3 h, respectively (Figure 
3.10a). The SD error bars from duplicate data sets showed very good 
reproducibility (Figure 3.10a). Permeated rates of MN assisted lidocaine 
NaCMC/gelatine hydrogels recorded in the first 0.5 h, were significantly bigger for 
1:2.3 mass ratio with a 20.5 fold increase when compared with PD and low for 1:2.0 
mass ratio with a 1.4 fold increase compared with PD (Figure 3.10b). Likewise as 
discussed, the error bars from duplicate data sets showed good reproducibility 
(Figure 3.10b). Lidocaine NaCMC/gelatine 1:1.6 mass ratio formulation represented 
the lowest MN assisted permeation flux of 3.8 μg/ cm2/ h (Figure 3.10c) despite a 
low microparticle size diameter of nearly 99 μm compared with other 
NaCMC/gelatine mass ratio formulations. In theory smaller microparticles should 
allow greater ease in passing skin pores and diffusing water plasma in the lower 
regions of the skin. Nevertheless the Zeta potential results with respect to a very 
low Zeta correlating to greater dispersion than agglomeration of microparticles is 
the main supporting concept for high permeation flux. The random error of 
permeation flux for the duplicate data sets showed good reproducibility (Figure 
3.10c). 
 
Figure 3.10: (Continued to next page). 
a 
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Figure 3.10: (a) Cumulative amount of lidocaine permeated through skin from NaCMC/gelatine 
with a four hour period. (b) Cumulative amount of lidocaine permeated through skin from 
NaCMC/gelatine with a 1 hour period. (results represent arithmetic mean ± SD values based on 
data from two reproduced hydrogel samples per mass ratio). (c) Lidocaine (2.4 % w/w) 
NaCMC/gelatine flux permeation through skin (results represents random error of two reproduced 
mass ratio samples for PD and microneedle values based on 90 % confidence level). 
 
b 
c 
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3.4 Discussion 
 
3.4.1  Surfactant and oil based continuous phase medium in emulsion stage 
preparation 
Paraffin oil as the continuous phase mixed with non-ionic surfactant, SPAN 80, for 
stabilising aqueous emulsion droplets possessed ideal properties (Marquez, 2007). 
Comparatively SPAN 20, SPAN 40 and SPAN 60 series were unsuitable 
surfactants because SPAN 80 is the most hydrophobic (Marquez, 2007). Paraffin 
oil, continuous phase medium aided the dispersion of polar droplets before further 
addition of glutaraldehyde for microparticle formation. The n-octonol/water partition 
coefficient of paraffin oil is noted, log P >3.5 (Fisher Scientific Ltd, Loughborough, 
UK) and the non-polarity is attributed to the high interfacial tension and lower 
dielectric constant in terms of percentage w/w solubilisation (El-Mahrab Robert et 
al., 2008). The formation of a NaCMC/gelatine polymeric hydrogel network is to 
entrap and crosslink a linear polymeric structure with a more branched structure in 
considering covalent bonding interactions to a lesser extent, thus permitting 
intermolecular dissociation in a continuous phase such as water (Chikh et al., 2011; 
Jenkins et al., 1996). Glutaraldehyde was used for fixing and strengthening the 
crosslinking of a polymer and co-polymer to form spherically shaped microparticles 
(Kajjari et al., 2011). 
 
3.4.2  The effect of increasing gelatine concentration on encapsulation efficiency of 
lidocaine NaCMC/gelatine 
Gelatine in greater concentrations in hydrogel NaCMC/gelatine microparticles 
influences the gelling properties of the hydrogel matrix with respect to crosslinking 
with NaCMC at low pH via electrostatic charges and hypothetically creating a more 
complex intertwined mesh to trap lidocaine molecules. In order to gain a better 
insight into the reason for a substantially valid increase in EE from 1:2.3 mass ratio 
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NaCMC/gelatine to 1:2.7 mass ratio requires electro-analytical research with 
respect to overall ionic charge distribution effects. However this is not within the 
scope of this thesis. 
 
3.4.3  Viscoelastic and particle diameter properties of lidocaine NaCMC/gelatine  
hydrogel 
Lidocaine is a weakly acidic and the positively charged tertiary amide on it has no 
effect on influencing the pseudoplasticity of the NaCMC/gelatine hydrogel (Figure 
3.5a). Increasing the gelatine mass ratio component in the lidocaine polymeric 
hydrogel microparticles slightly increases the pseudoplasticity of the hydrogel 
formulation caused by gelling thus appearing more pronounced with respect to 
lidociane NaCMC/gelatine 1:2.3 and 1:2.7 mass ratios. This has an influence on 
creating bigger microparticle sizes as discussed later in particle size distribution 
(Figure 3.7). Mild pseudoplasticity is a common viscoelastic property for lidocaine 
NaCMC/gelatine hydrogels despite low values pointing to shear thinning at a 
maximum shear of 200 s-1 (Figures 3.5a and 3.6). The reduced hydrogel matrix 
properties caused by a much lower gelatine mass ratio for lidociane 
NaCMC/gelatine hydrogel despite a constant high shear of 1000 rpm during the 
formulation preparation stages has a significantly profound decrease of mean 
particle size diameter when comparing NaCMC/gelatine 1:1.6 mass ratio with 
NaCMC/gelatine 1:2.3 and 1:2.7 mass ratios (Figure 3.7). Morphologically larger 
microparticles in lidocaine NaCMC/gelatine hydrogel are distinctly represented for 
the 1:2.7 mass ratio with respect to the highest concentration of gelatine co-polymer 
(Figure 3.9). A similar polymeric gelatine microparticle study (Rokhade et al., 2006) 
obtained volume mean particle size range from 247–535 μm for 1:4 and 1:9 
NaCMC/gelatine ratio non-steroidal anti-inflammatory drug (NSAID) mainly because 
of low overhead stirring speeds of 400 rpm, high viscosity grade NaCMC (500–800 
mPas) and higher copolymer, gelatine concentration in the ratio mixture. 
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3.4.4  Polyelectrostatic lidocaine NaCMC/gelatine and unloaded NaCMC/gelatine 
microparticles on Zeta potential 
A high concentration of weakly acidic lidocaine in a low polycationic gelatine weight 
ratio NaCMC/gelatine hydrogel formulation is likely to influence slightly more 
agglomeration of microparticles. Also the high lidocaine concentration disrupted the 
complex coacervate formation before the permanent fixation and assembly of 
droplets into defined spherical microparticles by glutaraldehyde (Figure 3.8a). Low 
agglomeration was already deduced from low Zeta potential values and there was 
no significant difference for further reduced agglomeration and metastable particle 
stability when lidocaine 2.4% w/w or 2.8% w/w is encapsulated in either 
NaCMC/gelatine 1:1.6 or 1:2.3 mass ratios, respectively (Figure 3.8b). However 
lidocaine 7.0% w/w loaded in NaCMC/gelatine 1:1.6 and 1:2.3 mass ratios showed 
significantly higher, positive, Zeta potential values and therefore slightly more 
agglomeration of microparticles (Figure 3.8b). The Zeta potential effect of charged 
particles with a charge distribution density on the inner core provides a good 
indication of a metastable and non-agglomerated particulate hydrogel in the 
empirically determined range of −31.0 to −40.0 mV (Schramm, 2005; Riddick, 
1968). The surface charges in the microparticles of lidocaine NaCMC/gelatine 
hydrogel are negative due to dissociation of acidic groups on gelatine and lidocaine 
contributing to an acidic environment in forming a spherical core shell structure in 
conjunction to electronegative DI water molecules, basic carboxylate groups in 
NaCMC and conjugate base of acetic acid contribute to the outermost shell 
boundary (Riddick, 1968; Koul et al., 2011).  
 
Zeta potential is a fairly common and valid analytical technique for determining the 
lidocaine NaCMC/gelatine microparticles in dispersal from weak acid medium of pH 
4.0 to a near neutral plasma pH medium. Placebo NaCMC/gelatine hydrogel 
microparticles outline the minima (dζ/d(pH)=0) which is representative of the lowest 
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Zeta value showed the most desirable pH value at −58.6 mV (Figure 3.8e) so pH 
4.0 was the ideal and adapted pH for NaCMC/gelatine overall hydrogel media in the 
encapsulation of lidocaine. Above acidic conditions of pH 4.0 for the placebo 
NaCMC/gelatine 1:2.3 mass ratio resulted in a gradual increase in Zeta potential 
which is likely caused by reduction in dissociated polycationic gelatine and 
polyanionic NaCMC, and microparticle agglomeration is more defined. 
 
3.4.5  Lidocaine from NaCMC/gelatine hydrogels as a transdermally permeating agent 
The minimum therapeutic level for In Vitro studies is a prediction of the 
concentration or permeated amount of drug with the potential to invoke a 
therapeutic response. The minimum therapeutic and toxic level permeation 
threshold values were taken from references (Stenson et al., 1971; Greco, 2011), 
converted from micrograms per millilitre concentration of lidocaine into micrograms 
per square centimetres for permeated concentration using equation 3.1 and 
expressed using constants derived from FDC receptor compartment volume and 
receptor area of aperture in equation (3.4). 
Q =  5𝜕𝜕1.93                                                                                         (3.4) 
Commercially acquired AdminPatch MNs (Nanobiosciences, Sunnyvale, CA, USA) 
created hypothetical channels and widened skin pores for the drug to bypass the 
SC layer and diffuse into the VE layer. Staining techniques have shown similar 
length AdminPatch MNs to penetrate beyond the SC layer of skin from a recent 
study (Han and Das, 2013). Imperatively the use of MNs is to allow the drug to 
diffuse just above the minimum therapeutic levels at lower recorded time durations 
than PD which is devoid of any needles. The effective diffusional area in 
considering the barrier diffusing membrane properties of skin was adapted from 
Fick’s first law for explaining the permissible trends for PD and microneedle 
assisted cumulative diffusion of lidocaine NaCMC/gelatine hydrogels through the 
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skin. The lidocaine 2.4% w/w NaCMC/gelatine hydrogels are permeating the 
uppermost layer, highly lipophilic layer of skin very slowly for upto 30 min (Figure 
3.10b). This highly lipophilic layer is suitable for the passive diffusion of small 
molecular weight lipophilic drugs for which lidocaine HCl is not the case. After 30 
min, the permeating amount of lidocaine diffuses at a much faster rate because the 
lower section layer of skin is less lipophilic and pseudo steady state conditions are 
observed for all lidocaine NaCMC/gelatine hydrogels after 1.5 h (Figure 3.10a).  
 
Lidocaine NaCMC/gelatine microparticles enter the opened MN treated skin cavity 
while for PD the hair follicles and sweat pores are the natural cavities for these 
microparticles (Todo et al., 2010). The natural cavities in skin are considerably 
smaller openings when compared with post MN ones (Todo et al., 2010). Excised 
skin used in vitro will generally have lower moisture content because of high trans-
epidermal water loss (TEWL) values and microparticles will tend to cause a 
reservoir effect in VE or dermis layers of skin (Victoria Klang et al., 2013). After 30 
min, the permeating amount of lidocaine diffuses at a much faster rate because the 
lower section layer of skin is less lipophilic and pseudo steady state conditions are 
observed for all lidocaine NaCMC/gelatine hydrogels after 1.5 h. The cumulative 
skin permeation of the three lidocaine 2.4% w/w NaCMC/gelatine hydrogels 
depicted good overall high rates than compared with PD, especially past the time of 
0.5 h (Figure 3.10a and b). Emerging plateau levels of cumulative permeation 
amounts through skin were already documented post 4.5 h. However, the aim for a 
higher lidocaine amount permeated past minimum therapeutic levels were 
particularly targeted at the most plausible shorter time duration than a long 
sustained release profile hence comparative cumulative permeation studies were 
conducted in a short time range. Increasing the gelatine concentration in a lidocaine 
2.4% w/w NaCMC/gelatine hydrogel outlined an increase in permeation flux for both 
PD and MN assisted permeation (Figure 3.10c). Lidocaine 2.4% w/w 
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NaCMC/gelatine mass ratio 1:2.3 showed a highly favourable permeation flux with 
respect to MN assisted delivery of lidocaine.  
 
The EE of lidocaine 2.4% w/w NaCMC/gelatine mass ratios are similar and 
therefore cannot explain the effect of increasing lidocaine release rates when the 
gelatine mass ratio is increased in the hydrogel vehicle in terms of correlating with 
an unchanged EE just above 15%. However, lidocaine 2.4% w/w NaCMC/gelatine 
mass ratio 1:2.7 provided a substantially high EE of 32% and a reciprocally poor, 
highly insignificant, low value skin permeation flux which was interpreted as a no 
result. A high gelatine mass weight of 3.3% w/w in lidocaine 2.4% w/w 
NaCMC/gelatine mass ratio 1:2.7 hydrogel provided for a more compacted gelling 
and adsorbing properties, thus preventing the release of a detectable quantity of 
lidocaine. The high gelation of lidocaine 2.4% w/w NaCMC/gelatine mass ratio 1:2.7 
microparticles are responsible for agglomeration by high Zeta potential (Figure 
3.8c). However, lidocaine 2.4% w/w NaCMC/gelatine mass ratio 1:2.3 had a slightly 
higher and a favourably closer Zeta potential to −40 mV and therefore the 
permeation flux for PD and MN assistance is influenced to be highest because of 
less microparticulate agglomeration or clustering effect. 
 
3.5 Chapter summary 
Lidocaine NaCMC/gelatine is a highly potential and promising hydrogel formulation 
requiring MN assisted delivery to excel low PD flux rates by relatively significant 
proportions. MN assisted lidocaine 2.4%w/w NaCMC/gelatine mass ratio 1:2.3 
hydrogel is found to be the most ideal formulation for exceeding the minimum 
therapeutic permeation threshold of 3.11 μg/cm2 just after 70 min but requiring 
removal before 140 min. A seventy minute duration for pseudo steady state 
permeation, concerning lidocaine 2.4% w/w NaCMC/gelatine mass ratio 1:2.3 is 
highly beneficial in numbing the immediate skin region in a hypothetical case of 
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multiple lacerations in close proximity that require wound cleaning and suturing. 
Lidocaine 2.4% w/w is the most ideal loading concentration for NaCMC/gelatine 
1:1.6 and 1:2.3 mass ratio hydrogel because of reproducible and stable 
approaching values of −40.0 mV Zeta potential. A buffered pH 4.0 was essential in 
the induction of an anionic polymer and cationic co-polymer polyelectrolyte 
interaction and facilitation of dispersed hydrogel microparticles as measured by a 
Zeta of −58 mV. There are significant differences in visco-elasticity caused by 
polymeric ratios of NaCMC and gelatine than the constant loading concentration of 
lidocaine when an ideal polymeric mass ratio 1:2.3 is implemented.  
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Chapter 4 
Lidocaine carboxymethylcellulose with gelatine co-polymer 
hydrogel delivery by combined microneedle and ultrasound 
 
Chapter overview 
A study that combines MNs and sonophoresis pre-treatment was explored to 
determine their combined effects on percutaneous delivery of lidocaine from a 
polymeric hydrogel formulation. Varying ratios of NaCMC/gelatine ranges 1:1.6–
1:2.66 loaded with lidocaine were prepared and characterized for Zeta potential and 
particle size. Additionally, variations in the formulation drying techniques were 
explored during the formulation stage. In vitro permeation studies using FDCs 
measured lidocaine permeation through porcine skin after pre-treatment with 
stainless steel MNs and 20 kHz sonophoresis for 5 and 10 min durations. A stable 
formulation was related to a lower gelatine mass ratio because of smaller mean 
particle sizes and high Zeta potential. Lidocaine permeability in skin revealed some 
increases in permeability from combined MN and ultrasound pre-treatment studies. 
Furthermore, up to 4.8 fold increase in the combined application was observed 
compared with separate pre-treatments after 30 min. Sonophoresis pre-treatment 
alone showed insignificant enhancement in lidocaine permeation during the initial 2 
h period. MN application increased permeability at a time of 0.5 h for up to  ̴17 fold 
with an average up to 4 fold. The time required to reach therapeutic levels of 
lidocaine was decreased to less than 7 min. Overall, the attempted approach 
promises to be a viable alternative to conventional lidocaine delivery methods 
involving painful injections by hypodermic needles as mentioned in Chapter 3. The 
mass transfer effects were fairly enhanced and the lowest amount of lidocaine in 
skin was 99.7% of the delivered amount at a time of 3 h for lidocaine 
NaCMC/gelatine 1:2.66 after low-frequency sonophoresis and MN treatment. 
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4.1  Introduction 
This chapter is concerned with the delivery of lidocaine HCl, a common anaesthetic, 
from a lidocaine carboxymethylcellulose with gelatine co-polymer hydrogel 
formulation such as discussed recently by Nayak et al. (2014a). Lidocaine HCl, 
termed as lidocaine, is a water soluble weak acid, fully ionized at pH 5.0 and 
administered into the plasma rich layer under the skin surface (Igaki et al., 2013). 
However, this administration is conventionally performed via hypodermic needles 
as a low cost and fast acting method (Hedge et al., 2011; Kim et al., 2012b). This is 
known to cause significant pains as mentioned in section 2.2. Alternatives, such as 
EMLA, topical lidocaine, require at least an hour of application to achieve effective 
analgesia, thus limiting its use especially in emergency situations (Nayak and Das, 
2013). Therefore, there are important rationales for the pursuits of alternative 
lidocaine administration (Nayak and Das, 2013; Nayak et al., 2014a). This can be 
evidenced in the European paediatric drug legislation which backs innovation to 
develop ‘‘easy to administer’’ and ‘‘minimally invasive’’ drug delivery methods (Shah 
et al., 2011). The alternative rationales for lidocaine delivery include increased 
safety amongst the patients and healthcare providers, increased compliance with 
those who possess a fear of needles, reduced discomfort and pain especially in the 
case of applying anaesthetics as well as improved ease of delivery (Giudice and 
Campbell, 2006; Gill and Prausnitz, 2007; Li et al., 2010). The initial goal of this 
chapter is to further discuss enhanced lidocaine skin permeation from a 
NaCMC:gelatine hydrogel via an Ultrasound treatment, MN poke and skin coat 
technique as compared with lidocaine hydrogel application alone.   
 
Low bioavailability of some drugs limits the therapeutic target effect (De Boer et al., 
1979; Huet and Lelorier, 1980; Benet et al., 1996; Shipton, 2012). Lidocaine’s oral 
bioavailability is approximately reduced by 65–96% by digestive enzymes (Fen-Lin 
et al., 1993; Fasinu et al., 2011). In principle, innovative percutaneous delivery 
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could overcome the barriers associated with direct injection and oral drug 
administration (Polat et al., 2011) such as lidocaine. The rate of PD of drugs by 
percutaneous delivery depends on the molecular structure, size and hydrophobicity 
in conjunction with the drug concentration gradients. However, many studies have 
used combinations of PD and non-invasive techniques with varying success, e.g. 
MNs and ultrasound (Chen et al., 2010; Han and Das, 2013). This is the topic of 
this chapter and it is discussed in more detail below. 
 
MNs are needle like structures of the size order of microns commonly arranged in a 
matrix (Gill and Prausnitz, 2007; Olatunji et al., 2014; Zhang et al., 2014). The 
lidocaine NaCMC/gelatine hydrogels pseudo-plasticity property permits seepage 
into MN cavities to bypass the SC skin layer compared with PD (Nayak et al., 
2014a). Research has shown significant increases in skin permeability using 
optimized MNs when considering factors of MN length, number of MNs, the length 
and width aspect ratio and surface area (Al-Qallaf and Das, 2008, 2009; Olatunji et 
al., 2012, 2013; Guo et al., 2013). It has been suggested that MNs can be adapted 
to aid lidocaine delivery yielding many fold increase in delivery rate (Kwon, 2004; Li 
et al., 2008; Wilson et al., 2008; Zhang et al., 2012a, b; Kochhar et al., 2013; Ito et 
al., 2013; Nayak et al., 2014a). A number of studies have successfully delivered 
numerous active molecules using MNs, e.g. hepatitis B vaccine (Guo et al., 2013), 
Solaraze® gel in extending pore opening (Ghosh et al., 2013b) and naltrexone co-
drug with diclofenac drug (Banks et al., 2011). In another recent study, it has been 
shown that MNs can be combined with ultrasound for increasing the delivery rate of 
a large macromolecular drug (Han and Das, 2013). These studies have directed the 
hypothesis that MNs and ultrasound combination could be used for greater 
epidermal lidocaine delivery in order to determine the significance of optimum 
sonophoretic power related effects on lidocaine permeation. 
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In this context, it is important to state that sonophoresis is generally based on 
ultrasound frequency. The low frequency sonophoresis (LFS) is defined to be within 
20–100 kHz and the high frequency sonophoresis is usually for above 0.7MHz 
(Polat et al., 2011). The mechanism by which enhanced permeability is achieved 
via ultrasound can be linked to a number of physical phenomena, including thermal 
effects, formation of cavitation, mechanical effects and convective localized fluid 
velocities in skin. However, in the ultrasound pre-treatment experiment, it is 
generally accepted that inertial cavitation is the largest contributor to the 
enhancement in skin permeability. It is more so with LFS as described by Merino et 
al. (2003) due to larger bubble size at low frequency range. Inertial cavitation 
occurs due to pressure variations induced by ultrasound, resulting in rapid growth 
and collapse of bubbles formed in the coupling medium. The collapsing of the 
aforementioned bubbles near skin surface will cause micro-jets due to 
asymmetrically release of energy. These micro-jets have been confirmed as the 
main contributors to the permeability increment (Wolloch & Kost, 2010). The effects 
of ultrasound have been studied for the enhancement of TD lidocaine delivery with 
significant results for both pulsed and continuous output mode of LFS (Ebrahimi et 
al., 2012). However, as far as we are aware of, these techniques are yet to be 
combined and studied for permeability enhancement levels, particularly for 
lidocaine. The potential for MN assisted lidocaine delivery via hydrogel 
microparticles was discussed to summarise that there is significant commercial 
potential for lidocaine MNs (Zhang et al., 2012a, b; Nayak et al., 2014a). Polymeric 
hydrogel microparticles are good for the purpose of controlling spreading (i.e. 
controllable spreading radius, droplet height and contact angle) of the drug 
formulation over skin (Nayak et al., 2014a). 
 
In this particular study, the drug vehicle for lidocaine encapsulation is polyanionic, 
carbohydrate based NaCMC cross-linked with polycationic, protein based gelatine 
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in forming a hydrogel (Nayak et al., 2014a). Previously lidocaine formulation 
bypassing the SC epidermal layer was outlined, the viscoelastic properties in 
adapting a NaCMC/gelatine network hydrogel prevent slippage of the drug 
formulation when applied to the skin and the possibility of non convective flow 
through the opened cavities of the skin from MN treatment (Milewski and 
Stinchcomb, 2011; Ghosh et al., 2013a). To try and exploit this potential, the main 
aim of the study is to combine the techniques in MN array and ultrasound 
technology as a pre-treatment to meet the definition of an ideal anaesthetic delivery 
method. A major advantage is that an extended release is possible using this 
approach. A carbohydrate based visceral hydrogel formulation was prepared as a 
model anaesthetic as this provides flexible properties and ability to encapsulate 
considerable amounts of liquid drug, lidocaine in this instance (Milewski and 
Stinchcomb, 2011), as discussed in the following section. Furthermore, the 
spreading behaviour of the prepared formulation was studied and compared with 
the spreading behaviour lidocaine solution as a Newtonian liquid. Unlike numerous 
studies performed using synthetic substrates, this study implements porcine skin as 
a lipophilic substrate as was attempted by Chow et al. (2008). 
 
4.2 Materials and methods 
NaCMC and gelatine emulsion was cross-linked to form hydrogels with 
encapsulated lidocaine as described in section 3.2. This formulation setup is highly 
beneficial because of fairly efficient preparation times in achieving a finished drug 
formulation in adaptation of green chemistry. 
 
4.2.1  Materials 
The reagents used in the preparation of lidocaine NaCMC/gelatine hydrogels were 
the exact specification as outlined in section 3.2.1. Methylene blue (50% v/v) was 
purchased from Sigma Aldrich Ltd (Dorset, UK). The column and and reagents 
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used in HPLC analysis were also taken from sections 3.2.1 and 3.2.11. Amputated 
porcine ears (age of pig: 5-6 months) were processed as mentioned in section 
3.2.5. Also, 10mm x 10mm squares of same porcine skin were dissected as a 
substrate for droplet spreading. MN patch used is mentioned in section 3.2.5. 
Branson Digital Sonifier 450 (Danbury, CT) was chosen as the ultrasound output 
system. This ultrasound system includes an auto-calibrated transducer and a digital 
output controller. The frequency of the ultrasound is fixed at 20 kHz but the output 
powers are adjustable between 4 and 400 W. The equipment for droplet spreading 
studies was AVT Pike F-032 high-performance camera (Allied Vision Technologies 
UK), Camera i-speed LT high speed video (Olympus, UK). 
 
4.2.2  Formulation of lidocaine NaCMC/gelatine hydrogel 
The formulation of lidocaine NaCMC/gelatine hydrogel was taken from section 
3.2.2. Each variation of the hydrogel formulation was coded with a letter F and 
outlined in Table 4.1. In the case of F5 residual paraffin and n-hexane were 
removed by rotary evaporation (Heidolph Instruments, Essex, UK) instead of the 
vacuum oven method from section 3.2.2.  
 
Table 4.1: Lidocaine NaCMC/gelatine (gel) hydrogel mass ratio with particle size values 
Sample ID NaCMC 
(% w/w) 
gel     
(c % w/w) 
NaCMC:gel 
ratio 
Drier type Mean particle 
diameter ± S.D. 
(μm) 
Particle 
diameter 
range (μm) 
F1  
 
1.2 
2.0 1:1.6 Vacuum 5.89 ± 0.0026 1 - 13 
F2 2.4 1:2.00 Vacuum 6.04 ± 0.0027 1 - 14 
F3 2.8 1:2.33 Vacuum 6.81 ± 0.0029 2 - 17 
F4 3.2 1:2.67 Vacuum 7.42 ± 0.0029 3 - 17 
F5 3.2 1:2.67 Rotary 
Evap. 
14.60 ± 0.0067 4 - 31 
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4.2.3  Zeta potential of lidocaine NaCMC/gelatine hydrogel 
The samples for Zeta potential were analysed as described in section 3.2.8. The 
results were obtained in triplicate. The Zeta potential (ζ) was measured in terms of 
electrophoretic mobility (μ) via an optical technique, and ζ (mV) (Park et al., 2005) 
of the diluted hydrogel was computed from the Smoluchowski equation (equation 
4.1), where μ is the referenced with latex (m2v-1s-1), η is the DI volume viscosity 
(m2s-1), ε0 and εr are the permittivity in a vacuum and relative permittivity of DI water 
as medium, respectively (Sze et al., 2003). 
ζ =  4𝜋𝜋𝜋𝜋𝜋𝜋(𝜀𝜀𝑟𝑟𝜀𝜀0)                                                                                     (4.1) 
 
4.2.4  Viscometric analysis of lidocaine NaCMC/gelatine hydrogel 
The viscometric analysis of lidocaine NaCMC/gelatine hydrogel was characterised 
as in section 3.2.9. 
 
4.2.5  Optical micrographs of lidocaine NaCMC/gelatine hydrogel 
Micrographs were taken as described in section 3.2.10. Micrographs were pictured 
in triplicate for each formulation. Image processing software (ImageJ) was adapted 
in pixel measurement via graticule calibration to interpret particle size diameters 
from a random selection of 50 microparticles per image.  
 
4.2.6  Controlled release of lidocaine from NaCMC/gelatine hydrogel 
Lidocaine NaCMC/gelatine hydrogel (0.1 ± 0.05 g) was placed in an amber vial and 
25.0 ml of DI water was dispensed before the sample was placed in a pre-heated 
thermostat bath at 37.0 ± 0.5˚C (Grant Instruments, Cambridge, UK). Subsequently, 
1 ± 0.0005 ml of heated sample removed by autopipette (Eppendorf, Stevenage, 
UK), filtered using Nylon membranes (Posidyne, 0.1 μm) and analyzed for lidocaine 
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content using HPLC instrumentation. The results were measured in triplicate and 
the standard deviation from sample mean was taken. 
 
4.2.7  In vitro skin permeation study of lidocaine NaCMC/gelatine hydrogel 
The in vitro skin permeation for PD and MN characterisation was adopted as in 
section 3.2.5. The FDC receptor chamber volume was 5.0 ml. The aperture surface 
area was 1.33 cm2. In vitro experiments were grouped as PD, MNs only pre-
treatment, LFS only pre-treatment, MNs and LFS pre-treatment. The continuous 
viscoelastic properties of skin are unlikely to allow for MNs to penetrate beyond 200 
mm when considering 1500 mm needle length rollers penetrating a depth of 150 
mm (Roxhed et al., 2007; Badran et al., 2009).  MNs were carefully applied to the 
skin ensuring penetration and held in place using a constant pressure device 
comprising a pneumatic piston (0.05 MPa) for 3 or 5 min. LFS was supplied for pre-
treatment only using a probe set to 20 kHz frequency for 5–10 min. Continuous 
mode of ultrasound was chosen due to no significant difference being observed 
during pre-treatment applications (Herwadkar et al., 2012). The inter-coupling 
distance between the skin and probe was set to 2mm with coupling medium of DI 
water. In the case of MNs combined with ultrasound pre-treatment, the MN patch is 
applied before the ultrasound treatment. A minimum lidocaine concentration of 1.5 
μg/ml was deduced from the literature as the permissible effective drug therapeutic 
value in plasma (Grossman et al., 1969; Schulz et al., 2012). 
 
4.2.8  Spreading of lidocaine NaCMC/gelatine 1:2.33 across porcine skin 
The setup for measurement of spreading radius, droplet height and apparent 
contact angle of droplet was similar to Chao et al. (2014). A square section of 
porcine skin (10mm x 10 mm) was placed flat in a closed sample box. A sample 
droplet (3.0 ± 0.5 ml) was dispensed on the porcine skin, camera frame rate 
capture of 1.85 frames per second (fps) was maintained and the results recorded. 
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Results were obtained in duplicate for the optimum particle size-controlled 
formulation and compared with a duplicate set of lidocaine solution of the same 
lidocaine loading weight (2.44 % w/w). 
 
4.2.9  Histological study 
The determination of MN insertion depth into skin by post MN treatment of skin was 
adapted from Cheung et al. (2014). First, the skin sample is pre-treated using 1100 
mm MN patch for 5 min. Then, the porcine skin sample is stained using methylene 
blue (50% v/v) and merged into embedding compound (Bright Cryo-m-Bed, 
Huntingdon, UK) which is filled in a cuboid mould. The whole sample is then put 
inside the microtome (Bright Cryostat 5030, Huntingdon, UK) to solidify. The frozen 
sample is cut into 15 μm slices and analyzed under the microscope for the 
histology. 
 
4.3 Results and discussions 
 
4.3.1 Lidocaine NaCMC/gelatine hydrogel microparticle size diameters and 
morphology 
Lidocaine encapsulated hydrogel microspheres based on NaCMC and gelatine 
were prepared using glutaraldehyde in transforming emulsion droplets to defined 
microparticles. As the mechanisms for ionic interactions in forming spherical 
microparticles are known (Gupta and Ravi Kumar, 2000; Berger et al., 2004), it is 
not discussed in detail in this thesis. The morphological observations of lidocaine 
NaCMC/gelatine microparticles are spherical, well-formed and slightly 
agglomerated for a significant number of them (Figure 4.1a and b). Mean particle 
size diameters (Table 4.1) in the formulation ranged from 5.89 to 14.60 mm 
depending on the formulation with an increase in mean particle size observed with 
an increased gelatine ratio. This is the likelihood of increased gelatine component 
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of the hydrogel, producing larger droplets during the w/o emulsification and 
subsequent hardening after the addition of glutaraldehyde. The rotary evaporation 
method yielded significantly larger particle sizes in comparison to vacuum drying. 
Interestingly, a positively skewed particle size distribution was observed for all 
lidocaine hydrogel formulations (Figure 4.2). 
 
Figure 4.1: (a) lidocaine NaCMC/gelatine 1:2.33 hydrogel showing distinctly formed 
microparticles. (b) lidocaine NaCMC:gelatine 1:2.66 hydrogel showing larger and 
slightly more agglomerated microparticles. 
 
 
Figure 4.2: Particle size distribution of lidocaine NaCMC/gelatine hydrogels. 
 
4.3.2  Dispersion of lidocaine NaCMC/gelatine hydrogel microparticles 
Zeta potential studies in lidocaine NaCMC/gelatine hydrogels demonstrated a 
stable and fairly dispersed microparticulate system. The results (Figure 4.3) 
a b 
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expressed a trend of decreasing stability with an increase in the gelatine ratio, 
which in theory should impact a greater level of microparticle agglomeration thus 
likely affecting the permeability through skin. The pH of all formulations was kept 
constant and therefore it should not have affected the Zeta potential although the 
slight decline of ζ-potential in the positive direction is linked to the increase in 
gelatine ratio caused by gelatine in conjunction to lidocaine possessing a positively 
charged tertiary amide group at pH 4.0 and thus contributing to the increasing 
negative surface charge. The anionic polymer, NaCMC has a ζ-potential value of -
30mV (Ducel et al., 2004) and electric charge neutralization did not occur or was 
not significantly induced by gelatine or lidocaine, so the overall lidocaine 
NaCMC/gelatine hydrogel charge was greater than -30mV. Nevertheless, reduced 
agglomeration is the result of a medium pKa, higher dielectric constants in 
comparison to a polymeric hydrogel components converging to significantly low 
overall ζ-potential range of -35 to -40mV and the effect of electrostatic particle 
repulsion (Xu et al., 2007). 
 
Figure 4.3: Lidocaine NaCMC/gelatine 1:1.6-1:2.66 (F1-F4) and lidocaine 
NaCMC/gelatine 1:2.66 by rotary evaporation preparation (F5) for Zeta potential.  
 
 Lidocaine carboxymethylcellulose with gelatine co-polymer hydrogel by combined MN and US 
 
83 
 
4.3.3  Viscoelasticity of lidocaine NaCMC/gelatine hydrogel 
Viscosity determination (Figure 4.4) revealed a lenient pseudoplastic nature for the 
formulation with lidocaine NaCMC/gelatine hydrogel with good correlative best fit 
curves observed for individual set of data points (R2 > 0.93). The dynamic viscosity 
plots showed similar mild pseudo-plastic behaviour between the formulations with 
lidocaine NaCMC/gelatine 1:2.66 hydrogel being marginally higher when 
considering the upper viscosity range of 0.5–0.6 Pa.s at a starting shear of 25 s-1 
and then more defined shear thinning behaviour observed above 100 s-1. Lidocaine 
with NaCMC as a polyanionic vehicle alone will not be sufficient in enhancing 
pseudo-plastic properties and a recent study has shown that the profile of a 
dynamic viscosity plot is Newtonian (Alaie et al., 2013). 
 
Figure 4.4: Lidocaine 2.44% w/w NaCMC/gelatine (NaCMC/gel) ratio pseudoplasticity. 
 
4.3.4  Control of lidocaine NaCMC/gelatine 1:2.33 spreading on porcine skin 
The spreading radius and height of lidocaine NaCMC/gelatine 1:2.33 outline 
significant control on its spreading behaviour compared with lidocaine solution of 
the same mass loading (Figure 4.5a and 4.5b). The beginning of the plateau effect 
is observed after 10 s and therefore, there is expected to be a localization effect on 
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the skin surface (Figure 4.5a and 4.5b). The dynamic contact angles of lidocaine 
NaCMC/gelatine 1:2.33 droplets are considerably higher than the lidocaine solution 
contact angle droplets, near to the skin impact time of 0 s (Figure 4.5c). Dynamic 
contact angle stability is noticed after 40 s (Figure 4.5c). Our results also show that 
the lidocaine solution is a Newtonian liquid that can spread much faster than 
lidocaine NaCMC/gelatine microparticles. 
 
 
 
Figure 4.5: (Continued to next page). 
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Figure 4.5: Lidociane NaCMC/gelatine (NaCMC/gel) 1:2.33 comparison with Newtonian 
liquid solution according (a) droplet heights (b) spreading radii (c) dynamic contact 
angles. The results suggest that the spreading of lidocaine NaCMC/gelatine 1:2.33 on 
the skin surface much more predictable/ controllable as compared with lidocaine 
solution. 
 
4.3.5  The percentage release of lidocaine from controlled release of lidocaine 
All four lidocaine NaCMC/gelatine hydrogels outline rapid release of lidocaine 
directly in DI water during the first 1 h with steady state conditions observed in the 
next 3 h (Figure 4.6a). A 0.3 fold decrease in cumulative release is observed in the 
first hour when comparing lidocaine NaCMC/gelatine 1:1.6 with lidocaine 
NaCMC/gelatine 1:2.66 as the highest releasing outline. Also, a 0.1 fold decrease in 
cumulative release was observed in the next three hours when comparing lidocaine 
NaCMC/gelatine 1:1.6 with lidocaine NaCMC/gelatine 1:2.66. This shows that the 
variation between hydrogel ratios is not significantly large as permeation release 
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profiles explained in the following sections. The percentage release of lidocaine 
from NaCMC/gelatine hydrogels was determined by the following: 
Percentage drug release =   𝑀𝑀𝑠𝑠 −𝑀𝑀𝑡𝑡
𝑀𝑀𝑠𝑠
 ×  100                                  (4.2) 
where Ms is the maximum mean cumulative steady state concentration of drug and 
Mt is the mean cumulative concentration of lidocaine taken specifically at release 
time. The highest amount of lidocaine released was from NaCMC/gelatine 1:1.6 
hydrogel in which 32.3% was detected in the DI water media in one hour (Figure 
4.6b). This is because the smaller particles sizes of lidocaine NaCMC/gelatine 1:1.6 
ratio allow for a greater surface area and encapsulated lidocaine thus rapidly 
dissolves in DI water. The lidocaine NaCMC/gelatine 1:2.66 ratio comprises larger 
microparticles and therefore a smaller surface area is exposed for DI water 
dissolution so the percentage of lidocaine released was 17.4% in one hour. 
Significantly less amounts of lidocaine is released for all NaCMC/gelatine hydrogel 
formulations after 1 hour reflecting the steady state conditions of the hydrogel as 
the DI water media becomes a saturated solution. 
 
Figure 4.6: (Continued to next page). 
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Figure 4.6: The controlled release of lidocaine 2.44% w/w loaded (a) NaCMC/gelatine 
1:1.6 (F1), NaCMC/gelatine 1:2.0 (F2), NaCMC/gelatine 1:2.33 (F3) and 
NaCMC/gelatine 1:2.66 (F4). (b) as a percentage into DI water medium from 
NaCMC/gelatine 1:1.6 (F1), NaCMC/gelatine 1:2.0 (F2), NaCMC/gelatine 1:2.33 (F3) 
and NaCMC/gelatine 1:2.66 (F4). The error bars in (a) the standard deviation of mean 
represents the error (b) No error bards indicated. 
 
4.3.6  Histological analysis on the MNs 
The MNs that are employed in the histological experiment are 1100 mm in length. 
The purpose of the histological experiment is to determine the insertion depth of 
this MN patch under thumb pressure for which post MN treated skin is micrograph 
imaged (Figure 4.7). According to Figure 4.7, the insertion depth is between 300 
and 400 mm which are much lower than the real length of MNs. This is caused by 
several reasons, such as the viscoelastic properties of the skin, the geometry of the 
MNs and the insertion force. This reduced insertion depth can further affect the 
permeation results. 
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Figure 4.7: The MN insertion depth of skin sample using 1100μm MNs under thumb 
pressure. The histological studies show that although the MNs are 1100μm, for the MN 
density in the array and force applied, they create holes of approximately 400μm. 
 
4.3.7  Passive diffusion of lidocaine NaCMC/gelatine hydrogel 
Skin PD experiments were carried out in order to provide a control from which any 
pre-treatment enhancement results can be compared and contrasted. The lowest 
polymeric microparticle ratio 1:1.6 of lidocaine (Figure 4.8a) outlines the most 
desirable cumulative permeation for lidocaine in crossing the minimum threshold 
therapeutic level after 0.57 h. This is the shortest lag time for reaching the pain 
receptors for lidocaine in the deep dermis region rich in watery plasma and nerves. 
The hydrogel microparticle chemistry is a combination of significantly high negative 
Zeta potential and smaller mean particle size contributing to an increased 
permeation.  
 
All lidocaine NaCMC/gelatine ratio hydrogels have demonstrated a very low initial 
permeation at a maximum of 0.3 μg/ml reached in 0.5 h. This is the normal lag time 
because of a longer path length for microparticle permeation when considering the 
topmost SC layer surface area bigger than the accessible VE layer microcavities. 
However, lidocaine NaCMC/gelatine 1:2.0 and lidocaine NaCMC/gelatine 1:2.66 
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hydrogels are the next two favorables after the most desirable formulation 
containing a polymeric mass ratio 1:1.6 for bypassing the minimum therapeutic 
threshold at a shorter time interval. Initially, lidocaine is diffusing through the fresh 
skin because of microparticulate disruption to the hydrogel formula caused by 
natural skin moisture hence the low initial concentration rates proceeding upto 0.5 
h. Due to the requirements of lidocaine as an fast acting anaesthetic, the current 
results confirm enhancement of permeation is required if minimum therapeutic 
threshold of lidocaine (1.5 μg/ml) are to be reached within a suitable time frame for 
this technique to be of practical use. The lag time to cross a minimum therapeutic 
level is slightly greater than 1 h in lidocaine NaCMC/gelatine 1:2.33 hydrogel and 
just over 2 h for lidocaine NaCMC/gelatine 1:2.66 hydrogel, a rotary evaporation 
method with respect to PD alone which is considerably a long, unreasonable 
waiting time for a promising polymeric hydrogel ointment drug. The cumulative 
lidocaine thresholds tend to stabilize post 4 h, where equilibrium is reached and no 
more drug is released into the concentrated dermal region. This means that the 
lidocaine hydrogel ointment can be washed off the skin. 
 
FDCs are in vitro glass cells in which soluble drugs can dissolve in a known volume 
of liquid solvent before timed removal and replacement of fresh solvent. The 
challenges in using FDCs are minimizing the occurrence of trapped air during the 
replaced of a volume of dissolved drug solution with fresh solvent (Sintov & 
Shapiro, 2004). Also large trapped air bubbles may be observed sometime while 
placing sectioned skin sample across the aperture of the receptor chamber. 
Overfilling the receptor aperture by 0.4 ml minimizes the introduction of large air 
bubbles. Lidocaine NaCMC/gelatine hydrogel was compared with lidocaine solution 
permeation from the literature (Sekkat et al., 2004). Prior to this PD comparison 
with lidocaine solution PD, the permeation units of μg/ml were converted into 
μg/cm2 by the product of the known receptor volume followed by the quotient of the 
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adjustment factor value of 2.36 (3.14 cm2/1.33 cm2) due to the increase in FDC 
diffusion area when comparing a similar study using a smaller aperture diameter 
(Sekkat et al., 2004). The current lidocaine NaCMC/gelatine 1:1.6 hydrogel crosses 
the minimum therapeutic threshold by 1.8 fold than lidocaine solution on similar full 
thickness skin despite lidocaine solution permeating initially at 1.4 fold faster before 
a half an hour time frame and not anywhere near the minimum therapeutic 
threshold (Sekkat et al., 2004). Most FDC techniques appear a common place for 
PD studies and there is still a relatively big gap in adopting FDCs for MN based 
permeation studies. Lidocaine NaCMC/gelatine 1:2.66 and lidocaine 
NaCMC/gelatine 1:2.66 hydrogel formulated by rotary evaporation were chosen to 
be studied for further enhancement via pre-treatment. The factor of permeation 
enhancement can be deduced when making this comparison. 
 
 
 
Figure 4.8: (Continued to next page). 
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Figure 4.8: (Continued to next page). 
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Figure 4.8:  Cumulative lidocaine permeation from lidocaine (a) NaCMC/gelatine 1:1.6 
(F1), NaCMC/gelatine 1:2.0 (F2), NaCMC/gelatine 1:2.33 (F3) and NaCMC/gelatine 
1:2.66 (F4) and PD, NaCMC/gelatine 1:2.66 by rotary evaporation prep stage (F5). (b) 
F4 PD and comparative pre-treatment with ultrasound at 15 W and 18 W for 5 and 10 
min, respectively. (c) F4 adapting MN patch for a 3 min and 5 min pre-treatment 
duration for lidocaine NaCMC/gel 1:2.66. (d) F4 adapting NaCMC/gelatine 1:2.66 (F4 
PD), NaCMC/gelatine 1:2.66 (F4 US, 18W 10 min), NaCMC/gelatine 1:2.66 (F4 MN, 5 
min) and NaCMC/gelatine 1:2.66 (F4 MN 5 min and US 18W 10 min).  (e) 
NaCMC/gelatine 1:2.66 (F5 PD), NaCMC/gelatine 1:2.66 (F5 LFS, 18W 10 min), 
NaCMC/gelatine 1:2.66 (F5 MN, 5 min) and NaCMC/gelatine 1:2.66 (F5 MN 5 min, 
LFS, 18W 10 min). 
d 
e 
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4.3.8  Ultrasound only pre-treatment of lidocaine NaCMC/gelatine ratio 1:2.66 hydrogel 
To observe the effect of power and application time of LFS has on permeation, LFS 
was applied continuously with varying power and exposure time as shown in Figure 
4.8b. Theoretically, the exposure of LFS should form inertial cavities in the coupling 
medium and develop micro-jets toward the skin surface to aid permeation. 
However, lidocaine transport through the skin saw no significant enhancement up to 
2 h after which a significant enhancement, especially power induction, 18 W at 10 
min for lidocaine NaCMC/gelatine 1:2.66 (T-test p < 0.026) outlined a greater 
permeation profile. The results conclude that an increase in power has a greater 
enhancement effect compared with an increase in LFS exposure time; however, no 
significant increase in lidocaine transport through the skin was observed during the 
initial stages after varying respective power induction and time durations while 
maintaining constant NaCMC/gelatine ratios of lidocaine hydrogel drug application. 
It is predicted that a higher LFS power level would further increase diffusion; 
however, the risk of thermal effects would be too high for this to be of practical use. 
 
4.3.9  MN pre-treatment of lidocaine NaCMC/gelatine ratio 1:2.66 hydrogel 
PD permeation (Figure 4.8d) and MN assisted permeation (Figure 4.8c) with a post 
application time limit of 3 and 5 min concurrently were compared altogether. MN 
only pre-treatment of lidocaine NaCMC/gelatine 1:2.66 hydrogel generated a 
substantial increase in lidocaine permeation for both the 3 and 5 min post MN 
duration (Figure 4.8c). A statistically significant difference (p < 0.04) was observed 
for MN application duration. Initial (t=0.5 h) permeation for the 3 and 5 min patch 
duration resulted in increases of 9 and 17 fold, respectively. An average 3 fold 
increase in permeation was observed for the 3 min MN application and 
comparatively an increase by 4 fold for a 5 min MN application. The results indicate 
that therapeutic levels of lidocaine could be reached within 0.15 h or 9 min post 
application MN, in comparison to no pre-treatment requiring 40 min (Figure 4.8c 
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and 4.8d). The reason for this short lag time is due to lidocaine microparticles 
traveling at a shorter path length to the deep dermis layer. The SC layer has been 
bypassed by artificial MN cavities. MN assisted cumulative release study with 
respect to lidocaine formulations has not been performed In vivo to date. However, 
in vivo release studies have been performed using non degrading polymeric MN 
array coating of lidocaine alone, sustained approximately 15 min of delivery thus 
proven successful for rapid emergency anaesthesia (Zhang et al., 2012a,b). In vivo 
release studies with ex vivo cumulative release studies are completely 
incomparable due to obvious differences in experimental procedures and removal 
of active drug for characterization. The lidocaine NaCMC/gelatine 1:1.6 ratio (Figure 
4.8a) hydrogel crosses the therapeutic level at significantly slower time duration, 
greater than 30 min in lidocaine NaCMC/gelatine 1:2.66 ratio in comparison of MN 
and LFS treatment. This is due to the fact that MNs and ultrasound are involved in 
either cavity engulfing of larger sized hydrogel microparticles. 
 
4.3.10  MN and ultrasound (dual) pre-treatment of lidocaine NaCMC/gelatine ratio 
1:2.66 hydrogel 
Both pre-treatments (dual) were combined and studied for further permeation 
enhancement in comparison to MN or LFS pre-treatment only. Lidocaine 
NaCMC/gelatine 1:2.66 hydrogel in which combining a 10 min application of 18W 
LFS after a 5 min application of MNs demonstrated an initial faster permeation by 
23 fold with an average 4.8 fold increase over 30 min of application when compared 
with separate device treatments and PD (Figure 4.8d). Therapeutic levels of 
lidocaine could theoretically be reached after 7 min post application in terms of 
reaching the deep dermis layer of skin as the target. A general increase in 
permeation throughout the period of experimentation can be noticed rather than 
post 2 h as seen with LFS pre-treatment only, this could be due to efficiency of LFS 
pre-treatment is further enhanced on porous skin sample formed via the MN patch. 
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4.3.11  Dual pre-treatment of lidocaine NaCMC/gelatine 1:2.66 hydrogel via a rotary 
evaporation method 
Lidocaine NaCMC/gelatine 1:2.66 hydrogel with the rotary evaporation method as 
described earlier, favoured an additional time of nearly 0.9 h or 50 min after the 
application of 18W LFS at 10 min (p < 0.04) to reach minimum therapeutic level in 
conjunction to a two fold average increase in permeation after 1 h, compared with 
the same formulation without rotary evaporation method (Figure 4.8d and 4.8e). 
This was the likelihood of higher heating temperatures compromising the 
glutaraldehyde fixation and thus resulting in larger microparticle as previously 
reported. Higher heating temperatures were required in the large volume removal of 
n-hexane and paraffin oil mixture by solvent evaporation. A 5 min application of the 
MN array led to an initial increase by 2.8 fold and subsequently an average 3.4 fold 
increase was observed with respect to the deep dermis layer skin target. Combining 
the two pre-treatments resulted in an initial permeation increase by 3.8 fold followed 
by an average increase by 4.1 fold in comparison to PD only (Figure 4.8d and 
4.8e). Therapeutic levels of lidocaine were reduced from just over 2 h to less than 1 
h on average. 
 
4.3.12  Mass transfer of lidocaine from NaCMC/gelatine 1:2.66 hydrogel 
The percentage of lidocaine remaining inside ex vivo skin was determined by the 
subtraction of the mass of lidocaine initially encapsulated during formulated 
preparation (125 000 μg) by the cumulative amount detected in DI water from 
controlled release studies. The purpose of using controlled release studies is to 
determine the amount of lidocaine contained in the vehicle as mass balance before 
the subtraction of the mass of lidocaine in the receptor in which the DI water in the 
receptor is the deep dermis. All mass balances were carried out in μg and 
converted from cumulative concentration units of μg/ml before the percentage of 
lidocaine remaining inside the skin was determined (Figure 4.9). Overall the mass 
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transfer of lidocaine with respect to all treatment applications appeared to outline a 
gradual, a slow process of diffusing through the full thickness appendage. However, 
there is a fairly substantial decline in the percentage of lidocaine remaining inside 
the skin when MN and ultrasound treatment (LFS) method was applied. This can be 
interpreted as diffusion of lidocaine molecules through skin cells and layers before 
clearance into the blood stream. The lowest percentage of lidocaine remaining in 
the skin is 99.7% after a time of 3 h (Figure 4.9). 
 
 
Figure 4.9: Percentage of lidocaine contained in (F4) NaCMC/gelatine 1:2.66 (PD), 
(MNs, 3 min), (MNs, 5 min), (LFS 5 min 15W), (LFS 10 min 18W), (MN + LFS). Error 
bars outline a random error range of 0.005%) 
 
4.4 Chapter summary 
This study aimed to use LFS and MNs as a pre-treatment to skin in order to 
enhance permeation of lidocaine encapsulated in a formulation. A significantly more 
microparticle stability was found with lower gelatine ratios (1:1.6); however, all 
formulations were sufficiently stable (Zeta potential: ≥ -30 mV). Our diffusion 
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experiments revealed a small increase in diffusional permeation when LFS was 
used in combination with a MN array pre-treated skin. However rotary evaporation 
during the final polymeric drug formulation stage caused significant reductions in 
lidocaine permeation levels. Nota bene that the main purpose for utilizing rotary 
evaporation was for reduced time in the removal of a large volume of residual 
paraffin and n-hexane as the final operative method compared with vacuum oven 
drying (data not shown).  
 
Lidocaine NaCMC/gelatine 1:2.66 and lidocaine NaCMC/gelatine hydrogel 1:2.66 
formulated by rotary evaporation showed a decreased time required to reach 
minimum therapeutic levels of lidocaine by 5.7 and 2 fold, respectively. Generally, 
lidocaine permeation was significantly increased with higher sonophoresis power 
and increasing exposure duration demonstrated a minor increase in the permeation 
rate for lidocaine NaCMC/gelatine hydrogel formulations. Also, the MN application 
time duration of 5 min resulted in a highly favourable increase in lidocaine 
permeation. Furthermore, combining MN and LFS pre-treatments allowed for the 
time to reach minimum therapeutic lidocaine levels to be significantly reduced, For 
example, in the case of lidocaine NaCMC/gelatine, 1:2.66 hydrogel therapeutic 
thresholds of lidocaine were reached within 7 min of application. The mass transfer 
effects in which the percentage of lidocaine remained in the full skin depicted the 
gradual movement of drug in targeting pain receptors below the SC layer. The 
lidocaine NaCMC/gelatine 1:2.66 hydrogel treated by MNs and LFS shows a 
greater mass transfer profile. The US and MN treated lidocaine NaCMC/gelatine 
1:2.66 has a 0.18% mass transfer of lidocaine through skin within 2 h compared 
with 0.01% mass transfer of lidocaine through skin. Therefore, this method is 
promising and could be of medical use as a painless, easy to administer technique 
for drug delivery overcoming the time constraints associated with delivery of 
lidocaine. The resources and materials in developing a lidocaine NaCMC/gelatine 
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1:2.66 hydrogel without rotary evaporation is economical on a batch scale at 
present. Lidocaine NaCMC/gelatine 1:2.33 formulation with defined morphological 
appearance is able to remain on the surface of the skin for longer durations 
compared with a lidocaine solution of the same mass loading. 
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Chapter 5 
Lidocaine permeation from a lidocaine NaCMC/gelatine microgel 
formulation in microneedle-pierced skin: vertical (depth averaged) 
and horizontal permeation profiles 
 
Chapter overview  
Common local anaesthetics such as lidocaine are administered by the hypodermic 
parenteral route but it causes pain or anxiety to patients. Alternatively, an ointment 
formulation may be applied which involves a slow drug diffusion process. In 
addressing these two issues, this chapter aims to understand the significance of the 
‘poke and patch’ MN treatment on skin in conjunction to the lidocaine permeation, 
and in particular, the vertical (depth averaged) and horizontal (e.g. lateral) 
permeation profiles of the drug in the skin. The instantaneous pharmacokinetics of 
lidocaine in skin was determined by a skin denaturation technique coupled with 
FDC measurements of the drug pharmacokinetics. All pharmacokinetic profiles 
were performed periodically on porcine skin. Three MN insertion forces of 3.9, 7.9 
and 15.7 N were applied on the MN to pierce the skin. For the smaller force (3.9 N), 
post MN treated skin seems to provide an ‘optimum’ percutaneous delivery rate. A 
10.2 fold increase in lidocaine permeation was observed for a MN insertion force of 
3.9 N at 0.25 h and similarly, a 5.4 fold increase in permeation occurred at 0.5 h 
compared to PD delivery. It is shown that lidocaine permeates horizontally beyond 
the area of the MN treated skin for the smaller MN insertion forces, namely, 3.9 and 
7.9 N from 0.25 to 0.75 h, respectively. The lateral diffusion/permeation of lidocaine 
for larger MN treated force (namely, 15.7 N in this work) seems to be insignificant at 
all recorded timings. The MN insertion force of 15.7 N resulted in lidocaine 
concentrations slightly greater than control (PD) but significantly less than 3.9 and 
7.9 N impact force treatments on skin. We believe this likelihood is due to the skin 
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compression effect that inhibits diffusion until the skin had time to relax at which 
point lidocaine levels increase. 
 
5.1 Introduction 
The specific nomenclature expressed in chapter 4, lidocaine HCl, to be called as 
lidocaine herein, is a drug which is used as a local anaesthetic for superficial skin 
wounds (Smith et al., 1999; Quinn et al., 2014). Traditionally, lidocaine is delivered 
by hypodermic injection for parenteral administration. This causes pain and often 
trepidation coupled with patient phobia, which may obstruct the successful delivery 
of the drug (Nir et al., 2003; Kim et al., 2014). Other traditional methods of lidocaine 
delivery involve the use of topical ointment (e.g., AnestenTM, Haim International, 
Seoul, Korea) and TD patch (e.g., Lidoderm® patch, 2013). However, they have a 
disadvantage of taking a longer time for the drug to diffuse into the dermis layer 
through the SC layer of skin (Singh and Morris, 2011). In percutaneous lidocaine 
delivery, the formidable challenge is to bypass the SC. This layer is 10-15 μm thick 
and it is the skin’s uppermost barrier to foreign particulate entry into skin (Akhtar, 
2014; Sivamani et al., 2005). This chapter carries forward the formulated lidocaine 
NaCMC:gelatine 1:2.3 microgel for a direct, depth averaged, In Vitro skin analysis 
via the poke and coat technique. Common conventional FDC methods are severly 
restricted to deep dermal and systemic clearance diffusion of drugs.  
 
 In general, the mass flux due to diffusion of drug molecules through the SC is 
affected by the molecular hydrophilicity and the concentration gradient across 
different skin depths (Allen, 2002). FDC is typically adopted to determine the in vitro 
mass transport properties of the active molecules passing the SC (Raphael et al., 
2013) or the whole skin thickness (Nayak et al., 2014a; Nayak et al., 2014b). 
Depending on the direction of concentration gradient and permeability, an active 
molecule can, however, diffuse both vertically and horizontally in skin tissues. In the 
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present context, horizontal permeation is taken in a broad sense. It may imply both 
lateral and transverse permeation in a cartesian coordinate system or radially for 
circular co-ordinate system. 
 
The migration of the active molecules due to a concentration gradient from the skin 
surface is the most commonly accepted in vitro vertical (depth averaged) TD 
delivery. The meaning depth average is the average depth of full thickness skin 
sections devoid of SC. The depth average of full thickness skin cannot be deduced 
metrologically accurate because of the known elastic property of skin.  These 
molecules bypass the VE and dermis layer before appearing into the receptor 
compartments of FDC. In a similar manner, the horizontal permeation of the drug 
molecules is achieved from in vitro skin biopsy. Following this, a direct drug 
transport quantification technique in the lateral (x-direction), transverse (y-direction) 
or radial (r-direction) directions at different distances from an epicentre of the skin 
(Figure 5.1a) provided the drug transport can be determined analytically. In the 
case of MN treated skin, e.g., ‘poke and patch’ type delivery (Bal et al., 2010), the 
origin of a drug can be the outermost (e.g., skin surface) and/or the inner locations 
of the skin (e.g., micro-cavity). As far as we are aware, there are few or no studies 
relating to the migration of a drug molecule in both vertical and horizontal directions 
in MN pierced skin, and in particular, lidocaine delivery using MNs. This issue can 
be particularly important for distribution of lidocaine delivered in skin via the 
implementation of this direct depth averaged biopsy technique. 
 
Skin can be interpreted as a complex hydrophobic membrane because of the 
inherent barrier property against most exogenous molecules. In most cases, small, 
hydrophobic molecules migrate by intracellular and intercellular routes inside the 
skin. At a given time, biopsied sections of the skin can be homogenised and 
denatured for the purpose of disrupting the skin tissue structure and releasing the 
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active molecules into sample vials for determining their concentrations, e.g. 
analyses using HPLC (Peira et al., 2014). The homogenisation and denaturing of 
skin is discussed further in this chapter. 
 
In a number of recent studies, it has been discussed that MN assisted 
percutaneous delivery of lidocaine may be beneficial in numbing a larger surface 
area of skin and minimising possible clearance from predominate vertical 
permeation of the drug (Nayak et al., 2014a; Nayak et al., 2014b; Zhang et al., 
2012a; Mitragotri, 2003). Parenteral administration of lidocaine may increase the 
chances of clearance resulting in its depleted levels in the systemic circulation 
(Bari, 2010). Hypodermic needles in parenteral administration are common in 
reaching systemic circulation depths because of their macroscopic dimensions.  
Therefore hypodermically delivered lidocaine will clear in blood circulation.  
Lidocaine is metabolised in the systemic circulation by various enzymes, and 
additional medications such as statins and chemotherapeutic agents can potentially 
increase the clearance of lidocaine influenced by the metabolism (Olkkola et al., 
2005; Gudin, 2012). Furthermore, the diffusion of hydrophobic and hydrophilic 
molecules in SC layer has been reported to be faster laterally than vertically across 
the skin because of the continuous nature of the intercellular pathway (Johnson et 
al., 1997; Schwindt et al., 1998). As far as we know, there is only one reported 
experimental study on horizontal permeation of lidocaine in full thickness skin 
(Zhang et al. 2012a). In this study, a method of dip coating MNs with lidocaine and 
single patch application was attempted. After skin samples were enzymatically 
digested, it was found that therapeutic thresholds could be sustained for short 
durations and higher lidocaine concentrations could be obtained for longer 
durations when combined with a vasoconstrictor epinephrine after treatment with 
dip coated liquid crystalline polymer MNs (Zhang et al., 2012a). 
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As a drug delivery method, MNs have been reviewed significantly in the literature 
and therefore, they are not discussed in length in this chapter (Nayak and Das, 
2013; Cheung et al., 2014; Cheung and Das, 2014). The MNs can be constructed 
from silicon, metals or polymers (Allen et al., 2002; Nayak and Das, 2013; Olatunji 
et al., 2014). Hypodermic needles are restricted to metallic materials which is 
normally medical grade stainless steel. In principle, they should pierce past the SC 
layer to form micro-cavities in the skin before drug application or pre-loaded with 
drugs at the point of application. In other cases, the MNs dissolve once in the skin 
releasing the drug to allow increased permeation rates (Yeu-Chun et al., 2012). The 
re-sealing time of MN induced cavities in skin has evoked interest when considering 
the poke and patch technique (Bal et al., 2010) and, drug pharmacokinetic 
thresholds have been found to be affected when pore closure is considered. For 
example, Brogden et al. (2012) expressed the half-life of pore closure from placebo 
MNs at 18.2 h and 87.5–97 % of microcavities were closed between 54.7–91.2 h. In 
the case of lidocaine application with the help of MN, time duration of 45 min to 1 h 
may be short in attempting to relate the possible effects on pore closure time with 
micro-cavity drug permeation; however, there is little or no evidence in this regards 
at the moment. 
 
Recently, a lidocaine NaCMC/gelatine bipolymeric formulation has been suggested 
for controlled permeation of lidocaine in MN pierced skin (Nayak et al., 2014a; 
Nayak et al., 2014b) where the authors have used a poke and patch approach for 
percutaneous delivery of lidocaine. Subsequently, the permeation profiles of the MN 
pierced skin for various mass ratios of NaCMC/gelatine with lidocaine were 
determined. The MN pierced skin showed faster lidocaine permeation than 
untreated MN skin for vertical layer skin profiles. Lidocaine was released into the 
skin from the formulation and it bypassed the SC layer because of the MN cavities. 
Transverse microsliced, treated skin imaged microscopically initially showed the 
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irregular morphology of artificial micro-cavities. This irregular morphological outline 
is very different from a rounded natural pore micro-cavity. From skin micrographs, 
the penetration depths were accurately measured. Furthermore, the physico-
chemical properties of the formulations, encapsulation efficiency, Zeta potential, 
mean particle size and morphology have been studied. In principle, the MN 
treatment of skin allows further increase in the efficacy of lidocaine permeation as 
well as controlled spreading of the drug formulation along the skin surface as 
demonstrated in the above studies. 
 
In general, homogenisation of skin adopts mechanical forces of shearing and 
compression of skin into shredded tissue components. For example, a rotor 
component of a rotor/stator homogeniser may be used which creates low pressure 
areas, moving suspension material (e.g., skin tissue debris) towards a sub 500 μm 
gap between the rotor and stator, shearing any trapped suspension material 
(Goldberg, 2008). However, the adaptation of a rotor/stator homogeniser is 
unsuitable for shredding dissected thin skin slices below 500 μm thickness. This is 
due to the skin not being properly sheared if it enters and exits the rotor/stator. An 
alternative homogeniser is a glass tissue grinder (e.g., constructed from Teflon) and 
comprising of a specialist mortar test tube (Akin and Norred, 1976). Sharp blade-
based shear homogenisation is not a regular process for skin tissue samples 
despite not requiring external power sources. An example application of this can be 
found in cutting of porcine ear tissue before denaturation by dimethylsulfoxide 
solution (Peira et al., 2014). 
 
Another method which involves the pestle and mortar skin homogenisation 
(Entenman, 1961) without the need for direct current or alternating current supply 
was adopted in our study. There have been a relatively small number of 
publications outlining the details of this technique for skin homogenisation prior to 
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drug quantification in skin layers. Conceptually, the method aims to increase the 
amount of ruptured cells and dissemble the organised cell packing in skin tissues 
randomly. There is a likelihood of tissue sections that have not been exposed to 
sufficient shear forces. Therefore, this alone cannot suffice for the purpose of drug 
detection and, hence, a second step of cellular denaturation is required to release 
the drug molecules for subsequent detection. The second stage of enzymatic 
protein denaturation of skin specimens are outlined in examples of quantification of 
hydroxyproline as a byproduct of α-chymotrypsin hydrolysis from fragmented 
collagen (Fligiel et al, 2003) and the quantification of combined chemical enhancers 
such as 5-aminolevulinic acid with glycerol monooleate in epidermal skin delivery 
(Steluti et al., 2005). However, diode array detection and peak area quantification of 
active macromolecules eluting at similar detection wavelengths ranges to enzyme 
and skin protein by products is unachievable by LC-DA analysis alone. Therefore, 
heat denaturation technique may be used.  
 
High temperatures above 50 °C for a long period allow for intra and extracellular 
denaturation of skin proteins (Viglianti et al., 2014). Denaturation temperature of 
human skin at 38.5 °C allows the appearance of imino acid residues in protein 
breakdown (222 imino residue parts per 1000 part amino acids) (Bornstein and 
Piez, 1964). Collagen based porcine skin has a denaturation temperature of 37 °C 
(Lui et al., 2007; Nagai, 2002). Also, dry heating (e.g., a thermal effect generated by 
passing hot air) at temperature ranging from 100 to 315 °C on skin surfaces result 
in the weakening of mechanical properties and disorder of keratin network of the 
skin (Park et al., 2008). Adaptation of dry heat ablation of skin at high temperatures 
occurred during micro second time frames as longer durations would have 
denatured more skin proteins below the upper layers (Park et al., 2008). Also, 
prolonged dry heat ablation would burn skin into powdered carbon ash and 
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lidocaine will be undetectable by LC-DA methods as the chemical structure would 
be changed completely. 
 
Keeping the above discussed points in mind, lidocaine permeation rates have been 
analysed in the vertical and horizontal directions in this chapter specifically for 
lidocaine NaCMC/gelatine bipolymeric formulation. Alternatively, to Zhang et al. 
(2012a), enzymatic denaturation technique, homogenisation followed by heat 
denaturation of the in vitro skin biopsy was performed to determine the horizontal 
permeation profile in the MN pierced skin from the epicentre location.  FDC was 
used to determine the vertical permeation profiles into clearance. For the purpose 
of this work, a poke and patch technique was adopted using fixed MN insertion 
forces (Cheung et al, 2014; Olatunji et al., 2014; Milewski et al., 2013) with the 
purpose to obtain reproducible artificial micro-cavities and to enhance the 
percutaneous lidocaine delivery in bypassing the SC layer of skin. Constant MN 
insertion forces from a pneumatic pressure based force device are applied and held 
for fixed time duration to allow the MNs to pierce the skin as uniformly as possible 
(Cheung et al., 2014). This also ensures that the MN cavities are formed so as to 
just pierce past the SC providing small MN holes for percutaneous drug delivery. 
 
In the context of this chapter, we aim to relate the effects of MN insertion forces 
with the instantaneous pharmacokinetic distribution of lidocaine towards vertical 
(depth averaged) and horizontal permeation in skin. Ideally, the lag time for 
therapeutic level of lidocaine permeation needs to be the shortest possible for 
affecting the skin target region. Nevertheless, a sustained therapeutic level for up to 
45 min is considered to be most ideal in numbing the area, for example, in the 
treatment of skin wounds or localised biopsy of abnormal skin tissue. Procedures 
such as ablative skin resurfacing requiring at least 60 min for uniform anaesthetic 
effect can potentially be shortened to 45 min duration maximum for regaining 
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complete local sensation in the area and reducing patient waiting time (Sobanko et 
al., 2012). Within this work, a method of measuring the vertical diffusion coefficient 
through porcine skin is also attempted. This required first the use of a FDC followed 
by centroid and diametric from centroid punching of the square sectioned skin 
which were subsequently homogenised mechanically and heat denatured. It is 
expected that this chapter would allow better understanding of vertical and 
horizontal permeation of lidocaine in MN pierced skin. 
 
 
 
 
 
 
 
 
 
Figure 5.1: Schematic diagram a) the epicentre punch where the blue circle shows the 
area/size of the chosen microneedle patch b) the orientation of microneedle imprints in 
obtaining a slice in quantifying micro-cavity pathlengths. c) pre-fabricated microneedles 
adopted (AdminPatch®, Sunnyvale, USA) for ‘poke and patch’ drug delivery in this 
work.  
 
5.2 Material and methods 
 
5.2.1  Materials 
The reagents used in the preparation of lidocaine NaCMC/gelatine hydrogels were 
the exact specification as outlined in section 3.2.1. The column and reagents used 
in HPLC analysis were also taken from section 3.2.1 and 3.2.11. However the 
buffering reagent for HPLC was replaced with trifluoroacetic acid (>99 % assay) 
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purchased from Sigma-Aldrich Ltd, Dorset, UK. The purpose for using trifluoroacetic 
acid was to further reduce peak broading of lidocaine which is detected in acidic 
conditions. Skin was acquired as mentioned in section 3.2.5. Essential materials for 
stainless steel MNs (AdminPatch®1200, nanoBioSciences PLC, California, USA) 
and FDCs (Logan Instruments Inc., ‘FDC-6’, New Jersey, USA) were already 
available.  
 
5.2.2  Preparation of lidocaine NaCMC/gelatine microgels 
The optimum lidocaine NaCMC/gelatine 1:2.3 microgels were prepared exactly as 
outlined from the methods stated in Nayak et al. (2014a) devoid of the rotary 
evaporation method. The principle of rotary evaporation is removal of excess water 
and organic solvent mixture containing paraffin oil and n-hexane. The reason for 
choosing NaCMC/gelatine 1:2.3 as the optimum vehicle was due to the ideal 
physico-chemical properties outlined in Chapter 3. 
 
5.2.3  Percentage encapsulation efficiency 
The characterised percentage EE for our lidocaine microgel formulation (equation 
3.3) was calculated as discussed earlier (Nayak et al., 2014a; Nayak et al., 2014b). 
 
A 5 % of the mean total sample weight was used to save time in preparation of new 
batches of formulation for one set of tests. Lidocaine microgels formulated on a 
batch scale was a time consuming process and complete samples were not tested 
here. The lidocaine hydrogels were diluted with 20 ml of ultrapure water as excess 
solvent heated to 40 ± 0.5 °C and sonicated (Branson Digital Sonifier 450, USA) at 
15–20W for 2 min. This allows lidocaine to dissolve in ultrapure water. Normal 
sonication frequencies cut approximately 24 h maximum time required to disrupt the 
electrostatic and covalently held microparticle interactions between NaCMC and 
gelatine by high temperature denaturation without boiling the drug (Banerjee et al., 
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2012). Also the time for sonication here was a fifth less than the one performed in 
section 3.2.7. This was because a probe device directed ultrasonic waves directly 
into the medium than a bath arrangement with a constant power of 35 W (Fisher 
Scientific, Loughborough, UK). The ‘dissolved lidocaine’ was filtered using Nylon 
6,6 membranes of 0.1 μm pore size (Posidyne membranes, Pall Corporation, 
Portsmouth, UK) before quantification by HPLC analysis. 
 
5.2.4  Microgel morphology and microparticle diameters 
The morphology of lidocaine NaCMC/gelatine 1:2.3 microgels was characterised as 
described in section 3.2.10 and analysed via ImageJ software as described in 
section 4.2.5. 
 
5.2.5  In vitro permeation studies 
The amounts of lidocaine in the VE layer and systemic layer (receptor of FDC) were 
determined from in vitro studies. The pharmacokinetics was subsequently deduced 
from in vitro quantification for vertical and horizontal permeation of lidocaine 
assuming homogeneity of the VE layer for molecular diffusion, i.e. isotropic diffusion 
profiles (Naegel, 2013). 
 
5.2.6  Skin preparation 
As recommended in Meyer et al, (2007), whole porcine auricle squares of 4.0 cm2 
were laterally thin sliced and the cartilage, connective tissue and fatty components 
were discarded. All visible hair was removed using scissors to minimise any 
obstruction with the placement of lidocaine microgel on skin. MNs (AdminPatch® 
1200) were applied on the skin for up to 5 min. Each needle was preset to 1100 μm 
length with a MN density of 43 in 1 cm2 surface area. MNs fabricated at 1000 μm 
length have the same pain scores from a visual analogue scale on human subjects 
in comparison to the borosilicate glass material extruded at 500 μm length when a 
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saline volume of up to 0.6 ml was delivered in the dermis layer of skin (Gupta et al., 
2011b). Normally, the entire length of MNs from base to tip does not penetrate the 
skin with the needle base touching the skin surface because of the elastic folding 
effect of skin (Allen et al., 2002). A full thickness skin piercing using 1100 μm length 
MNs and the MNs density resulted in approximately 400 μm deep cavities (Nayak 
et al., 2014b). However, we controlled the MN cavities to a much smaller length so 
as to just pierce the SC in this work as discussed below. 
 
5.2.7  Application of MN insertion force 
In order to ensure that uniform force is applied to pierce the skin, the MN patch was 
applied on the skin samples at 0.5, 1.0 and 2 bar pressures equating to forces of 
3.9, 7.9 and 15.7 N, respectively. The minimum insertion force achievable using an 
in-house pressure/force device (Cheung et al., 2014) was 3.9 N. The three insertion 
forces adopted here were constant forces as a hypothetical standard if an 
applicator device were to be fabricated to insert the MNs into skin. Thumb pressure, 
as often done to insert MN on skin, was not applied as they may introduce some 
variability in the forces applied. Furthermore, the forces were chosen so as to just 
pierce the skin keeping in mind the percutaneous delivery of lidocaine where the 
MNs cavities are small rather than large which facilitate TD permeation of the drug. 
The insertion forces were applied via a vertically arranged pressure/force impact 
device (SMC Pneumatics Ltd., Buckinghamshire, UK; serial: CD85N16-50-B) as 
adopted from Cheung et al, (2014). The insertion force was calculated using 
equation 5.1: 
𝐹𝐹 =  𝑝𝑝𝜋𝜋𝑑𝑑24                                                                                         (5.1) 
Where F is the force (N), p is the pressure (N/mm2), and d is the piston bore 
diameter (mm). As the piston rod is lowered far down the cylinder compartment so 
that the punch unit touches the MN substrate, the outstroke impact of a double-
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acting cylinder is the dominating force in a double acting pressure device 
(Padmanabhan et al., 2014). Independent air pressures at 0.5-2 bar ranges were 
impacting on the bore area of the lowered piston rod. The bore area was contained 
inside a closed piston chamber so that compressed air could not escape the piston 
chamber and impact the tissue directly. Therefore, equation 5.1 is implemented in 
determining the vertical compression force. 
 
5.2.8  Colour dye of skin samples 
Skin samples were dyed to show qualitative MN piercing patterns through skin in 
plan (top) view as a quick method to determine if MNs have pierced the skin. As in 
in vitro studies, the device outlined by Cheung et al. (2014) was used to treat skin 
samples at 3.9, 7.9 and 15.7 N for up to 5 ± 0.1 min. Samples were observed after 
dyeing with a natural blue food colouring (Sainsbury’s, Loughborough, 
Leicestershire, UK). 
 
5.2.9  Characterisation of microcavities 
Similar MN impact forces and time taken as mentioned in sections 5.2.7 and 5.2.8 
were subjected on the skin samples. The largest cross sectioned row of channels 
was viewed by micro-dissecting strips in plane to MN path as shown in Figure 5.1b. 
An image of a MN patch (AdminPatch®) adopted for the poke and patch method 
throughout this study is shown in Figure 5.1c. As described in Section 4.2.9, the 
skin samples were cyroglued prepared, cryotomed (5 μm), dyed in methylene blue 
solution (0.5 % w/v) (Sigma-Aldrich, Dorset, UK), observed under the microscope 
(Ceti S035, Chalgrove, Oxfordshire, UK) and scaled using an image processing 
software (ImageJ, National Institute of Health (NIH), USA) with a certified graticule. 
Unlike in the previous method of using proprietary food colouring, the distinct blue 
colour density between SC and VE layer can only be observed by methylene blue 
dye. Methodology for this was adapted from Chueng et al, (2014). Additionally, 
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flash freezing was adopted to preserve pierced holes created as compared with 
slow 24 h freezing at −30 °C in a cryotome. As stated above, the SC layer is 
accepted to be the topmost (first) ~15 μm thick skin layer in accordance with 
literature e.g., Sivamani et al, (2005). It was also confirmed by dissecting 5 μm 
transverse slices of skin and studying under the microscope after dying the skin 
surface with methylene blue solution (0.5% w/v) (Sigma-Aldrich Ltd., Dorset, UK). 
The recommended concentration of methylene blue solution and the approximate 
time in allowing dye diffusion through skin was adopted from Singh and Banga, 
(2013) and Kalluri and Banga, (2011). 
 
5.2.10  Permeation study 
Lidocaine permeation studies were performed using MN treated skin, which were 
compared with PD profiles of the drug. The FDC setup was similar to section 3.2.5. 
The lidocaine loaded in the microgel was 2.44% w/w. The FDC receptor orifice was 
measured 0.679 cm2. Lidocaine formulations were dispensed on the epicentre of 
the skin (Figure 5.1a) (Nayak et al., 2014a; Nayak et al., 2014b). The total receptor 
volume was 5.0 ± 0.025 ml. Receptor volumes (1.5 ± 0.5 ml) were removed at 0.25 
h intervals. The total duration of in vitro study was 1 h. After the FDC experiments, 
the epicentre and diametrically opposite regions of the skin was biopsied (Figure 
5.1a) (RS International, Nottinghamshire, UK). The epidermis of punched skin was 
temporarily bonded using Cryo-M-bed inert glue (Bright Instrument Company Ltd., 
Cambridgeshire, UK) onto pre-chilled sample holders frozen in a cryotome (−30 °C) 
for 30 min (Bright Instrument Company Ltd., Cambridgeshire, UK). Horizontal SC 
layer micro dissection followed and first 15 μm thick layer was accepted as the SC 
layer (Swindle, 2008) with the remaining skin layer saved as VE for lidocaine 
quantification. The VE and dermis boundary was not possible to separate 
accurately as compared to the SC and VE boundary by cryotome dissection. 
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The depth resolved mass transfer of lidocaine through the skin involved treated skin 
samples separated into the VE and systemic layer as clearance. The SC layer was 
discarded because the amount of lidocaine was found to be inconclusive and, we 
are primarily interested in the permeation from the micro-cavities created by the 
MNs. There is a likelihood of parts per billion amounts of lidocaine that cannot be 
traced by LC-DA methods as adopted in this work. 
 
The VE samples were homogenised in a pestle and mortar containing pipetted 1.5 
± 0.03 ml DI water (ThermoFisher Scientific, Loughborough, Leicestershire, UK) 
before being denatured in a water bath (Nickel-electro Ltd., Somerset, UK) at 60 °C 
for 1.5 h. Conceptually, lidocaine HCl readily dissolved in the excess solvent water 
due to the thermolabile nature of proteins and onset of denaturation at 40 °C 
(Lepock et al., 1993). After centrifugation at 4443g (8500 rpm) (Eppendorf Minispin, 
Hamburg, Germany), the supernatant was filtered using polyethersulfone (PES) 
membranes (Pall Life Sciences, Portsmouth, UK) with a trapping MW of 1 kDa in 
preventing excess skin proteins and polypeptides contaminants accumulating with 
the released lidocaine. HPLC (PerkinElmer 1200, Abingdon, Oxfordshire) protocol 
was then implemented to analyse the lidocaine allowing deduction of permeation 
kinetics (Nayak et al., 2014b). This study was performed in triplicate. In addition to 
the in vitro studies under taken, several synergistic characterisations were 
performed as discussed in the subsequent sub-sections. 
 
The appearance of lidocaine in “other”, biopsied skin region and clearance 
compartments is an overall mass transfer correlation expressed as a percentage. 
The correlation of lidocaine in the “other” compartment, VE layer (vertical), VE layer 
(lateral) and systemic clearance were calculated as the percentage lidocaine. The 
VE (lateral) was the sum total of lidocaine from all four diametric regions of skin. 
The percentage lidocaine was the total lidocaine detected just after a period of one 
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hour.  The “other” compartment refers to the percentage lidocaine in drug vehicle 
and the remaining non-biospied skin which was discarded. Systemic clearance 
displayed the unit’s µg/ml. All values reported in µg/ml were converted into µg/g of 
lidocaine from the maximum amount released under control after a period of 1 hour 
(g). The percentage lidocaine contained in each compartment is from the total 
amount of drug released from the lidocaine NaCMC/gelatine microgel.  
 
5.2.11  Determination of lidocaine diffusion in skin 
The exploration of lidocaine diffusional pharmacokinetics such as apparent diffusion 
coefficient and permeation flux are obtained from Fick’s diffusion law as shown in 
equation 2.2. When MNs are inserted to pierce of skin, the concept is to increase 
the diffusion coefficient Dm effectively so that there is an increase in mass transfer 
through the SC into the VE layer. If this is achieved, MN poke and patch would 
decrease the dependence on hypodermic needles and improve on the current use 
of creams.  
 
For an infinite donor solution, the concentration of active molecules in a drug 
vehicle is constant and can be adopted from equation 2.2.1 by replacing ΔCvs with  
Ci in which is the concentration of active molecules in a drug vehicle is constant. 
The infinite donor method describes a practice of dispensing the drug on the donor 
area for increased reproducibility (Wagner et al., 2000). In this case, the source of 
the lidocaine is from NaCMC/gelatine microgels (Nayak et al., 2014a; Nayak et al., 
2014b).  
 
Graphically, the cumulative amount of active molecule or drug permeated is plotted 
against time and the linear region of the slope in a polynomial based function graph 
is the permeation rate of drug at steady state (Moser et al., 2001). Due to the 
insignificant number of nociceptive receptors in the SC layer, the VE and dermis (D) 
 Lidocaine permeation from a lidocaine NaCMC/gel microgel form. in MN skin: vertical & horizontal 
 
115 
 
are defined as the target layers where lidocaine is required for effective anaesthetic 
action. A minimum therapeutic lidocaine concentration of 1.5 μg/ml (Ghafari et al., 
2012) is defined to be necessary in the VE and dermis layers for this to be the case. 
Separating the VE layer from the dermis is only possible through histological 
detection of the boundary between cell morphological changes. As mentioned 
earlier, the VE and dermis layer cell boundaries could not be detected uniformly 
and efficiently. The dermis layer skin thickness can vary from 200 to 350 μm (Liu 
and Bergstrom, 1996). However, there is no distinct, fast procedure for VE and 
dermis layer boundary identification, followed by micro dissection according to 
fundamental histological changes in strata. 
 
5.3 Results and discussions 
 
5.3.1  Effects of insertion forces on MN cavities in skin 
As we mentioned earlier, we controlled the MN insertion forces directed on the skin 
surface to ensure reproducible and minimum variability of path lengths for the 
cavities. MN impact forces ranging from 3.9–15.7 N were used in this work. All 
forces were applied for 5 min durations and, in each case, the MNs pierced skin 
(Figure 5.2 and 5.3). In the figures, the dark blue spots were due to liquid dye 
pooling and increased diffusing into the MN micro-cavity’s viable strata. The skin 
images did not show all of the MNs that had punctured the skin at 90° to a 
horizontal plane, as in a small number of cases the regular array triangular based 
pattern could not be identified (Figure 5.3). This effect was caused by needles not 
entering into the skin vertically due to the elastic nature and inherent roughness of 
the skin. The SC layer emerged as a dark blue band along a transverse slice of skin 
as highlighted by a yellow line (Figure 5.3). Initial dissecting of skin at 15 μm 
thickness showed some blade skin stretching due to the applied shear forces 
resulting in some SC thicknesses greater than 30 μm. Thinner transverse slices at 5 
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μm minimised any substantial blade stretching. An average SC thickness of 18.6 
μm was deduced. Although this is marginally larger than the 15 μm conventional 
depth taken in in vitro studies, it was decided that due to the likelihood of minor 
blade stretching of the skin during dissection, the 15 μm would be retained as the 
average thickness of the SC in this study as mentioned in several literature 
sources. Blade stretching effects on 5 μm sliced skin was fairly evident when 
compared with a 15 μm sliced skin that resulted in up to 33 μm SC layers. This 
means that the insertion forces should be designed so as to enable the MNs to 
pierce 15 μm on top of the skin. 
 
After analysis of the skin samples (n=6) corresponding to each MN insertion force, 
the average cavity lengths corresponding to each MN insertion force are calculated 
which are shown in figure 5.4. As expected, increasing the force increases the path 
length. A direct proportionality relationship between the insertion force and cavity 
length (e.g., doubling the force resulting in a doubling of cavity length) was not 
observed. 
 
Figure 5.2: Typical surface images a) Non-treated skin sample. b) MN treated skin with 
insertion force of 3.9 N. c) MN treated skin with insertion force of 7.9 N. d) MN treated 
skin with insertion for of 15.7 N, all after a constant application time of 5 min. The dye 
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(blue colour) is from Spirulina used in the food colouring (Sainsbury’s, Loughborough, 
Leicestershire, UK).   
The cavity length increased 18.4 and 15.8 % from 3.9 to 7.9 and 7.9 to 15.7 N, 
respectively. This suggests that increasing force decreases potential cutting effect 
through the skin. This is likely caused by a resultant force skin compression effect 
from the excess perpendicular force on the skin. As the skin compresses, it may 
become more dense (e.g., higher viscoelasticity) and harder to penetrate deeper 
into the skin. In fact, the increasing force may cause more deformation of the skin. 
This may cause the entering needles to buckle and therefore, they may be unable 
to penetrate as deeply as expected into the skin. Other factors have been shown to 
affect the size of cavities that can be made by MNs such as the viscoelasticity of 
the microgels filling the cavities. This is discussed further by Cheung et al. (2014). 
 
5.3.2  Optimum lidocaine NaCMC/gelatine 1:2.3 microgel 
A favourable mass ratio microgel vehicle according to strong physico-chemical 
interactions between NaCMC and gelatine was chosen for this study. The optimum 
gelatine to NaCMC mass ratio of 2.3 for lidocaine derives from the previous studies 
on Zeta potential and particle sizes by Nayak et al. (2014a). 
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Figure 5.3: Typical microscope images of MN cavities (yellow circle) in micro-dissected 
skin for different MN insertion forces.  
 
 
 
 
 
 
 
 
 
Figure 5.4: Average lengths of MN cavity in skin for different MN insertion forces (n=6 
per force). The results show that the cavity lengths are slightly bigger than the top layer 
of the skin (SC). These are relevant for percutaneous delivery of lidocaine.  
 
This section expresses comparisons with particle morphology and outlines the 
challenge in controlling the encapsulation efficiency of microgels. Lidocaine 
NaCMC/gelatine 1:2.3 microgels were observed to be spherically defined and 
polydisperse (Figure 5.5). 
 
An average of 53 % encapsulation efficiency was deduced for lidocaine 
encapsulation. In comparison to Nayak et al. (2014a) this was slightly higher. The 
observed microparticles range was 1.7-8.0 μm (Figure 5.5) in this work had a 
smaller range than in Nayak et al. (2014a) which would contribute a greater 
encapsulation efficiency because of larger microparticle surface areas (Figure 5.5). 
The polydispersity of the applied formulation was less than in Nayak et al. (2014a) 
because the difference in microgel diameter was 15 μm compared with our current 
study of 6.3 μm microgel diameter.  
 Lidocaine permeation from a lidocaine NaCMC/gel microgel form. in MN skin: vertical & horizontal 
 
119 
 
 
Figure 5.5: Lidocaine NaCMC/gelatine 1:2.3 microgels. 
 
5.3.3  Vertical percutaneous lidocaine permeation 
The trend on the effects of MN insertion force, cavity depths and permeation of 
lidocaine vertically (depth averaged) through the skin are discussed in this section. 
The VE layer is the main focus for lidocaine permeation because we consider this 
to be the target region in skin. It seems that a small force such as an MN impact 
force of 3.9 N was the most favourable for lidocaine permeation through the vertical 
VE layer. A 10.2 fold increase in permeation was observed for a 3.9 N force at 0.25 
h and similarly a 5.4 fold increase in permeation occurred at 0.5 h compared with 
PD permeation (Figure 5.6a). The lidocaine permeated in the VE layer for 7.9 and 
15.7 N MN treated skin was less than the 3.9 N treated skin. This result, at first, 
may appear to be a contradiction to increasing trends because the longer the cavity 
path length, the shorter time and greater concentration of drug in reaching the VE 
layer. However, we believe that the elasticity of the skin causes a cushioning effect 
for the MN arrays and higher MN insertion force does not necessarily allow the 
whole set of MNs in the array sequence to penetrate the skin at double or treble 
depths of proportional MN force (Figures 5.2 and 5.4). This could be worsened by a 
‘bed of nails effect’ in which the MNs are close enough together to spread the force 
causing it to compress the skin rather than penetrating it. Once compressed, the 
diffusion coefficient (Dm) (equation 2.2) of the skin could be decreased, making it 
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more difficult for the molecule to diffuse through the skin despite the increased path 
length (Olatunji et al., 2012).  
 
The error bars representing standard deviation outline good reproducibility, 
especially for the MN permeation results up to t=0.75 h (samples n=3) (Figure 5.6). 
Overall, for the MN chosen, the smallest force (i.e., the force of 3.9 N) showed a 
more favourable transient permeation profile because of substantial increases in 
lidocaine in the VE layer epicentre and a slight plateau effect emerging just after 0.5 
h (Figure 5.6a). The largest MN insertion force, namely, 15.7 N, also shows a 
favourable transient profile with respect to a plateau appearing after 0.25 h but the 
amount of lidocaine permeated in the VE layer is 2.0 and 2.8 folds less than the 
amounts observed for 3.9 N at timings of 0.25 and 0.5 h, respectively (Figure 5.6a). 
 
The main target skin layer for local anaesthesia is the VE layer as outlined in the 
introduction. Figure 5.7 outlines the instantaneous lidocaine permeation profile in 
blood plasma clearance, namely, the receptor cell of FDC (n=3). The Grubb’s test 
(British Standards, 2002) identified outliers from pooled data sets and all outliers 
were eliminated. A coefficient of variance (CoV) identified other possible random 
errors (equation 5.2). 
CoV =  𝑆𝑆𝐷𝐷
𝜕𝜕
                                                                                      (5.2) 
Where SD is standard deviation and 𝜕𝜕 is the arithmetic mean of data points. A 
threshold of up to 30% CoV was taken to justify disregarding any data that caused 
significant increases in SD. The lowest CoV values were taken in triplicate. In cases 
where results were seen to be anomalous, it was likely to be caused by errant skin 
proteins that partially denatured or passed through the pores of the ultrafine PES 
membranes during the released drug filtration stage (permeation study section). 
The concentration of lidocaine (μg/ml) detected in the epicentre VE layer was 
 Lidocaine permeation from a lidocaine NaCMC/gel microgel form. in MN skin: vertical & horizontal 
 
121 
 
converted to permeation-based concentrations (μg/cm2) using equation 3.1, which 
were subsequently used to compute the diffusion coefficients according to equation 
2.2.1. The denominator of equation 3.1 is 0.679 cm2. 
 
In the VE layer of skin, all three MN insertion forces (3.9-15.7 N) (Figure 5.6b) helped 
bypassing the minimum lidocaine therapeutic level of 1.5 μg/ml (Ghafari et al., 2012). This 
was achieved in a small fraction of 15 min despite the control samples appearing to reach 
that level slightly longer. On a dry skin surface, the likelihood of slow PD is a balance in 
stability between electrostatic interactions of polymers, lidocaine and covalent Schiff’s base 
interaction by glutaraldehyde (Nayak et al., 2014a). 
 
With improved formulation giving a greater concentration gradient, this may allow therapeutic 
levels to be reached in a relatively short period of time. The permeation of lidocaine into the 
clearance plasma compartment showed favourable trends for all three MN insertion forces 
and control within 0.75 h (Figure 5.7). 
 
 
Figure 5.6: (Continued to next page). 
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Figure 5.6: Lidocaine permeated into VE skin layer vertically. a) Control and 
microneedle pierced skin at given force induced depths. b) Control and microneedle 
pierced skin crossing the minimum therapeutic level for lidocaine before 0.25 h.   
 
The smallest force of 3.9 N showed the lidocaine crossing over the toxic plasma 
level of lidocaine (5 μg/ml) at a time of nearly 1 h. Usually, a range of 5 to 10 μg/ml 
is considered to be a toxic concentration for lidocaine in blood plasma (Woodruff et 
al., 2010). 
 
5.3.4  SC layer permeation 
The SC layer has the potential to bind certain drug molecules despite not being a 
target region of lidocaine and other local anaesthetics. It is fairly important to outline 
if a significant amount of lidocaine has remained in this layer, and if not, it can then 
be defined that the applied lidocaine has permeated into the lower skin layers 
(Nayak et al., 2014b). 
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Figure 5.7: Lidocaine clearance in control, microneedle treated skin forces (3.9 to 15.7 
N) and the toxic level for lidocaine in plasma clearance concentration.  
 
In this work, the SC layer contained no lidocaine, irrespective of instantaneous MN 
treatment or PD. The results of numerous ‘no result’ and occasional very small (~60 
x 10-5 μg/cm2) lidocaine detected in the SC lead to CoV >30 % and also high 
standard deviations of the results. In any case, the SC layer concentration detected 
and amount permeated retained in the SC was taken as negligible. Although the SC 
layer is the major barrier to diffusion into the skin, it does not retain large quantities 
of hydrophilic molecules in the present context. The rate limiting step appears 
evident in PD of lidocaine into the VE layer as there is a 5.2 fold permeation 
decrease at 0.25 h as compared to MN 15.7 N treated skin. However, due to the 
lack of nociceptive receptors, anaesthesia will not be affected by this and minimum 
therapeutic levels as stated in the introduction are non-applicable. For this reason, 
the SC layer permeation will not be discussed further within this thesis. 
 
5.3.5  Horizontal permeation of lidocaine in VE layer 
The horizontal permeation for lidocaine was depicted as a square apex in the VE 
layer which is outlined and explained according to MN treated skin. The mass 
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transfer of lidocaine was expressed from knowing the mass released for lidocaine in 
excess DI water. The lidocaine concentration and mass transfer observed were 
deduced as favourable with respect to crossing the minimum therapeutic levels. 
The minimum therapeutic level of lidocaine is reported to be 100 μg/g by Zhang et 
al. (2012a). The aim is to understand the shortest possible lag time for horizontal 
permeation of lidocaine. The horizontal permeation colour charts of lidocaine 
permeating at a maximum distance of 1 cm from the epicentre were outlined as 
localised concentration (Figure 5.8) and mass transferred (Figure 5.9). Both figures 
outline completely different minimum therapeutic level trends for lidocaine observed 
in the VE layer. The mass of lidocaine (M) was computed according to equation 5.3. 
M =  𝑑𝑑𝑠𝑠 𝑉𝑉
𝑀𝑀𝑡𝑡
                                                                                       (5.3) 
The coefficients Cs and V are the same as in the numerator for equation 3.1. In the 
denominator, Mt is the calculated mass of lidocaine released from the 
NaCMC/gelatine 1:2.3 vehicle from known periodic timings from controlled release 
studies Nayak et al., (2014a). Full skin thicknesses were an average 670 μm (± 50 
μm) thick. 
 
When considering the concentration of lidocaine permeated in VE layer, all 
regimens including control showed horizontal permeation at minimum therapeutic 
levels (Figure 5.8). A more substantial concentration of horizontal permeation was 
observed for the smallest MN insertion force (3.9 N) from 0.25 to 1 h. This is 
because the same concentration range was observed for all four corners of the 
permeation square. The second most favourable horizontal permeation trend was 
observed for control as concentration equal to or greater than 10 μg/ml was 
sustained from 0.50 to 1 h. However, as expected the horizontal permeation in skin 
for 3.9 and 7.9 N forces showed greater drug concentrations in three to four corners 
of a square as compared with control (Figure 5.8). The mass transfer of lidocaine 
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horizontally is favourable for MN treated skin at 3.9 and 7.9 N because of high 
distributions of lidocaine from 0.25 to 0.75 h. Unlike the previous concentration-
based colour profiles (Figure 5.8), the horizontal diffusion (control) and permeation 
of lidocaine (MN treated 15.7 N) showed below therapeutic mass transfers of 
lidocaine (Figure 5.9). Usually, lidocaine administered by injection potentially results 
in faster permeation dependent on injection depth which is variable, initial drug 
volume from average loading dose of solution and pressure related liquid flow rates 
into site of delivery (Zhang et al., 2012a; Gupta et al., 2011b). The injection of 0.6 
ml or greater volume of a fluid such as saline requires applied pressures greater 
than 1000 mmHg (Gupta et al., 2011b). 
 
The poke and patch method used in this study allows the pseudoplastic microgel 
drug to permeate into the microcavities by pooling and without the need of flow. In a 
similar lateral based study by Zhang et al, (2012a), the lidocaine mass transfer was 
maintained successfully for up to 15 min and two biopsied areas from a total of 
three showed therapeutic levels when considering a distance of 1 cm from the 
epicentre and full thickness skin up to 4000 μm. 
 
5.3.6  The partitioning, flux rate and diffusion coefficient of VE layer for lidocaine 
permeation 
The pharmacokinetics relating to the permeation of lidocaine affected by the MN treatment at 
the chosen forces is outlined and explained in this section. It is evident that lidocaine 
concentration for 3.9 N insertion force increases after 0.25 h as the VE layer concentration is 
increased. This is because the concentration gradient is the driving force for mass transfer 
into the clearance layer. In the last 0.25 h of the experiment, the lidocaine is permeating into 
systemic circulation at a greater concentration than in any previous time interval (Figure 5.7). 
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Figure 5.8: Colour codes to outline the local area and distance for drug permeation 
(horizontal) in the VE layer of skin according to concentration of lidocaine. 
 
The concentration driving force permits lidocaine molecules to disperse across cellular 
structures inside skin both vertically (within epicentre) and laterally, also known as 
horizontally. The slow dispersion of lidocaine molecules within skin is ideal for observing low 
lidocaine contentrations within 0.5 h in systemic clearance, expecially with MN treated skin 
regimens (Figure 5.7).   
 
The MN assisted permeation of lidocaine at the small (3.9 N) and medium (7.9 N) forces 
outline increasing partition coefficients (K), especially 3.9 N treated samples as more 
lidocaine is detected in the skin than the bipolymeric vehicle (Figure 5.10). 
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Figure 5.9: Coloured contrast circles to outline the local area and distance for drug 
permeation (horizontal) in the VE layer of skin according to the mass of lidocaine.  
 
Nevertheless, all three MN pierced skin samples outlined K for lidocaine to be 
significantly greater than the control samples. Normally, K is deduced at observed 
steady state regions of charts at specific time duration in order to derive a constant 
K value as a point of reference. We define pseudo steady state at smaller time step, 
and K values were calculated for different time (Figure 5.10). At a time over 0.75 h 
the maximum partition, K of 0.58 was deduced for the 3.9 N treated samples as 
compared with other treatment technique (Figure 5.10). Drug based partition 
coefficients are normally fractions because the vehicle drug loaded mass is greater 
than the drug in a defined layer of skin.  
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The lidocaine permeation flux outlines a very consistent increasing trend for 3.9 N 
treated skin than control and 15.7 N treated VE layer of skin (Figure 5.11a). As 
expected, the flux was a lot higher for 3.9, 7.9 and 15.7 N MN treated VE skin than 
control (Figure 5.11a). Comparatively, the 3.9 N MN treated VE skin resulted in flux 
values of 13.9 and 10.5 folds greater than control at times of 0.25 and 0.50 h 
(Figure 5.11a). This is because of lidocaine bypassing the rate limiting SC layer of 
MN treated skin and diffusing through the VE layer faster. The permeation flux for 
all treatment regimens in the clearance layer of skin show lower lidocaine flux rates 
from 0.25 to 0.75 h (Figure 5.11b). The permeation flux for 7.9 N treated skin show 
significantly greater clearance levels than control, 3.9 and 15.7 N treated skin 
(Figure 5.11b). The likelihood is because of horizontal permeation as observed 
previously otherwise clearance flux rates would be just as high as VE layer flux 
when considering vertical permeation alone.  
 
The apparent diffusion coefficient derived from rearranging Fick’s first law in terms 
of coefficient Dm was taken from equation 2.2.1. Assuming pseudo steady state 
conditions, the 3.9 N treated VE layer outlines high lidocaine apparent Dm with good 
consistency as compared with control and 15.7 N (Figure 5.12). A relatively high 
lidocaine apparent Dm of 0.02 cm2/h was observed for 15.7 VE treated skin at 
t=0.75 h which corresponds to the highest flux of lidocaine permeated (Figure 5.11a 
and 5.12). Like K based profiles (Figure 5.10), Dm is deduced at observed steady 
state in deriving a constant Dm value for reference. 
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Figure 5.10 The partition coefficient (K) of lidocaine between vehicle and VE layer. 
 
 
Figure 5.11: (Continued to next page). 
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Figure 5.11: The permeation flux of lidocaine in a) VE skin layer b) clearance component 
(receptor cell in FDC). 
 
 
Figure 5.12: The apparent diffusion coefficients of lidocaine (vertical permeation). 
0
20
40
60
80
100
0.25 0.50 0.75 1.00
Control 3.9 N
15.7 N 7.9 N
J (
µ
g/
cm
²/
h)
 
Time (h) 
b 
0
0.005
0.01
0.015
0.02
0.025
0.03
0.25 0.5 0.75
Control 3.9 N
7.9 N 15.7 N
Time (h) 
Ap
pa
re
nt
 D
 (c
m
²/h
) 
 Lidocaine permeation from a lidocaine NaCMC/gel microgel form. in MN skin: vertical & horizontal 
 
131 
 
5.3.7  The percentage correlation of Lidocaine in specific compartments 
A total compartmental based correlation as a percentage of lidocaine from NaCMC:gelatine  
1:2.3 microgel was performed. This provides an overall idea of lidocaine residing in specific 
compartments or regions of the skin. Lidocaine slowly diffuses or permeates through the skin 
from a microgel vehicle to the systemic layer down a concentration gradient. Most Lidocaine 
molecules are trapped inside the skin as a substantial amount was detected in both the 
lateral and vertical region of biosiped skin (Figure 5.13). The error bars in Figure 5.13 
represent mean SD. Relatively small percentages of lidocaine are detected in the clearance 
compartment as higher amounts of lidocaine are traaped inside skin within 1 hour (Figure 
5.13). Lidocaine in MN 3.9 and 7.9 treated skin outlines higher content percentages in both 
vertical and horizontal layers (Figgure 5.13). This is more because of easier access for 
lidocaine filling the artificial micropores caused by MNs. Also lateral layer permeation shows 
higher lidocaine percentages regarding MN 3.9 and 7.9 N than vertical layer permeation 
(Figure 5.13).  
 
 
Figure 5.13: The percentage lidocaine contained in the vertical, lateral VE layer of skin and 
systemic circulation according to poke and coat and control treatment with lidocaine microgel.  
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Figure 5.14: The percentage lidocaine contained NaCMC:gelatine 1:2.3 microgel vehicle and   
other regions of skin according to poke and coat and control treatment.  
 
The percentage of lidocaine detected in skin even via the MN 3.9 N skin treatment, appears 
very small in a much broader concept. In terms of prilimary inspection, it appears that high 
percentages of lidocaine in “other” compartments infer high non-bioavailability and wastage 
of drug. This prilimary inference can be grossly misleading because a very high lidocaine 
percentage, especially in the clearance compartment is likely to pertain towards drug toxicity. 
These “other” compartments were described ealier in section 5.2.10. The control shows the 
highest percentage of lidocaine, 99.7 %, in “other” compartments as compared with all 
microneedle treated skin regimens adopted (Figure 5.14). The lowest percentage lidocaine in 
“other” compartments is from the 3.9 N, MN treated skin regimen at 97.7 % (Figure 5.14).     
 
5.4 Chapter summary 
The initial assumption of a 15 μm deep SC layer was confirmed as acceptable 
when examining the SC layer under microscope image gave an average of 18.6 
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accepted average depth of 15 μm. Transverse skin slicing showed that even the 
lowest pressure of MNs impact penetrated the skin rather than simply deforming it. 
The initial premise that increasing the pressure, and therefore the force on MN 
treatment, was confirmed when cavity length studies showed approximately 18 and 
16 % increases from 3.93 to 7.85 to 15.71 N. 
 
In vitro studies of lidocaine diffusion gave slight mixed results as compared to PD; 
the samples treated with MNs at 3.9 N force had consistently larger concentrations 
of lidocaine in the VE layer. There was a steady increase in this concentration 
beyond 0.5 h, showing a significantly high mass transfer drug permeation at this 
time. Also, the increasing partition coefficient trend at increasing time for 3.9 NMN 
treated skin, VE layer, is very favourable for lidocaine bipolymer. In comparison to 
conventional creams, this is a great improvement and with an improved formulation 
or a MN array that does not suggest the bed of nails effect. 
 
 The horizontal permeation of lidocaine from adopted regimens of PD to MN-
assisted 15.7 N treatment. All regimens show complete favourable trends at 
therapeutic level above 1.5 μg/ml solely for direct concentration results without 
further calculations with lidocaine controlled release adjustments in obtaining mass 
transfer profiles. The PD and a higher MN insertion force (15.7 N) are the most 
unfavourable regimens for horizontal permeation-based transfer of lidocaine in VE 
layer. This is because the mass transfer of lidocaine is below the minimum 
predicted therapeutic mass transfer for local anaesthesia in skin. The MN assisted 
3.9 and 7.9 N delivery of lidocaine horizontally in VE layer are the most favourable 
regimens. This favourability was due to lidocaine permeating at 100 μg/g and higher 
from 0.25 till 0.75 h. 
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Chapter 6 
Spreading of lidocaine NaCMC/gelatine 1:2.3 hydrogels on 
microneedle treated skin 
 
Chapter overview 
The spreadability of a liquid drug formulation on skin is an indication of it either 
remaining stationary or distributing (spreading) as a droplet. Factors determining 
droplet spreadability of the formulation are spreading area, diameter of the droplet 
base, viscosity of the liquid, contact angle, volume of droplet on skin and any 
others. The creation of microcavities from the application of microneedle (MN) has 
the potential to control droplet spreading, and hence, target specific areas of skin 
for drug delivery. However, there is little work that demonstrates spreading of liquid 
drug formulation on MN treated skin. Below, spreading of a lidocaine hydrogel 
formulation and lidocaine solution (reference liquid) on porcine skin is investigated 
over MN treated skin. Controlled spreadability was achieved with the lidocaine 
hydrogel on MN treated skin as compared with lidocaine solution. It was observed 
that the droplet spreading parameters such as spreading radius, droplet height and 
dynamic contact angle were slightly lower for the lidocaine hydrogel than the 
lidocaine solution on skin. Also, the lidocaine hydrogel on MN treated skin resulted 
in slower dynamic reduction of droplet height, contact angle and reduced time taken 
in attaining static advancing droplets due to the MN microcavities. 
 
6.1  Introduction 
Percutaneous absorption/permeation of a drug molecule (e.g., lidocaine) through 
skin depends on the contact between the formulation and skin properties through 
which the drug molecules are absorbed into different skin layers. The possibility of 
the drop of a liquid drug formulation either remaining static or distributing 
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(spreading) horizontally on the skin surface relies on its spreadability. If the droplet 
is capable of spreading, then the contact line between the formulation and skin 
moves over the skin. The rate of movement of the contact line can be defined as 
the spreadability of the formulation. 
 
Spreadability has significant importance in localised application and efficacy of 
topical drugs (Chow et al., 2007). However, the characteristic time scales for 
spreading of a drug formulation on skin (~seconds to minutes) is significantly 
smaller than the characteristic time scales for drug absorption/permeation into skin 
(~10s of minutes to hours). Therefore, most studies of percutaneous or transdermal 
drug delivery do not characterise spreading behaviour of the drug formulation over 
skin. Spreadability is primarily determined by the area/diameter of the formulation 
droplet on a substrate (e.g., skin below), viscosity of the formulation, contact angle, 
the volume of a droplet (permeant amount) (Jelvehgari and Montazam, 2011), and 
any others. 
 
Over recent years a number of researchers have discussed the possibility of 
enhanced permeation of lidocaine (a common anaesthetic) via a ‘poke and patch’ 
approach with the help of solid MN arrays (Banks et al., 2011; Hamzah et al., 2012; 
Nayak et al., 2014a,b). This approach involves treating the skin with well-defined 
MNs to create micro-cavities in skin followed by the deposition of a droplet of 
lidocaine solution on the MN treated area. For example, Nayak et al. (2014a,b, 
2015) demonstrated this approach using a lidocaine NaCMC/gelatine 1:2.3 
hydrogel formulation and determined the permeation profiles of lidocaine in porcine 
skin. While the lidocaine droplets spread over the skin, the lidocaine molecules also 
permeate through the treated area (Nayak et al., 2014a,b; Nayak et al., 2015). The 
duration of lidocaine hydrogel droplet spreading is in seconds, which is much faster 
as compared with that for drug permeation which normally takes about an hour to 
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reach equilibrium lidocaine concentration in skin. It is known that MNs have been 
primarily developed to control the mass transfer distance and time as a drug 
molecule is absorbed in the skin. However, the creation of microcavities using MN 
to accelerate penetration in the skin (Figure 6.1) allows controlling of spreading of 
the drug formulation droplet on skin and, hence, targeting a specific skin area over 
which the drug absorption/permeation can take place. On the other hand, a liquid 
droplet on a normal skin (i.e. untreated skin) is likely to spread in a low controlled 
manner, with low reproducibility and more rapidly as compared with a MN treated 
skin. At the moment, there is little or no study that specifically analyses in detail 
such spreading dynamics of drug formulation on MN pierced skin and the role that 
the MN cavities play in determining the formulation spreading behaviour. This work 
aims to address this gap in this chapter. 
 
 
Figure: 6.1 A liquid droplet on microneedle treated matrix and percolation of liquid 
into microcavities. The arrows illustrate droplet spreading (horizontal), droplet 
height (vertical) and contact angle (slanting). The letter L represents the droplet 
spreading radius.  
 
Below, lidocaine was loaded in a hydrogel biopolymer with a gelatine to NaCMC 
mass ratio of 2.3 as discussed earlier in Nayak et al. (2014a,b) and Nayak et al. 
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(2015). This mass ratio represents optimum drug and vehicle physico-chemical 
properties for a formulation (Nayak et al., 2014a,b). For the developed approach, 
controlling the spreadability of lidocaine hydrogel on skin is important to acquire 
liquid distribution of a liquid over the skin surface. A slower droplet spreading on 
skin coupled with a faster time in attaining static advancing contact angle is a 
favourable outcome in ensuring localised permeation of lidocaine at the treatment 
site. 
 
Lidocaine NaCMC/gelatine 1:2.3 hydrogel is a non-Newtonian liquid at standard 
room temperatures and pressure (Nayak et al., 2014a). The Ostwald de Waele 
power law (equation 6.1) can be used to describe the pseudoplastic behaviour of 
for such a fluid as follows: 
𝜋𝜋 = 𝑘𝑘(𝛾𝛾)n−1                                                                (6.1) 
Where η is the apparent viscosity, γ is the shear rate, k is the consistency constant 
of the substance and n is the power law or flow index. A log-log plot of viscosity (η) 
on shear rate (γ) for lidocaine NaCMC/gelatine 1:2.3 taken from Nayak et al. 
(2014a) provides an index value n = 0.392. As the index value is less than 1, the 
fluid is identified as pseudoplastic (Fang and Hanna, 1999). Its physical property 
can be exploited in quantifying and controlling the spreading of a lidocaine hydrogel 
droplet on an untreated flat skin surface without the need for manual rubbing across 
the whole area. For example, the pseudoplastic properties of the hydrogel is likely 
to provide a better control in droplet spreading as discussed earlier by Nayak et al. 
(2014b). 
 
 Below a comparison of spreadability between lidocaine NaCMC/gelatine 1:2.3 
hydrogel (higher viscosity) and lidocaine solution (lower viscosity) is conducted in 
order to understand the spreading behaviour. The loading dosage of lidocaine in 
both the hydrogel and solution form containing water was 2.4% w/w. The objective 
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of the study is to examine the spreadability of lidocaine NaCMC/gelatine 1:2.3 
hydrogel droplets on MN treated and untreated skin in relation to the viscosity of the 
formulation. Surface layers of skin treated with MN contain microcavities, which 
allow controlling the spreading of the lidocaine hydrogel and achieving static 
advancing contact angles and decreased spreading radius faster as compared with 
untreated skin. Three different MN types are applied to the skin samples in order to 
create controlled cavity depths past ~ 15μm thick stratum corneum (SC) layer of 
skin. Evaporation of the droplet is defined to be negligible due to the high boiling 
point of residual paraffin content in the lidocaine hydrogel, and relatively short 
duration of the spreading experiments. Our study specifically focuses on a drug 
formulation spreading on MN treated skin, which is the first attempt to investigate 
this process to the best of our knowledge. 
 
6.2 Materials and methods 
A lidocaine NaCMC/gelatine 1:2.3 hydrogel formulated by Nayak et al. (2014a) was 
adopted for characterising spreadability on porcine skin. The method of preparation 
of the hydrogel can be found in Nayak et al. (2014a,b) and Nayak et al. (2015). As 
stated earlier, the gelatine to NaCMC mass ratio of 2.3 was chosen for this study 
because of a faster permeation of lidocaine into the skin. The lidocaine 
NaCMC/gelatine 1:2.3 hydrogels were formulated using the vacuum oven method 
during final stage evaporation of excess paraffin dissolved in n-hexane as 
described in Nayak et al. (2014a,b). To prepare lidocaine solution, lidocaine HCl (> 
98% assay) was added to deionised water (DI) and heated gently to ensure a 
dissolved solution at 2.4% w/w. However, no lidocaine permeability experiments 
were conducted in this chapter. This work is focussed on determining the spreading 
radii, droplet heights, dynamic contact angles and characteristic spreading times of 
lidocaine hydrogel and solution (i.e., lidocaine dissolved in DI water) on both 
porcine skin and an artificial skin membrane, namely, Strat-M. 
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6.2.1  Reagents and materials 
Lidocaine HCl (Sigma Aldrich UK, Dorset, UK), lidocaine NaCMC:gelatine 1:2.3 
hydrogels, autopipette 0-10 μl (Thermofisher Ltd, Warrington, UK), Camera i-speed 
LT high speed video (Olympus, Essex, UK), MNs (AdminPatch, California, U.S.A), 
porcine skin (local butcher, UK), piston enabled pressure/ force device (SMC 
pneumatics Ltd, Buckingham-shire, UK), synthetic transdermal membrane (Strat-
M™, Merck Millipore, Hertfordshire, UK), temperature and humidity probe 
(Standard, Maplin Electronics, Leicestershire, UK) were used 126 in experiments 
below. 
 
6.2.2  Preparation of skin for spreading experiments 
The procedures for skin preparation were similar to the ones used for FDC 
experiments for determining drug permeation in skin, e.g., please see method 
stated in chapter 3. Briefly, these procedures involved the following steps: (i) either 
fresh porcine skin pieces originating from the porcine ears were washed in DI water 
and dried using a tissue, or frozen porcine skin pieces originating from the porcine 
ears were thawed at room temperature, washed in DI water and dried using a 
tissue; (ii) the cartilage, subcutaneous fat, blood vessels and connective tissue 
were removed from the underlying dermis sections of all skin samples; (iii) the skin 
samples were dissected further into 10 mm x 10 mm square pieces; (iv) the skin 
was placed on microscope slides with SC layer facing upwards for observation of 
the spreading dynamics. 
 
6.2.3  MN treatment of skin 
Stainless steel MNs of two lengths (1100μm and 600μm) were placed in the centre 
of a prepared porcine skin sample. A perpendicular piston barrel device (SMC 
pneumatics Ltd, serial: CD85N16-50-B) was used for transmission of controlled 
pressure induced force onto the chosen MN as described by Cheung et al. (2014). 
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Using the system, constant pressures of 0.5 bar, 1.0 bar and 2.0 bar equating to 
impact forces of 3.9 N, 7.9 N and 15.7 N were held for five minutes on the base of 
the MN (Nayak et al., 2015; Cheung et al., 2014). The forces (3.9 N, 7.9 N and 15.7 
N) used to treat the skin with the MNs (Nayak et al., 2015). The MN patch was 
removed from the porcine skin prior to droplet spreading experiments. 
 
6.2.4  Spreading of lidocaine NaCMC/gelatine 1:2.3 over skin surface 
The experimental procedures for studying the spreading of lidocaine hydrogel 
droplet on porcine skin were adapted from Chao et al. (2014). A lidocaine hydrogel 
droplet (volume of 3.0 ± 0.5 μl) was deposited using a pipet onto a piece of skin 
resting on a microscope slide as carefully as possible to prevent splashing or fast 
inertial spreading. The i-speed LT high speed camera (Olympus, UK) recorded 1.85 
frames per second until a stationary droplet profile or full disappearance was 
reached. The procedure was repeated twice for the control lidocaine solution. The 
real time capture of stages of the droplet spreading by camera configurations (i-
speed, LT high speed) focused on the droplet is presented in Figure 6.2. This 
arrangement is based on liquid spreading and imbibition experiments for Newtonian 
liquids (Chao et al., 2014). 
 
Figure: 6.2 A diagram of experimental setup for the capture of droplet spreading. 
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6.2.5  Spreading of lidocaine NaCMC/gelatine 1:2.3 hydrogels on the surface of 
artificial skin Strat-M membrane 
Besides porcine skin, synthetic membrane which is sometimes used as a substitute 
for skin in transdermal in vitro studies were used as a substrate. These are 
composed of polyether-sulfone and polyolefin and are known by the trade name 
Strat-M (Merck Millipore Ltd, Hertfordshire, UK). Strat-M membranes were chosen 
as control matrices for spreadability studies because of a relatively uniform flat 
surface as compared with the less uniform and rough surfaces of natural skin 
samples. The characterisation of droplet spreading parameters, especially contact 
angles, was adopted from Chao et al. (2014). A square section of membrane 
substrate (15 mm x 15 mm) from a larger section was cut and taped to an edge of 
the glass side. This allows closer distance and improved resolution between the 
droplet and the camera lens. A hydrogel droplet of volume 3.0 ± 0.5 μl was 
immediately deposited on the membrane in the same way as in the case a natural 
skin. The recording procedure was identical to that described in the previous 
section. The droplet images of all formulations used were processed using Vision 
Builder software (National Instrument, UK) to determine droplet spreading 
parameters: contact angle, droplet height and spreading radius. 
 
6.2.6  The measurement of relative humidity and temperature 
The percentage relative humidity (% RH) and temperature of the droplet environment were 
recorded using an electronic probe (Standard, Maplin Electronics, Leicestershire, UK). The 
data were acquired in triplicate. 
 
6.3 Results and discussion 
Comparative trends for lidocaine droplet spreading on porcine skin samples and 
Strat-M membrane were deduced starting with lidocaine solution as a control 
sample. The results are discussed below. 
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6.3.1  Spreadability of lidocaine 2.4 % w/w solution (lidocaine dissolved in DI water) 
The spreading of lidocaine 2.4% w/w solution droplets on normal skin (i.e., 
untreated porcine skin) were significantly more rapid and showed an almost linear 
dependence of spreading radius on time as compared with those for MN treated 
skin (Figure 6.3a). Likewise, the droplet heights of lidocaine solution droplets 
showed faster reduction and the droplet heights at static profiles was achieved after 
approximately 130 seconds (Figure 6.4a). The dynamic contact angle for the same 
case showed a faster reduction reaching the static advancing contact angle 
approximately of 11° after 130 seconds (Figure 6.5a). A sharp reduction in the 
contact angle was observed within the first 40 seconds for the lidocaine solution on 
the untreated skin. This suggests a slightly steeper reduction profile as compared 
with that for the lidocaine solution on 3.9 N MN treated skin for MNs of 600 and 
1100μm lengths, respectively (Figure 6.5d). The microcavity depths for both 600μm 
and 1100μm long MNs are expected to be shallow for the force applied on the MNs 
(Nayak, et al., 2015) and, therefore, significantly less reduction in the contact 
angles was observed when compared with those for non-MN treated skin (Figure 
6.5c). 
 
Figure 6.3: (Continued to next page).  
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Figure 6.3 Time evolutions of droplet spreading radius for a) lidocaine solution on 
microneedle and non-microneedle treated skin b) lidocaine microgels on 
microneedle treated skin c) lidocaine solution and lidocaine microgels on 
microneedle treated skin. The abbreviation C is control lidocaine solution and S is 
sample lidocaine hydrogel. 
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Droplets of the lidocaine solution have an initial contact angle of 57.1° at the 
moment of deposition (t≅0) on the non-MN treated skin. The viscosity of lidocaine 
solution is very similar to DI water and both are Newtonian fluids. However, the 
initial contact angle was near 90° for DI water on non-MN treated skin as reported 
earlier by Elkhyat et al. (2004), which is significantly higher than observed for the 
lidocaine solution. The high contact angle of DI water was caused by the low sebum 
content on skin and there is a big variation in the initial contact angle depending on 
skin location (Elkhyat et al., 2004). Sebum is a natural mixture of lipids. Lidocaine 
solution on non-MN treated skin is devoid of artificial cavities and excess liquid 
cannot retain inside cavities and slow down droplet spreading. 
 
The 1100 μm long MN induced microcavity depths for 3.9 N, 7.9 N and 15.7 N 
forces are reported to be 19.5 μm, 23.1 μm and 26.7 μm, respectively (Nayak et al., 
2015). The mean microcavity depths using 600 μm long MN for the same forces are 
small but they are not easily detectable for transverse visualisation of skin 
microcavities as the forces applied are relatively small (implying smaller microcavity 
length). However, AdminPatchTM microneedles at 600μm length are shown to 
increase drug permeation. For example, drug permeability studies by Kaur et al. 
(2014) demonstrated a 14.3 fold increase in permeation flux as compared with PD 
for the transdermal delivery of an anti-hypertensive agent, thus implying that 
microcavities were formed in skin. These depths cross the typical SC layer depth of 
15 μm (Nayak et al., 2015). 
 
The dynamic contact angles of lidocaine solution on 7.9 N force treated MN skin 
outlines slow decreases in contact angles, which is especially more significant for 
the 1100 μm long MNs (Figure 6.5a). The spreading radius and droplet height of 
lidocaine solution are significantly less for 7.9 N force treated skin (Figures 6.3a and 
6.4a). This is because of deeper MN cavities capturing excess liquid during droplet 
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spreading of lidocaine solution. Nevertheless, it was not possible to determine using 
conventional cryotome techniques if a large quantity of MN in a patch created a 
uniform depth microcavity for both specific MN lengths. MNs were impacted on skin 
for 5 minutes maximum using one specific force, so an assumption that most MNs 
have successfully pierced skin at significant microcavity depths will be made here. 
 
 
Figure 6.4: (Continued to next page). 
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Figure 6.4 Time evolutions of droplet height for a) lidocaine solution on microneedle 
and non-microneedle treated skin b) lidocaine solution and lidocaine microgels on 
Strat-M membrane c) lidocaine microgels on microneedle and non-microneedle 
treated skin d) lidocaine solution and lidocaine microgels on microneedle treated 
skin. The abbreviation C is control lidocaine solution and S is sample lidocaine 
hydrogel.   
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6.3.2  Spreadability of lidocaine NaCMC/gelatine 1:2.3 hydrogel 
The spreading of lidocaine NaCMC/gelatine 1:2.3 hydrogel show similar trends for 
600μm long MN treated skin, particularly closer for 3.8 N and 7.8 N forces (Figure 
6.3c). The fluid properties of the formulation which affect the spreading behaviour 
have been discussed earlier (Nayak et al., 2014a, b). 
 
 
Figure 6.5: (Continued to next page). 
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Figure 6.5 Time evolutions of dynamic contact angle for a) lidocaine solution on 
microneedle and non-microneedle treated skin b) lidocaine solution and lidocaine 
microgels on Strat-M membrane c) lidocaine microgels on microneedle and non-
microneedle treated skin d) lidocaine solution and lidocaine microgels on 
microneedle treated skin. The abbreviation C is control lidocaine solution and S is 
sample lidocaine hydrogel 
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The 15.7 N force on a 600μm MN patch treated skin showed increasing spreading 
radius than 3.9 N as compared with the lowest force of the same MN length (Figure 
6.3c). This is because the MN cavity depths are likely not to be deep enough. The 
reason is because of an observable reduction in spreading radius caused by 
deeper micro-cavities from higher MN forces. Lidocaine hydrogel droplets for the 
insertion forces of 3.9 N, 7.9 N and 15.7 N for 1100 μm long MNs provide less 
rapidly increasing spreading radius, less rapidly decreasing droplet heights and less 
rapidly decreasing dynamic contact angles (Figures 6.3c, 6.4c and 6.5c) before 
static profiles were reached. Nevertheless, there were minor contradictions in 
reporting lower spreading radii when droplet heights were not decreasing rapidly 
because of the mild pseudoplastic properties of the lidocaine hydrogel (Nayak et al., 
2014a). For example, lidocaine hydrogel from 3.9 N, 600μm treated skin should 
hypothetically outline faster spreading than 7.9 N, 1100μm on skin because the 
latter usually possess deep microcavites (Figure 6.3c). Skin microcavities created 
by MNs do not produce exact replicates of microcavity lengths as shown in 
transverse section micrographs due to variability in the viscoelastic property of skin 
(Nayak et al., 2015). Further, lidocaine hydrogel droplets were sometimes difficult to 
dispense with accurate volumes within ± 0.05 μl because of the viscous nature of 
the formulation. 
 
The results show that the lidocaine solution spreading radii for 3.9 N and 7.9 N 
forces of 1100 μm long (longer MNs) MN is distinctly different as compared to the 
lidocaine hydrogel spreading radii (Figures 6.3a and 6.3c). However, no significant 
difference in droplet spreading radii was observed when comparing 3.9 and 7.9 N 
force of 600 μm long MN (shorter MNs) for lidocaine solution (Figure 6.3a). In 
further scrutinising spreading patterns the lidocaine solution showed rapid 
spreading, faster decrease in droplet height and rapid decrease in dynamic contact 
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angle as compared with lidocaine hydrogel when the same forces, namely, 3.9 N 
force was applied on the skin (Figure 6.3d). 
 
The artificial membrane (Strat-M), which is normally implemented in drug based in 
vitro PD studies, was a control for skin because of a relatively smooth surface 
(Uchida et al., 2015). The spreading radii of lidocaine solution and hydrogel droplets 
could not be measured reliably with a good repeatability because of the horizontal 
placement of camera and liquid percolation through the pores in the membrane. 
However, there is a slight decrease in droplet height and dynamic contact angle for 
lidocaine solution droplets (Figures 6.4b and 6.5b). This slight decrease can be 
attributed to the percolation of lidocaine solution into Strat-M pores despite no 
significant change in droplet spreading radius. 
 
Lidocaine hydrogel droplets showed significant change in spreading radius, droplet 
height and dynamic contact angle (Figures 6.4b, 6.5b) on Strat-M. The droplet 
spreading was likely to be caused by the lower surface tension of lidocaine 
hydrogel on the hydrophobic surface of Strat-M. Lidocaine hydrogel contains 
residual paraffin of low surface tension properties as compared with water. 
 
Lidocaine hydrogels and lidocaine solution droplets snapshots outline spreading in 
terms of observed changes in droplet shape at three distinct timings (Figures 6.6 
and 6.7). Lidocaine solution droplets have dome shape at the initial time of 
placement as compared with slightly flattened dome shaped droplets for lidocaine 
hydrogel (Figures 6.6 and 6.7). After a duration of 10 seconds, the lidocaine 
hydrogels spread more than the lidocaine solution, especially on skin treated with 
600 μm long MNs (Figures 6.6 and 6.7). In most cases, lidocaine solution shows 
distinct droplet with respect to 7.9 N force with 1100μm long MN treated skin and 
Strat-M membrane after 180 seconds (Figure 6.6). The remaining MN treated skin 
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variables appear not to retain more lidocaine solution droplets in the microcavities 
(Figure 6.6). After the duration of 180 seconds, the droplet outline is distinctly 
notable for lidocaine hydrogel after 1100μm MN treatment on skin (Figure 6.7). 
 
The relative humidity and temperature of the surrounding vicinity for droplet 
spreadability was 48.6 ± 4.31% at 20.1° ± 2.40°C, respectively. The standard 
deviation for relative humidity is observed because the surroundings are not an 
isolated system preventing the transfer of heat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Captured images of lidocaine solution droplets (C) on a substrate (skin 
or membrane) at three different time points. The figure shows the droplet 
morphology at the substrate for different forces of MN insertion and MN lengths 
which were used to treat the skin. 
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Figure 6.7 Captured images of lidocaine NaCMC/gelatine 1:2.3 hydrogel droplets 
(S) on a substrate (skin or membrane) at three different time points. The figure 
shows the droplet morphology at the substrate for different forces of MN insertion 
and MN lengths which were used to treat the skin. 
 
Normal environmental changes in relative humidity were expected because the 
duration of experiments were conducted upto 3 minutes and relative humidity can 
fluctuate in a matter of seconds. The reading of relative humidity of 48.6% is near 
average at a low room temperature. The likelihood of evaporation is low for these 
surrounding conditions and the short duration of the experiments. 
 
6.3.3  Dimensionless spreading parameters of lidocaine hydrogel and solution 
The spreading dynamics of lidocaine NaCMC/gelatine 1:2.3 hydrogel and solution 
are represented in this section in terms of dimensionless parameters, namely, 
dimensionless spreading radius � 𝐿𝐿𝑡𝑡
𝐿𝐿𝑚𝑚
�, dimensionless contact angle � 𝜃𝜃𝑡𝑡
𝜃𝜃𝑚𝑚
�, 
dimensionless droplet height � ℎ𝑡𝑡
ℎ𝑚𝑚
�, dimensionless spreading time � 𝑡𝑡
𝑡𝑡∗
� and 
dimensionless droplet volume � 𝑉𝑉𝑡𝑡
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
�. For the above five dimensionless parameters, 
the numerators, namely, Lt, θt, ht, Vt and t, are the droplet spreading radius, contact 
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a 
angle, height, volume and measured time periodically at different time intervals. On 
the other hand, the denominators of the fractions are the droplet base showing the 
maximum spreading radius, maximum contact angle, maximum droplet height, 
maximum droplet volume and static advancing droplet time. The dimensionless 
numbers, namely, 𝐿𝐿𝑡𝑡
𝐿𝐿𝑚𝑚
, 𝜃𝜃𝑡𝑡
𝜃𝜃𝑚𝑚
, ℎ𝑡𝑡
ℎ𝑚𝑚
 and 𝑉𝑉𝑡𝑡
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚
 are plotted as function of 𝑡𝑡
𝑡𝑡∗
 for various 
circumstances (Figure 6.8). Analyses of these parameters provide understanding of 
the time evolution of these parameters and give some generality to the results (e.g., 
see Chao et al., 2014). Figure 6.8 shows that the time evolutions of these 
dimensionless parameters are different implying that the spreading behaviour is 
different in different cases. These are discussed below. 
 
The lidocaine hydrogel spreading on 3.9 N and 7.9 N force treated skin with 1100 
μm and 600 μm long MN showed short durations in increasing dimensionless 
spreading profiles, thus attaining closeness to a plateau of dimensionless value of 
1.0 at a shorter time interval (Figure 6.8a). The lidocaine solution on non-MN 
treated skin could not be reported as dimensionless spreading because a linear 
profile was observed and Lm could not be deduced because of no plateau (Figure 
6.3a).   
 
 
 
 
 
 
 
 
 
Figure 6.8: (Continued to next page)  
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Figure 6.8. The lidocaine droplet plots outlining dynamic variation in a) spreading of 
hydrogel (S) or solution (C) on microneedle and non-microneedle treated skin b) 
droplet height of hydrogel (S) or solution (C) on microneedle and non-microneedle 
treated skin c) contact angle of hydrogel (S) or solution (C) on microneedle and 
non-microneedle treated skin. 
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The spreading of lidocaine hydrogels on 7.9 N and 15.7 N force treated skin with 
1100 μm long MN showed a long durations in increasing spreading radius; thus, 
attaining closeness to dimensionless value 1.0 above the fractional time of 0.90 
(Figure 6.8a). A short duration in increasing dimensionless spreading means a less 
dynamic spreading across the skin. As mentioned earlier in this chapter, the 
lidocaine hydrogel fill the skin microcavities and the spreading of the hydrogel slow 
down. 
 
All lidocaine hydrogels droplets on MN treated skin outlined slower reduction of 
dimension-less droplet height as the liquid fills the microcavities on MN treated skin 
(Figure 6.8b). Comparatively, the lidocaine solutions showed faster dynamic height 
reduction from maximum spreading height (t = 0) because of high initial droplet 
height fractions and faster spreading (Figure 6.8b). 
 
 
Figure 6.9: (Continued to next page). 
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Figure 6.9 The non-dimensional droplet volume on top of skin sample a) for lidocaine 
solution b) lidocaine NaCMC/gelatine 1:2.3. The abbreviation C is control lidocaine solution 
and S is sample lidocaine hydrogel.   
 
Slower dynamic reduction of contact angle was observed for all lidocaine hydrogel 
droplets on MN treated skin (Figure 6.8c). The lidocaine hydrogel on 3.9 N of 1100 
μm length, 7.9 N and 15.7 N of 600 μm treated skin showed slightly slower 
reductions in fractional contact angles (Figure 6.8c). Nevertheless, lidocaine 
hydrogel on 7.9 N and 15.7 N treated skin samples with 1100 μm long MN outlined 
slightly faster reductions in the dimensionless contact angle (Figure 6.8c). Static 
advancing droplets were found to arrive at shorter fractional timings for lidocaine 
hydrogels because of the viscous property of the hydrogel and presence of 
numerous MN microcavities as liquid percolates into the microcavity spaces. 
 
The lidocaine solution droplets show significantly more dynamic volume decreases 
as compared with lidocaine hydrogel droplets (Figure 6.9 a,b), which is due to the 
fact that the lidocaine solution percolates into the MN holes faster than the lidocaine 
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hydrogel droplets. The lidocaine hydrogels outline low droplet volume reductions in 
microneedle treated skin and fast appearance of static droplet volumes (Figure 
6.9b). There was a faster reduction in droplet volume for Strat-M and 15.7 N, 1100 
μm treated skin (Figure 6.9b). The roughness of skin and the pseudoplastic 
properties of the hydrogel are two factors in explaining the likelihood for the 
observed static advancing droplet profiles. Non-microneedle treated skin and Strat-
M membrane surfaces appear smooth, so there appears to be faster droplet volume 
decreases in those two substrate control parameters. 
 
6.4 Chapter summary  
The spreading of a liquid drug formulation, namely, lidocaine NaCMC/gelatine 1:2.3 
hydrogel, on MN treated skin is studied. The results of the study show improved 
control of the formulation spreadability as compared to those for lidocaine solution 
(lidocaine dissolved in DI water) alone. Lidocaine NaCMC/gelatine 1:2.3 hydrogel 
show a slightly lower spreading radius, sight decrease in droplet height and smaller, 
controlled decrease in dynamic contact angle as compared with lidocaine solution. 
The slower dynamic reduction of droplet height and contact angle and convergence 
to static advancing droplet at short initial timings for lidocaine NaCMC/gelatine 1:2.3 
hydrogel are indication of the seepage of the liquid inside MN microcavities in skin. 
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Chapter 7 
Conclusion and future work  
 
7.1 Conclusion 
In this PhD research, a natural bi-polymeric hydrogel was formulated with lidocaine 
and a microneedle (MN) “poke and patch” method was adopted for studying 
percutaneous drug delivery on porcine skin. The summary of the work which was 
outlined in various chapters have been directly mentioned in those chapters. 
Therefore, this chapter outlines the overall conclusions and main contributions of 
this PhD research.   
 
The work centres around the fact that both sodium carboxymethylcellulose and 
gelatine, which are natural polymers, are suitable for encapsulating lidocaine. A 
lidocaine sodium carboxymethylcellulose and gelatine bi-polymeric hydrogel was 
successfully formulated to encapsulate lidocaine molecules. The optimum mass 
ratio achieved to encapsulate lidocaine was gelatine to NaCMC of 2.3. Solid 
microneedle assisted delivery of this lidocaine bi-polymeric hydrogel through skin 
provided highly desirable permeation kinetics. Gelatine is ideal for forming ionic 
interactions with sodium carboxymethylcellulose, which permits good encapsulation 
and release properties for lidocaine. The mass ratio between these two polymers 
permits an intermolecular charge distribution with encapsulated lidocaine and 
therefore the lowest Zeta potential value corresponding to a greater hydrogel 
microparticle dispersion. This microparticle dispersion provides an occurrence of 
surface repulsion between hydrogel microparticles which is negative in our case. A 
low Zeta potential pertaining to low potential differences on the hydrogel particle 
surface repels neighbouring particle surface charges, which explains the decrease 
of particle agglomeration. 
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In this work the developed bipolymeric hydrogel showed an optimum mass ratio of 
1:2.3. The encapsulation efficiency of 53% for lidocaine NaCMC/gelatine 1:2.3 was 
a considerable improvement from previous encapsulation efficiency of 17.2% of the 
same mass ratio bi-polymeric lidocaine. This was due to batch formulation 
processing accuracy and low recorded particle sizes despite significant 
polydisperisity. The pseudoplasticity of lidocaine NaCMC/gelatine 1:2.3 was 
significant to further explore the spreadability of this hydrogel on skin. The gelatine 
component leads to formulation gelation and, thus contributes to the 
pseudoplasticity of the bipolymeric hydrogel. 
 
Lidocaine from NaCMC/gelatine 1:2.3 permeated at a minimum therapeutic level of 
1.2 μg/ml after 1.1 h post microneedle treatment on skin. Comparatively lidocaine 
passive diffusion showed time duration of 1.36 fold greater in bypassing the 
minimum therapeutic level with respect to the same hydrogel formulation mass 
ratio. A second result for lidocaine PD’s therapeutic advance was 0.4 h lower than 
the first PD result of 1.5 h. Here, the lidocaine detected was in the receptor 
compartment of the Franz diffusion cell (FDC) which represented the hypodermis. 
Full thickness skin was calculated at 670 ± 50 μm deep and therefore the receptor 
level depth has a bigger range and is greater than this. The passive diffusion (PD) 
of lidocaine from NaCMC/gelatine 1:2.66 was just under 0.75 h in reaching 
minimum therapeutic level. There is a large variability in lidocaine reaching the 
hypodermis level by PD. This can be attributed to the depth range or path length 
that lidocaine molecules travel past skin before detection.  
 
In taking lidocaine NaCMC/gelatine 1:2.66 as the favourable hydrogel, MN treated 
skin outlined 0.17 h in bypassing the minimum therapeutic level. This can be 
attributed to a high encapsulation efficiency of 32 % as mentioned in Chapter 3. 
However lidocaine NaCMC/gelatine 1:2.66 was not selected for further permeation 
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based studies because of large particle sizes and unfavourable Zeta potential 
results. The selection of lidocaine NaCMC/gelatine 1:2.3 successfully outlined 
depth averaged vertical and horizontal permeation of MN treated skin, bypassing 
therapeutic lidocaine levels at 0.25 h. This time accurate MN forces were 
implemented on skin with 3.9 and 7.9 N forces more favourable for sustained 
therapeutic lidocaine delivery within viable skin consisting of VE and dermis layer. 
The mass transfer of lidocaine regarding skin’s depth averaged vertical and 
horizontal permeation provided accurate results of lidocaine’s presence within 
viable skin because the known periodic lidocaine release quantities were 
subtracted.  
 
Already knowing the mild pseudoplastic properties of lidocaine NaCMC/gelatine 
1:2.3 hydrogel paved the way for spreadability based research. The spreadability of 
lidocaine NaCMC/gelatine 1:2.3 hydrogel on MN treated skin successfully showed 
spreading control. The static advancing contact angle was achieved at a lower time 
as compared with lidocaine solution on non-MN treated skin. The shorter the time 
for static advancing contact angle of lidocaine hydrogel droplets on skin means the 
longer the localised redency for percolation of liquid into microcavities. Also, manual 
rubbing or spreading the lidocaine formulation with fingers is not required.  
 
Overall lidocaine NaCMC/gelatine 1:2.3 hydrogel in tandem with solid microneedle 
assisted drug delivery shows a successful outcome in drug formulation 
development and percutaneous permeation kinetics. Also, the time taken for 
lidocaine to appear in the viable epidermis layer of skin was significantly less than 
conventional passive diffusion by lidocaine hydrogel alone. 
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7.2 Future work 
In the current work no focus was given to control and reduce the microgel 
polydispersity because the reduction in gelation and increase in covalent 
crosslinking reagents such as glutaraldehyde in the formation of polymeric 
microparticles may alter the current hydrogel properties of the formulation. 
However, we recognise that lidocaine NaCMC/gelatine hydrogel as an ideal 
painless, local anaesthetic formulation is likely to be an advancing area in the 
future. Therefore, further developmental work to reduce residual paraffin oil content, 
smaller micron-scale particle sizes and subsequently higher encapsulation 
efficiency could be the focus of further studies. In the context of electro-ionic 
interactions concerning the formulation, there is no significant quantitative study on 
ionic interactions between NaCMC, gelatine and lidocaine with respect to 
potentiometric measurements, pH thresholds and polarography analysis. These are 
fairly important parameters for relating ionic properties but Zeta potential analysis 
looks into the dispersion of microparticles in the hydrogel as a result of the degree 
in like charge repulsion which is discussed later.  
 
A Phase 1 double blind clinical study on human volunteers is the next stage in the 
proof of concept in percutaneous anaesthesia. Optimum lidocaine 1:2.3 mass ratio 
hydrogel with coat and poke method shall justify the attainment of fast minimum 
therapeutic levels below the SC layer of skin. Following current successful in vitro 
based studies in proving fast vertical and lateral permeation of lidocaine, the need 
for implementing in vivo studies is imperative. In deducing the lidocaine 
pharmacokinetics to be successfully desirable and reproducible in the application of 
emergency anaesthesia, further commercial based goals can be satisfied in 
achieving a new commercial microneedle product. 
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